query,response,reference,correctness_score,semantic_similarity_score,faithfulness_score,context_relevancy_score,answer_relevancy_score
What regulatory milestones has CytoSorb achieved in the United States?,"CytoSorb has achieved several regulatory milestones in the United States. In April 2020, the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for CytoSorb for use in patients with COVID-19 infection. Additionally, in the same month, the FDA granted Breakthrough Designation to CytoSorb for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.","CytoSorb has received FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery, and Emergency Use Authorization (EUA) for use in critically-ill patients with COVID-19 infection.",5.0,0.9236189173150798,1.0,1.0,1.0
What are the commercialization strategies for CytoSorb in different regions?,"CytoSorb's commercialization strategy involves establishing either direct sales or distribution through distributors and strategic partners in various countries. In the EU, registration can typically be achieved within several months due to CE Mark approval, facilitating quicker commercialization. Outside the EU, the registration process is more variable, taking several months to over a year, depending on differing documentation and clinical data requirements. The company actively supports its distributors and strategic partners in the registration process across these regions.

CytoSorb has distribution in numerous countries outside the EU, including Turkey, India, Sri Lanka, Australia, New Zealand, Russia, Serbia, Norway, Vietnam, Malaysia, Hong Kong, Chile, Panama, Costa Rica, Colombia, Brazil, Mexico, Argentina, Peru, Guatemala, Ecuador, Bolivia, the Dominican Republic, El Salvador, Iceland, Israel, UAE, Iran, Saudi Arabia, other Middle Eastern countries, and South Korea. Despite having established distribution in these regions, the timing of registration and commercialization is unpredictable, and there is no guarantee of achieving registration or generating meaningful sales due to factors like market adoption and reimbursement.

The company is continuously evaluating additional distributor and strategic partner networks in other major countries that accept CE Mark approval. To expand further, the company plans to pursue U.S. clinical trials to seek FDA regulatory approval for CytoSorb, with an intention to continue global commercialization efforts, provided there are sufficient resources, positive clinical data, adequate funding, and favorable results from ongoing clinical studies.","CytoSorbents Corporation employs a mixed strategy of direct sales through its subsidiaries in key markets like Germany, Austria, and Switzerland, and distribution through strategic partners and independent distributors in other countries, leveraging CE Mark approval for European markets and actively seeking registrations worldwide.",5.0,0.6371325378899954,1.0,0.875,1.0
What are the financial implications of using CytoSorb in treating sepsis patients?,"Using CytoSorb in treating sepsis patients has several financial implications. The therapy typically costs between $1,000 and $5,000 per treatment, depending on the number of sessions required. This cost is significantly lower than the expenses associated with standard sepsis treatment, which can range from $45,000 to $60,000 per patient in the U.S., including ICU care at approximately $4,300 per day. By reducing the severity of illness and potentially shortening ICU stays by one to two days, CytoSorb could be cost-effective, as it lowers overall treatment costs. The total addressable market for CytoSorb in the U.S. and EU for sepsis treatment is estimated at $6 billion to $8 billion, reflecting its potential financial impact. Additionally, with sepsis treatment costing nearly $20 billion annually in the U.S. alone, CytoSorb offers a promising opportunity to reduce healthcare expenditures while improving patient outcomes.","The use of CytoSorb in sepsis treatment is expected to improve clinical outcomes and reduce the need for costly ICU care, potentially saving significant healthcare costs. The therapy typically costs between $1,000 to $5,000, representing a fraction of the average cost of treating a severe sepsis patient, which can range from $45,000 to $60,000.",5.0,0.9006383573239577,1.0,0.875,1.0
What are the key risks associated with the discovery and development of our product candidates?,"Key risks associated with the discovery and development of product candidates include the uncertainty and high failure rate in identifying and validating new therapeutic candidates, particularly novel proteins and antibodies that may not prove effective or safe upon further study. The discovery process requires substantial technical, financial, and human resources, and there is no guarantee that research efforts will yield viable candidates due to factors such as inadequate efficacy, harmful side effects, or suboptimal drug profiles. Additionally, the development process is expensive, time-consuming, and subject to regulatory scrutiny, with clinical trials being particularly risky and potentially leading to delays or discontinuation. Manufacturing risks are also significant, as the company relies on external capabilities and lacks internal facilities for producing bulk drug substance or filled drug products, which could increase costs and limit supply. Failure to secure additional financing may hinder development and commercialization efforts. Furthermore, the company's business depends heavily on the success of initial product candidates targeting specific diseases, and any delays or setbacks in clinical trials could negatively impact timelines and market opportunities. Lastly, the reliance on the RAMP™ drug discovery program and the potential for competitors to develop alternatives create additional competitive and strategic risks.","The key risks include potential adverse impacts from COVID-19 on clinical trials, dependency on the success of lead product candidates, uncertainty of regulatory approval, and the high risk of failure in clinical trials.",4.5,0.5990867700979831,1.0,0.875,1.0
How does the COVID-19 pandemic affect our ability to conduct clinical trials?,"The COVID-19 pandemic affects our ability to conduct clinical trials in several ways. It may delay the startup of new clinical trial sites and patient enrollment due to the prioritization of hospital resources toward the pandemic, travel restrictions, and requirements for remote work. Some patients may be unwilling or unable to enroll or comply with trial protocols due to quarantines or disruptions in healthcare services. Increased demand at clinical trial sites and staff quarantines can reduce available personnel and resources, leading to delays or pauses in screening and trial operations. Trial sites may limit or prohibit on-site dosing and monitoring to reduce exposure, requiring the adoption of remote monitoring and other procedures. These disruptions may result in protocol deviations, reduced quality of data verification, and potential delays in trial timelines. Additionally, if clinical trial sites lack the capability for remote operations, new investigative sites may need to be engaged. Such impacts could delay clinical trial completion, affect regulatory approval, and hinder commercialization efforts.","The COVID-19 pandemic may delay startup of new clinical trial sites, reduce patient enrollment, and disrupt operations of third-party suppliers and manufacturers, leading to delays or disruptions in the supply of product candidates for clinical trials.",5.0,0.7864198115426179,1.0,1.0,1.0
"What are the potential consequences of failing to comply with environmental, health, and safety laws and regulations?","Failing to comply with environmental, health, and safety laws and regulations could result in substantial fines and penalties, remediation costs, property damage, and personal injury claims. It may also lead to the loss of permits, a cessation of operations, and harm to the business and financial condition. Additionally, liability can be joint and several and applied without regard to fault or negligence, and new laws may impose greater compliance costs or increase risks and penalties over time.","Non-compliance could result in fines, penalties, or increased costs associated with remediation, and could potentially harm our business operations and reputation.",5.0,0.7378426959635243,1.0,1.0,1.0
"How does the company's international operations expose it to additional risks, and what measures does it take to mitigate these risks?","Operating internationally exposes the company to a range of risks that could materially adversely affect its business. These include navigating multiple, conflicting, and changing laws and regulations across jurisdictions, such as privacy, tax, export, and employment laws, as well as securing and maintaining regulatory approvals for its products in various countries. The company also faces challenges related to intellectual property protection and enforcement, staffing and managing foreign operations, and managing diverse payor reimbursement systems, including government payors and patient self-pay models. Financial risks include longer payment cycles, difficulty collecting receivables, exposure to foreign currency exchange rate fluctuations, and impacts from regional financial crises. Additionally, the company is subject to operational risks such as natural disasters, political and economic instability, wars, terrorism, disease outbreaks, trade restrictions, and other disruptions. It also incurs additional expenses for travel, translation, and insurance, as well as regulatory and compliance obligations related to anti-bribery and anti-corruption laws, including the U.S. Foreign Corrupt Practices Act. The United Kingdom’s withdrawal from the European Union further introduces risks related to global economic and financial market instability, which could affect its business.

Given that the company currently has limited international operations, its primary measure for mitigating these risks is to focus on securing regulatory approval for its product candidates in the U.S. before considering international expansion. This allows the company to establish a strong domestic foundation before entering more complex international markets. However, no specific proactive mitigation strategies such as risk assessments, insurance, or compliance programs are explicitly mentioned in the provided context. The company may also rely on established legal and compliance frameworks to manage risks, though the extent of these efforts is not detailed.","The company's international operations expose it to risks such as challenges caused by distance, language, and cultural differences, as well as varying legal, economic, and political conditions in different countries. To mitigate these risks, the company employs various strategies, including compliance with local laws and regulations, careful selection of markets, and diversification of operations across different jurisdictions.",4.5,0.6579410564676741,1.0,1.0,1.0
"What are the potential impacts of data privacy and security laws on the company's operations, and how does it ensure compliance with these regulations?","The potential impacts of data privacy and security laws on the company's operations include increased costs for compliance, uncertainty in business operations due to evolving regulations, limitations on data collection, storage, transfer, and sharing practices, and the need to adopt more stringent contractual obligations. Non-compliance or perceived non-compliance could lead to negative publicity, government investigations, enforcement actions, litigation, claims from third parties, and damage to the company’s reputation, all of which may materially adversely affect its operations, financial performance, and business. Additionally, regulatory scrutiny may intensify as the company expands, and new or more stringent laws, such as those related to health information under HIPAA or state-specific privacy laws, could further constrain operations.

To manage these challenges, the company must adhere to applicable federal, state, and foreign laws and regulations, implement internal policies and procedures governing the processing of personal information, and maintain compliance with contractual obligations. While the specific mechanisms for ensuring compliance are not detailed, the company likely relies on ongoing monitoring of the legal landscape, adherence to established standards, and internal governance processes to address evolving requirements and mitigate risks.","Data privacy and security laws, such as the GDPR and CCPA, impose stringent requirements on the collection, storage, and use of personal information, which could increase the company's costs and expose it to potential sanctions and lawsuits if not complied with. The company ensures compliance through implementing robust data protection measures, regular audits, and staying updated on regulatory changes to adapt its practices accordingly.",4.5,0.6811079893671895,1.0,0.875,1.0
"What was the total amount of revenue expected to be recognized from remaining performance obligations as of March 31, 2020?",$24.0 billion,"As of March 31, 2020, approximately $24.0 billion of revenue was expected to be recognized from remaining performance obligations.",4.0,0.5230661188676947,1.0,1.0,1.0
What were the major elements contributing to the difference between the U.S. federal statutory tax rate and the effective tax rate in fiscal 2020?,"In fiscal 2020, the major elements contributing to the difference between the U.S. federal statutory tax rate and the effective tax rate included the national media goodwill impairment charge, which resulted in an income tax benefit of $26.9 million. Additionally, the effective tax rate was influenced by U.K. tax law changes enacted in July 2020, which led to a revaluation of deferred tax assets and liabilities at the 19% rate, resulting in a $65 million deferred tax expense. Other factors included favorable state apportionment changes due to the acquisition of Ellie Mae and favorable changes in certain international tax provisions as part of the TCJA in 2019.","The major elements contributing to the difference in fiscal 2020 included a non-deductible goodwill impairment charge, a non-taxable gain on an arbitration award, a change in the net valuation allowance on certain deferred tax assets, and an increase in Income Tax and Foreign Tax Credits.",4.0,0.6436559489194899,1.0,1.0,1.0
How did the Company's annual goodwill impairment analysis in fiscal 2020 differ from previous years?,"In fiscal 2020, the Company performed its annual goodwill impairment assessment as of July 1, 2019. Following a decline in its stock price and market capitalization, which were deemed substantial and sustained, the Company conducted quantitative goodwill impairment tests in the second and fourth quarters of fiscal 2020. These tests were carried out for all of DXC's reporting units, consistent with its policy. As a result, the Company recognized total non-cash impairment charges of $6,794 million, with $3,789 million in the GBS segment and $3,005 million in the GIS segment. In contrast, the annual goodwill impairment analysis for fiscal 2019, performed as of July 1, 2018, did not result in an impairment charge.","In fiscal 2020, the Company performed quantitative goodwill impairment tests during the second and fourth quarters due to a sustained decline in the Company’s stock price and market capitalization, leading to the recognition of total non-cash impairment charges of $6,794 million. This was a departure from previous years where no such impairments were recognized.",5.0,0.8053148554969473,1.0,1.0,1.0
How did the Company's approach to managing foreign currency risk through derivative instruments evolve in fiscal 2020?,"The Company's approach to managing foreign currency risk through derivative instruments in fiscal 2020 involved using foreign exchange contracts to hedge against currency risk, particularly for non-U.S. subsidiaries with revenue and expenses in currencies other than their functional currency. These derivatives were designated as hedging instruments, with total notional amounts of $340 million at December 31, 2020, and represented net fair value assets of $5 million. Additionally, the Company used foreign currency forward contracts to manage the risk associated with customer agreements priced in currencies different from the functional or local currencies of the parties involved, as well as to hedge certain foreign currency-denominated monetary assets and liabilities. As of December 31, 2020, the total notional amounts for these forward contracts were $3.4 billion. The Company also reported that it maintained a policy for managing this risk, which was reviewed and approved by the board of directors.","The Company continued to use foreign currency forward contracts as cash flow hedges to reduce foreign currency risk related to certain intercompany obligations and forecasted transactions. The notional amounts of these contracts designated as cash flow hedges increased to $455 million as of March 31, 2020, from $277 million as of March 31, 2019.",4.0,0.6166462040999584,1.0,0.875,1.0
"How does the company plan to commercialize its product candidates, and what are the associated risks?","The company plans to commercialize its product candidates by either establishing its own commercialization capabilities or collaborating with third parties. If approved, the commercial success of any product candidates will depend on their market acceptance by physicians, patients, healthcare payors, and others in the medical community. 

The associated risks include the possibility that the company may not be able to successfully develop and market its product candidates. These risks include failure to identify viable product candidates, competition from alternative products, issues related to patents and exclusive rights, potential harmful side effects or lack of effectiveness, changes in market demand, inability to produce products at a reasonable cost, and the complexity of navigating the regulatory pathway. Additionally, the company may allocate resources to product candidates that ultimately fail, or license or purchase products that do not meet financial expectations, potentially leading to missed opportunities and the relinquishment of valuable rights.","The company plans to directly market and commercialize its product candidates by developing its own sales and marketing force. The associated risks include the potential for increased expenses, the inability to hire and retain qualified personnel, and the possibility of failing to build a successful commercial infrastructure.",4.0,0.6513750143752822,1.0,0.875,1.0
What are the potential impacts of the COVID-19 pandemic on the company's business operations?,"The COVID-19 pandemic poses several potential impacts on the company's business operations. It could disrupt the ability of the company, its employees, suppliers, and partners to operate at full capacity due to disease spread or government-mandated shutdowns. The pandemic has already led to temporary measures such as remote work and reduced in-person meetings, which may affect operational efficiency and collaboration. Additionally, the ongoing spread and mitigation efforts have created economic uncertainty, potentially impacting the company’s ability to secure financing on favorable terms. The pandemic has also affected global supply chains, clinical development, research and development, sales, and marketing activities. Moreover, the pandemic may impact consumer health and behavior, potentially reducing attendance at events and affecting sales of virtual items, and could hinder recruitment efforts. These factors contribute to significant uncertainty regarding the overall impact on business operations, financial condition, and results of operations.","The COVID-19 pandemic could disrupt the company's preclinical studies, clinical trials, and operations, potentially leading to delays in patient enrollment, difficulties in conducting trials, and interruptions in the supply chain for its product candidates.",4.5,0.6402802752486736,1.0,1.0,1.0
How does the company's reliance on third-party contract manufacturing organizations (CMOs) impact its operations?,"The company's reliance on third-party contract manufacturing organizations (CMOs) impacts its operations by creating dependency on external providers for the production of product candidates. This reliance exposes the company to risks such as delays or interruptions in supply if a CMO fails to provide sufficient quantities, maintain quality standards, or comply with regulatory requirements. Since the company lacks internal manufacturing infrastructure, any disruption could halt or delay preclinical studies, clinical trials, or commercialization efforts. Additionally, replacing CMOs may require significant time and expertise due to the limited number of qualified providers, and transitions could result in extended delays. The company also faces competitive risks, as CMOs may serve competitors, potentially compromising proprietary information or development timelines. Overall, this dependence increases operational risk and could negatively affect the company's financial performance and ability to bring products to market.","The company's reliance on CMOs exposes it to risks such as supply chain disruptions, potential manufacturing defects, and the inability to quickly transition to alternative suppliers if needed, which could delay product development and commercialization.",5.0,0.7407691542127537,1.0,1.0,1.0
What are the potential consequences of the company's failure to comply with healthcare laws and regulations?,"The company may face civil, criminal, and administrative penalties, damages, disgorgement, monetary fines, and possible exclusion from participating in Medicare, Medicaid, and other federal healthcare programs. Individuals may also face imprisonment, and the company could incur reputational harm, diminished profits, and future earnings. Additional reporting requirements or oversight may be imposed if the company enters into a corporate integrity agreement or similar arrangement to resolve noncompliance allegations. Operations could be curtailed or restructured, and defending against such actions could be costly and time-consuming, potentially diverting personnel from normal responsibilities. If third-party providers fail to comply, they may also face sanctions, including exclusion from government-funded programs, which could impact the company's ability to operate.","Failure to comply with healthcare laws and regulations could result in significant legal, financial, and reputational harm, including the imposition of civil, criminal, and administrative penalties, damages, monetary fines, and potential exclusion from participation in government healthcare programs.",5.0,0.8036504619006143,1.0,1.0,1.0
What are the risks associated with the company's reliance on collaborations and licensing arrangements?,"The risks associated with the company's reliance on collaborations and licensing arrangements include the need to expend substantial operational, financial, and management resources, potential dilution of shareholder ownership through the issuance of equity securities, and the assumption of significant actual or contingent liabilities. The company may not be able to control the resources or timing of development and commercialization efforts by strategic collaborators. These collaborators may choose less effective indications or trial designs, delay or terminate trials, provide insufficient funding, or abandon product candidates. They might also decide not to pursue further development or commercialization of products, or fail to commit adequate resources to marketing and distribution, limiting revenue potential. Disputes with collaborators could lead to delays, litigation, or arbitration that divert management's attention and consume resources. Collaborators may face financial difficulties, fail to maintain or defend intellectual property rights, or misuse proprietary information, potentially leading to litigation or invalidation of rights. Changes in a collaborator’s business strategy or business combinations could affect their ability to fulfill obligations. Additionally, collaborators might develop competing products independently or with others, including competitors. Furthermore, collaborations may be terminated, potentially eliminating rights to commercialize product candidates or requiring additional capital. There is also a risk of failure in developing acquired or licensed drugs, entering unfamiliar markets with strong competition, and disruption to ongoing business operations.","The company's reliance on collaborations and licensing arrangements exposes it to risks such as the potential for partners to shift priorities, terminate agreements, or fail to fulfill their obligations, which could delay or prevent the development and commercialization of its product candidates.",4.0,0.7994888064191261,1.0,1.0,1.0
What are the potential benefits of intrathecal administration of AAV9-based gene therapies?,"Intrathecal administration of AAV9-based gene therapies offers several key benefits. It allows for direct delivery of the therapy into the cerebrospinal fluid, enabling optimal biodistribution and cell transduction within the central nervous system. This method results in a lower required dose compared to intravenous administration, as the vector is confined to the CNS with limited uptake into off-target tissues. Additionally, because the central nervous system is immune-privileged, intrathecal delivery can be administered even in the presence of pre-existing antibodies to AAV, potentially avoiding immune-related complications. The approach also limits exposure to peripheral organs, allowing a higher concentration of the vector to reach the diseased tissue of interest. This targeted delivery enhances the likelihood of achieving transformative efficacy for patients with severe neurological diseases.","The potential benefits of intrathecal administration of AAV9-based gene therapies include optimal biodistribution and cell transduction within the CNS, administration even in the presence of pre-existing antibodies to AAV, and limited exposure to peripheral organs.",5.0,0.8400228287998798,1.0,1.0,1.0
How does the company plan to finance its cash needs in the future?,"The company plans to finance its future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements, and other marketing or distribution arrangements. It may also rely on existing cash and cash equivalents, including revenue from collaborations, until it can generate substantial product revenues. Additionally, the company expects to use funds from a Business Combination to support operations, product development, international expansion, and working capital. However, the availability of such funding depends on financial, economic, and market conditions, which may be affected by factors such as disruptions in financial markets and the impact of the COVID-19 pandemic.","The company plans to finance its cash needs through a combination of equity offerings, government or private party grants, debt financings, and license and collaboration agreements.",4.5,0.7365099453344516,1.0,1.0,1.0
What are the risks associated with the company's reliance on third-party suppliers for materials used in the manufacture of its product candidates?,"The company faces several risks associated with its reliance on third-party suppliers for materials used in the manufacture of its product candidates. These include limited control over pricing, availability, quality, and delivery schedules of raw materials. As a smaller company, the company has limited negotiation leverage and may receive lower priority compared to larger competitors, potentially affecting its access to necessary supplies. There is no assurance that suppliers will continue to provide required quantities or meet anticipated specifications and quality standards. 

Any disruption in the supply of limited or sole-sourced raw materials could significantly impair the ability to manufacture product candidates until an alternative source is identified and qualified. The company may not be able to find a sufficient alternative supply channel in a timely manner or on commercially reasonable terms. Performance failures by suppliers could delay the development and potential commercialization of product candidates, including disrupting supplies needed for clinical trials and regulatory approvals.

Additionally, the company relies on a small number of suppliers for manufacturing its product candidates. If a supplier experiences a business disruption, either within or outside the United States, or is acquired by a competitor, there is a risk that the supplier may discontinue manufacturing for the company. Changing third-party contract manufacturers could result in production delays, increased costs, and require significant effort and expertise due to limited qualified alternatives. Any failure of contract manufacturing organizations (CMOs) to deliver materials at acceptable quality levels, prices, or in sufficient quantities, or to comply with regulatory requirements such as cGMP, could halt, delay, or reduce the profitability of development and commercialization efforts.","Risks include limited control over pricing, availability, and quality of materials, potential supply interruptions, and increased costs if alternative suppliers need to be found, which could delay clinical trials and commercialization efforts.",5.0,0.7604935856606339,1.0,1.0,1.0
How does the company's dependence on collaboration with UT Southwestern affect its research and development programs?,"The company's reliance on its collaboration with UT Southwestern significantly impacts its research and development programs, as it currently depends exclusively on UT Southwestern for all preclinical research and development capabilities. This includes discovery, preclinical development activities such as IND-enabling non-clinical studies, and research-grade manufacturing. The collaboration is central to the company’s entire pipeline, with the UT Southwestern Gene Therapy Program under Drs. Steven Gray and Berge Minassian playing a critical role. UT Southwestern is primarily responsible for leading interactions with regulatory authorities, such as the FDA, and holding the Health Canada CTA for TSHA-101. Any failure, delay, or disagreement in fulfilling obligations under the UT Southwestern Agreement, or a breakdown in the relationship, could materially harm the company’s ability to advance product candidates. Additionally, the expiration of the research funding portion of the agreement in November 2021, subject to renewal, introduces uncertainty about continued access to these resources, potentially disrupting future development efforts.",The company's dependence on UT Southwestern for preclinical research and development programs could lead to delays or failures in its development efforts if UT Southwestern fails to fulfill its obligations or if there is a breakdown in collaboration.,5.0,0.7559398660573825,1.0,1.0,1.0
"How did the adoption of ASC Topic 842 affect the Company's Consolidated Balance Sheets as of August 3, 2019?","The adoption of ASC Topic 842 resulted in the recognition of operating lease liabilities and corresponding right-of-use assets on the Company's Consolidated Balance Sheets. These amounts were based on the present value of the remaining lease payments for existing operating leases. Additionally, the adoption led to the derecognition of certain property and equipment for properties that did not qualify for sale-leaseback accounting, as the Company was determined to be the accounting owner during the construction phase. Adjustments to prepaid rent, deferred rent, lease intangible assets/liabilities, and closed property reserves were also reflected in the balance sheet.",The adoption of ASC Topic 842 resulted in the recognition of operating lease liabilities with corresponding right-of-use assets of approximately the same amount based on the present value of the remaining lease payments for existing operating leases.,4.5,0.8234979123896665,1.0,1.0,1.0
How did the Company account for the Supervalu acquisition in terms of goodwill and intangible assets?,"The Company recorded the assets and liabilities of Supervalu at their estimated fair values as of the acquisition date in its Consolidated Financial Statements. Goodwill arising from the acquisition was attributed to the Supervalu Wholesale and legacy Company Wholesale reporting units, which were later reorganized into a single U.S. Wholesale reporting unit. No goodwill was allocated to the Retail reporting unit or any other reporting units. Goodwill represents the future economic benefits from synergies expected from combining the operations of the Company and Supervalu that could not be individually identified and separately recognized, and a substantial portion is deductible for income tax purposes.

Identifiable intangible assets acquired were recorded based on final valuations and are expected to be amortized on a straight-line basis over their estimated useful lives. The fair value of these intangible assets was determined using income approaches, with significant assumptions based on company-specific information and projections, which are considered Level 3 measurements. The identifiable intangible assets and liabilities have been revised to reflect the updated presentation of Retail within continuing operations, and the fair value estimates were finalized during the first quarter of fiscal 2020, primarily involving immaterial changes to income taxes and property and equipment.","In conjunction with the Supervalu acquisition, goodwill resulting from the acquisition was assigned to the previous Supervalu Wholesale reporting unit and the legacy Company Wholesale reporting unit. Identifiable intangible assets were also recorded based on final valuations, with expected useful lives ranging from 5 to 20 years.",5.0,0.83739821511886,1.0,1.0,1.0
How did the Company's defined benefit pension plans perform in fiscal 2020 in terms of contributions and obligations?,"The Company's defined benefit pension plans in fiscal 2020 experienced significant changes in obligations and contributions. The accumulated benefit obligation for domestic defined benefit pension plans decreased to $150.4 million from $171.1 million in the prior year. For international defined benefit pension plans, the accumulated benefit obligation increased to $815.1 million from $725.3 million. The net periodic benefit cost included pension settlement charges in fiscal 2020, primarily due to lump-sum payments resulting from executive retirements and resignations in the prior year, as well as cash distributions exceeding a prescribed threshold in fiscal 2020. Additionally, there was a settlement charge related to the final settlement of the Company's German pension plan. These factors led to the realization of a portion of pension losses within accumulated other comprehensive loss during the period the related liabilities were settled. Contributions to the plans were made to cover benefits paid directly from Meredith assets, which are included in both employer contributions and benefits paid.",No minimum pension contributions were required to be made under either the SUPERVALU INC. Retirement Plan or the Unified Grocers pension plan in fiscal 2020. The Company expected to contribute approximately $0.0 million to $5.3 million to its other defined benefit pension plans and postretirement benefit plans in fiscal 2021.,4.0,0.5314724413475208,1.0,0.875,1.0
How did the adoption of the CARES Act affect the Company's deferred tax assets and liabilities?,"The adoption of the CARES Act affected the Company's deferred tax assets and liabilities by modifying certain provisions of the 2017 Tax Act. Specifically, the CARES Act allowed for the carryback of net operating losses (NOLs) generated in 2018 through 2020 for five years, a provision that had previously been disallowed under the Tax Reform Act. This change could have a material impact on the value of deferred tax assets, potentially resulting in significant one-time charges and increasing future U.S. tax expense.","The CARES Act allowed the Company to carry back net operating losses, resulting in a tax benefit of approximately $39.5 million. This was recorded as a current tax receivable in the Consolidated Balance Sheet as of August 1, 2020.",4.0,0.7405083693853942,1.0,0.75,1.0
How did the Company's decision to reclassify Retail operations from discontinued to continuing operations affect the financial statements?,"The Company's decision to reclassify Retail operations from discontinued to continuing operations in the fourth quarter of fiscal 2020 affected the financial statements by including Retail’s results of operations, financial position, cash flows, and related disclosures within continuing operations. This reclassification required the restatement of prior periods to conform to the current period presentation, ensuring that Retail was presented as part of continuing operations for all periods. As a result, amounts previously reported under discontinued operations were incorporated into the consolidated financial statements for all relevant periods.","The reclassification resulted in the inclusion of Retail’s results of operations, financial position, and cash flows within continuing operations for all periods, affecting the presentation but not the underlying financial performance or position.",5.0,0.7898730908905223,1.0,0.875,1.0
"What was the total net revenue for Quest Diagnostics in 2020, and how did it compare to the previous year?","The total net revenue for Quest Diagnostics in 2020 was $9.4 billion, representing a 22.1% increase compared to the prior year.","The total net revenue for Quest Diagnostics in 2020 was $9.4 billion, which was up 22.1% from the previous year.",5.0,0.9914793978796328,1.0,1.0,1.0
How did the COVID-19 pandemic impact Quest Diagnostics' testing volume and revenues in 2020?,"The COVID-19 pandemic had a mixed impact on Quest Diagnostics' testing volume and revenues in 2020. While there was a decline in testing volume in the base business—driven by factors such as reduced physician office visits, cancellations of elective procedures, and government policies aimed at reducing transmission—this was more than offset by increased demand for COVID-19 molecular and antibody testing. As a result, total testing volume increased by 6.6% compared to the prior year, with organic growth driven largely by COVID-19 testing. Revenues also rose significantly, with DIS revenues increasing by 23.4% year-over-year, primarily due to the surge in demand for COVID-19 testing. Additionally, revenue per requisition increased by 16.2%, largely due to higher contributions from COVID-19 molecular testing. Despite these gains in testing volume and revenue, DS revenues decreased by 7.0% compared to the prior year, reflecting the broader negative impact of the pandemic on certain segments of the business. Overall, the company saw a substantial increase in total net revenues of $9.4 billion, up 22.1% from the prior year.","The COVID-19 pandemic led to a decline in testing volume in Quest Diagnostics' base business by 11.4% in 2020, but this was more than offset by increased demand for COVID-19 molecular and antibody testing, which drove a 23.4% increase in revenues in the DIS business.",5.0,0.8274783626323179,1.0,1.0,1.0
How did Quest Diagnostics' capital expenditures and investments in technology and infrastructure evolve in 2020?,"Quest Diagnostics did not provide specific details on capital expenditures or investments in technology and infrastructure for the year 2020 in the provided context. However, it was stated that the company estimated investing approximately $350 million to $400 million in capital expenditures during 2021 to support and grow existing operations, with a focus on information technology, laboratory equipment and facilities, including COVID testing equipment and the completion of a new multi-year laboratory construction in New Jersey, as well as investments in advanced diagnostics and consumer growth strategies. There is no mention of how these expenditures evolved from 2020 to 2021, nor is there information on the exact capital expenditures made in 2020.","Quest Diagnostics invested approximately $350 million to $400 million in capital expenditures in 2020, focusing on investments in information technology, laboratory equipment and facilities, including COVID testing equipment, and completion of a new multi-year laboratory construction in New Jersey.",3.0,0.5511594437731905,1.0,0.75,1.0
"What were the key financial covenants associated with Quest Diagnostics' credit facilities, and how were they amended in 2020?","The key financial covenant associated with Quest Diagnostics' credit facilities was the leverage ratio, which was defined as the ratio of total debt to EBITDA. In April 2020, the company amended its credit facility to provide increased covenant flexibility. As part of this amendment, the leverage ratio covenant was temporarily increased during a specified period. After this period, the covenant reverted to no more than 3.5 times EBITDA. 

During the period of the increased covenant, the credit agreement included additional limitations and restrictions, such as limits on the repurchase of the company’s common stock, the amount of funds available for business acquisitions, the incurrence of secured indebtedness, and the payment of dividends. The amendment allowed the company flexibility in meeting financial obligations during a period of economic uncertainty while maintaining overall financial discipline.","The key financial covenant associated with Quest Diagnostics' credit facilities was the maintenance of a financial leverage ratio. In 2020, the Company amended the Credit Facility to provide increased covenant flexibility, increasing the leverage ratio covenant temporarily to provide more flexibility during the COVID-19 pandemic.",4.5,0.8317605776248641,1.0,1.0,1.0
What are the primary risks related to the company's financial condition and capital requirements?,"The primary risks related to the company's financial condition and capital requirements include the financial condition of clients and counterparties, concentrations of credit and market risk, increases in the allowance for credit losses, and changes in the assessment of loan portfolios. Additionally, the company faces risks related to the ability to meet funding requirements, adverse changes to credit ratings, financial difficulties or credit downgrades of mortgage bond insurers, and the potential need to adjust the timing of capital expenditures due to financing requirements. The availability of additional capital may be impacted by market volatility, economic conditions, and regulatory changes, with potential restrictions from debt financing that could limit operational flexibility. If the company cannot comply with covenants or service its debt, it may be forced to reduce investments, sell assets, restructure operations, or face foreclosure, which could materially adversely affect its business.","The company faces risks including a limited operating history, significant ongoing losses, and the need for additional funding to expand commercialization and development efforts. Failure to obtain necessary capital could force the company to delay or terminate product commercialization or development efforts.",2.5,0.6184075623381909,1.0,0.875,1.0
How does the company's reliance on a single supplier for key components impact its operations?,"The company's reliance on a single supplier for key components poses a significant risk to its operations. If the supplier is lost or unable to fulfill orders or meet manufacturing specifications, the company may not be able to identify or transition to alternative suppliers in a timely manner or on acceptable terms. This could lead to interruptions in production, delays in product development, or an inability to commercialize products, especially since the company does not have long-term contracts with these suppliers. Additionally, the time and cost involved in qualifying new suppliers and ensuring comparable quality could result in significant expenses and operational disruptions. The loss of a critical supplier could also impact the company’s financial performance, reputation, and market competitiveness. While the company currently maintains significant inventory to mitigate this risk, there is no assurance that it can continue to do so in the future.","The company's reliance on a single supplier, TSMC, for manufacturing and supplying wafers used in its probes poses a risk if TSMC fails to fulfill obligations or performs unsatisfactorily. This could negatively affect the company's ability to source its devices and potentially impact cash flows due to minimum purchase obligations.",4.5,0.621853832673045,1.0,1.0,1.0
What are the cybersecurity risks associated with the company's operations?,"The company faces cybersecurity risks including vulnerability to cyberattacks, hacking, and other security threats that could lead to unauthorized access, data breaches, or manipulation of information. These risks extend to the company’s electronic platforms, networks, and databases, as well as those of third-party service providers, participants, and external market infrastructures. Potential consequences include the wrongful disclosure, destruction, or misuse of confidential or sensitive data—such as proprietary information, client portfolios, or financial data—resulting in operational disruptions, litigation, regulatory actions, reputational damage, and potential liability. Specific threats include computer viruses, ransomware, denial-of-service attacks, social engineering, firewall or encryption failures, and system failures due to natural disasters, terrorism, or war. The increased reliance on technology and cloud-based systems, especially due to changes in work practices during the COVID-19 pandemic, heightens these risks and underscores the importance of secure data transmission and system reliability. Any failure in cybersecurity measures could disrupt operations and harm the business.","The company faces risks of cybersecurity incidents that could result in unauthorized access, data breaches, or operational disruptions, potentially leading to harm to customers, business interruptions, legal liabilities, reputational damage, and increased costs for remediation and protection.",4.5,0.6727852795588782,1.0,1.0,1.0
What are the risks associated with the company's reliance on open source software?,"The company faces several risks associated with its reliance on open source software. These include the potential for competitors to create similar products more easily if proprietary code is made publicly available, which could lead to a loss of product sales and revenue. There is also a risk of legal claims from third parties asserting ownership of open source software or alleging non-compliance with open source licensing terms. Additionally, the use of open source software may expose the company to security risks due to the public availability of such software, making it easier for hackers to compromise the technology platform and systems.

Furthermore, open source licenses often require the company to release source code for modifications or derivative works, and in certain cases, the company might be compelled to make its proprietary code available to the public if it combines proprietary software with open source software. This could undermine the company's competitive advantage. The legal interpretation of open source licenses in the U.S. remains uncertain, increasing the risk of unanticipated conditions or restrictions on commercialization. Even with monitoring processes in place, there is no assurance that these measures will effectively control the use of open source software, and failure to comply with license terms could result in the need to obtain costly licenses, re-engineer products, discontinue sales, or disclose proprietary code—any of which could negatively impact the business, operating results, and financial condition.","Using open source software may expose the company to risks such as requirements to disclose source code, potential infringement claims, and the possibility that competitors could use the same open source software to create similar products. Failure to comply with open source licenses could restrict the company's ability to sell its products and lead to legal challenges.",5.0,0.8106106339684898,1.0,1.0,1.0
How does Brandywine Realty Trust account for acquisitions of real estate that do not meet the definition of a business?,"Brandywine Realty Trust accounts for acquisitions of real estate that do not meet the definition of a business by recording them as asset acquisitions. These acquisitions are measured at the fair value of the assets acquired and liabilities assumed, with the consideration transferred. The transaction is not treated as a business combination, and any goodwill or other intangible assets are not recognized. Instead, the cost is allocated to the individual assets and liabilities based on their fair values at the acquisition date. This approach aligns with the accounting standards for asset acquisitions rather than business combinations.",Acquisitions of real estate that do not meet the definition of a business are accounted for as asset acquisitions. The acquisition consideration (including acquisition costs) is allocated to the individual assets acquired and liabilities assumed on a relative fair value basis.,5.0,0.6617753821705247,1.0,0.25,1.0
What method does Brandywine Realty Trust use to depreciate its buildings and improvements?,Brandywine Realty Trust depreciates its buildings and improvements over lives ranging from the life of the lease to 55 years.,Brandywine Realty Trust uses the straight-line method to depreciate its buildings and improvements over lives ranging from the life of the lease to 55 years.,4.0,0.9156805036695339,1.0,1.0,1.0
How does Brandywine Realty Trust determine the fair value of its real estate investments for impairment assessments?,"Brandywine Realty Trust determines the fair value of its real estate investments for impairment assessments by evaluating the reasonableness of significant assumptions related to estimated undiscounted future cash flows. These assumptions include market rental rates, capitalization rates, and recent sales data for comparable real estate investments. The assessment considers the past performance of the asset and whether the assumptions are consistent with evidence obtained in other areas of the audit. Additionally, management's assessment of indications of other than temporary impairment in investments in unconsolidated real estate ventures involves considering market economic conditions, past performance of the asset, and evidence obtained in other areas of the audit.","Brandywine Realty Trust determines the fair value of its real estate investments for impairment assessments using estimated undiscounted future cash flows expected to be generated from the operations and eventual disposition of the assets over, in most cases, a 10-year hold period. The estimates consider assumptions including market rental rates, capitalization rates, and recent sales data for comparable real estate investments.",4.0,0.8352136992442856,1.0,0.875,1.0
What are the key factors considered by Brandywine Realty Trust in its assessment of whether to consolidate a variable interest entity (VIE)?,"Brandywine Realty Trust considers several key factors in assessing whether to consolidate a variable interest entity (VIE). These include determining whether the entity is the primary beneficiary of the VIE by evaluating whether it has the power to direct the activities that are most significant to the VIE's economic performance. This power is assessed based on the VIE's purpose and design, risks passed through to investors, voting interests, management and service agreements, involvement in the initial design of the VIE, and any explicit or implicit financial guarantees. The assessment also involves evaluating the variable interests held by the entity, including the terms, characteristics, and size of those interests, as well as the entity's involvement in the VIE and its market-making activities related to the interests. The entity assesses both individually and in aggregate whether it has the obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE. The determination of whether the variable interest is significant requires judgment, and the entity reassesses its role as the primary beneficiary on an ongoing basis, typically quarterly, considering changes in governing documents or other circumstances.","Brandywine Realty Trust considers whether it is the primary beneficiary of a VIE, which involves having both the power to direct the activities that most significantly impact the VIE's economic performance and the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE.",5.0,0.7508128879881453,1.0,1.0,1.0
How has the COVID-19 pandemic impacted the company's underwriting results in 2020?,"The COVID-19 pandemic negatively impacted the company's underwriting results in 2020, primarily through pandemic-related catastrophe losses at the reinsurance segment and, to a lesser extent, at RSUI. These losses contributed to an underwriting loss in 2020 compared to an underwriting profit in 2019. Additionally, the casualty segment experienced a decline in underwriting profit due to pandemic-related catastrophe losses.","The COVID-19 pandemic significantly impacted the company's underwriting results in 2020 by causing an underwriting loss due to pandemic-related catastrophe losses, which included event cancellation coverage for conferences and sporting events, business interruption claims, and related estimated legal expenses.",4.0,0.8402194089265993,1.0,0.875,1.0
What measures has the company taken to mitigate the impact of catastrophe events?,"The company maintains insurance coverage at levels it believes are appropriate for its business to help mitigate the impact of catastrophe events. Additionally, the company has disaster recovery and business continuity plans in place to address potential disruptions. However, these plans may not be sufficient in the event of a serious disaster or similar incident, and the company acknowledges that insurance proceeds may not be adequate to cover all damages and losses, especially in cases involving catastrophic events, inflation, or changes in building codes and ordinances.","The company has taken several measures to mitigate the impact of catastrophe events, including considering catastrophe risks in underwriting and pricing decisions, purchasing reinsurance, monitoring and modeling accumulated exposures, and managing exposure in key geographic zones and product lines prone to catastrophe events.",3.0,0.6391574701190212,1.0,0.875,1.0
"How does the company account for prior accident year loss reserve development, and what impact does it have on financial results?","The company accounts for prior accident year loss reserve development as a component of net loss and LAE, which reflects the difference between actual loss emergence and the loss emergence patterns assumed in earlier periods. This development can be either favorable or unfavorable and is included in the financial results for 2020, 2019, and 2018.

Favorable prior accident year loss reserve development occurs when actual losses are lower than initially anticipated, leading to a reduction in reserves. This can be driven by factors such as favorable outcomes from specific events (e.g., Typhoon Hagibis, wildfires in California, Hurricane Harvey) or general loss emergence patterns. In some cases, favorable developments are partially offset by unfavorable developments related to other events, such as hurricanes or typhoons in different accident years.

Unfavorable prior accident year loss reserve development arises when actual losses exceed expectations, resulting in higher reserves. This impact is noted in the financial results as an increase in net loss and LAE. The extent of this impact varies depending on the accident year and the nature of the underlying events.

The favorable prior accident year loss reserve development contributes positively to financial results by reducing net losses, while unfavorable developments increase net losses. The overall effect depends on the net balance of favorable and unfavorable developments across different accident years and business lines.","The company accounts for prior accident year loss reserve development by periodically analyzing and adjusting the expected ultimate cost of liabilities to reflect favorable or unfavorable development in loss experience and new information. Adjustments to these reserves, both favorable and unfavorable, are reflected in the financial results of the periods in which these adjustments are made.",4.5,0.6545606814729418,1.0,0.875,1.0
"What is the role of non-GAAP financial measures in the company's financial analysis, and how are they reconciled with GAAP measures?","Non-GAAP financial measures, such as underwriting profit and adjusted earnings before income taxes, are used in the company's financial analysis to present results in a manner that management believes is most meaningful and useful to investors, analysts, rating agencies, and other stakeholders. These measures are included alongside GAAP financial statements to provide additional insights into performance, but they are not intended to be considered in isolation or as a substitute for GAAP financial information. The company acknowledges that these non-GAAP measures may differ from similar measures used by other companies, which limits their usefulness for comparison purposes. While the provided context does not include specific reconciliation details, it emphasizes that such measures are supplementary and should be viewed in conjunction with GAAP financial statements.","Non-GAAP financial measures, such as underwriting profit and adjusted earnings before income taxes, provide additional information to investors and analysts by highlighting specific aspects of performance that management believes are meaningful. These measures are not a substitute for GAAP measures and are reconciled with the most comparable GAAP financial measures in the financial statements.",4.5,0.6430630676249325,1.0,0.875,1.0
How has the company's capital structure and liquidity position been managed to support its operations during the financial year 2020?,"The company maintained a strong focus on managing its capital and liquidity positions throughout the financial year 2020 to support operations amid the challenges posed by the COVID-19 pandemic. It ensured that it remained ""well-capitalized"" as of December 31, 2020, with a Common Equity Tier 1 capital ratio of 12.47%, exceeding the regulatory minimum requirement of 4.50%. The company continued to access routine short-term funding sources, such as borrowings and repurchase agreements, and assessed longer-term funding options to sustain its financial flexibility. 

To further strengthen its position, the company conducted a range of internal stress tests evaluating various COVID-19-related scenarios, confirming the resilience of key balance sheet metrics including capital adequacy and liquidity. These efforts were supported by active management of risk appetite, improved data quality, and timely decision-making based on early warning indicators. Additionally, enhanced monitoring and governance practices were implemented to ensure models performed as intended and adjustments were made where necessary to reflect management judgment. This comprehensive approach enabled the company to provide increasing levels of financial support to customers while maintaining operational stability.","The company has managed its capital structure and liquidity position by maintaining a relatively liquid financial position at its unrestricted holding companies, issuing new senior notes, and utilizing credit facilities. These measures have ensured adequate funds for operational needs, including acquisitions and share repurchases, despite challenges posed by the COVID-19 pandemic.",4.5,0.625220660588945,1.0,1.0,1.0
What are the key assumptions used in the valuation of Huntington Bancshares Incorporated's mortgage servicing rights (MSRs)?,"The key assumptions used in the valuation of Huntington Bancshares Incorporated's mortgage servicing rights (MSRs) include those related to the discounted future cash flow model, which estimates fair value since MSRs do not trade in an active, open market with readily observable prices. These assumptions are sensitive to changes in interest rates, as expected future net servicing income depends on the projected outstanding principal balances of the underlying loans. The valuation is also influenced by the level of prepayments, which significantly impacts the projected principal balances. Specific assumptions may include factors affecting prepayment speeds, interest rate movements, and the discount rate used in the cash flow model. Changes in these assumptions can have a significant impact on the estimated fair value of MSRs.","The key assumptions used in the valuation of Huntington Bancshares Incorporated's MSRs include the discount rate, prepayment speed, and the servicing fee. These assumptions are used in a discounted future cash flow model to estimate the fair value of MSRs.",4.0,0.881567485022149,1.0,0.875,1.0
What is the significance of the allowance for credit losses (ACL) in the context of Huntington Bancshares Incorporated's financial reporting?,"The allowance for credit losses (ACL) is a critical component of Huntington Bancshares Incorporated's financial reporting, reflecting the estimated amount of losses inherent in its loan and lease portfolio. The adoption of ASU 2016-13, which introduced the current expected credit loss (CECL) model, significantly impacted the measurement and disclosure of the ACL. This change resulted in a $393 million increase in the total ACL at adoption, representing a 44% rise from the 2019 year-end level of $887 million. The new model requires the use of relevant information, including historical experience, current conditions, and reasonable and supportable forecasts, to estimate expected credit losses. This approach emphasizes forward-looking assessments, as seen in the increase in the assumed unemployment rate from 3.75% in the January 1, 2020 adjustment to 7.20% for the December 31, 2020 calculation, which contributed to a $979 million increase in the ACL. The adoption also necessitated enhanced quantitative and qualitative disclosures about credit risk and the monitoring of portfolio credit quality. Additionally, the transition involved a cumulative-effect adjustment to retained earnings, highlighting the significant impact on the company's balance sheet and financial performance.","The allowance for credit losses (ACL) is significant in Huntington Bancshares Incorporated's financial reporting as it represents the amount set aside to cover potential credit losses on financial assets measured at amortized cost, including loan receivables and held-to-maturity debt securities. The ACL is deducted from the amortized cost basis of a financial asset or a group of financial assets so that the balance sheet reflects the net amount Huntington expects to collect.",5.0,0.6995758182475196,1.0,1.0,1.0
How does Huntington Bancshares Incorporated manage its interest rate risk through derivative financial instruments?,"Huntington Bancshares Incorporated manages its interest rate risk through the use of derivative financial instruments primarily for asset and liability management purposes. These derivatives are used in balance sheet hedging activities, which are generally structured to qualify for hedge accounting treatment and can be classified as either fair value hedges or cash flow hedges. Fair value hedges are employed to offset changes in the fair value of existing fixed-rate debt and investment securities due to fluctuations in market interest rates. Cash flow hedges are used to modify the interest rate characteristics of designated commercial loans, aiming to mitigate the impact of future cash flow changes caused by market interest rate fluctuations. The net amounts receivable or payable on these derivative contracts are accrued as adjustments to either interest income or interest expense. Additionally, amounts related to the amortization of floor and forward-starting floor premiums, changes in the fair value of economic hedges, and terminated hedges reclassified from accumulated other comprehensive income are also recorded as adjustments to interest income.","Huntington Bancshares Incorporated manages its interest rate risk through the use of derivative financial instruments, principally interest rate swaps, caps, floors, and collars. These instruments provide flexibility in adjusting Huntington’s sensitivity to changes in interest rates without exposure to loss of principal and higher funding requirements. They are used in asset and liability management activities to protect against the risk of adverse price or interest rate movements.",5.0,0.8343909384046578,1.0,1.0,1.0
What was the total acquisition-date fair value of consideration transferred in the Sprint Merger?,The total acquisition-date fair value of consideration transferred in the Sprint Merger was $40.8 billion.,The total acquisition-date fair value of consideration transferred in the Sprint Merger was $40.8 billion.,5.0,1.0,1.0,0.0,1.0
How much did T-Mobile pay in Commitment Letter fees to certain financial institutions in connection with the Merger?,T-Mobile paid $355 million in Commitment Letter fees to certain financial institutions in connection with the Merger.,T-Mobile paid $355 million in Commitment Letter fees to certain financial institutions in connection with the Merger.,5.0,1.0,1.0,1.0,1.0
"What was the impact of the new credit loss standard on the allowance for credit losses as of January 1, 2020?","On January 1, 2020, the adoption of the new accounting standard resulted in a $10.4 million increase in the allowance for credit losses. This increase was comprised of a net increase to the allowance for loan losses and an adjustment to the reserve for unfunded lending commitments.","The new credit loss standard resulted in an increase to the allowance for credit losses of $91 million as of January 1, 2020.",3.0,0.84653869532289,1.0,1.0,1.0
"What was the total principal amount of Senior Secured Notes issued by T-Mobile USA on April 9, 2020?",$19.0 billion,"The total principal amount of Senior Secured Notes issued by T-Mobile USA on April 9, 2020 was $19.0 billion.",5.0,0.566750373288547,1.0,1.0,1.0
What are the primary risks associated with investing in the shares of the company as outlined in the financial report?,"The primary risks associated with investing in the shares of the company include the fact that it is a relatively new company with no operating history, which increases uncertainty and risk for investors. The company is a non-diversified, closed-end management investment company regulated as a BDC, and the adviser has not previously offered a non-traded business development company, so there is no prior track record of success. Additionally, the company's Board of Trustees has the authority to modify or waive operating policies and investment strategies without prior notice or shareholder approval, which could have adverse effects on financial performance. These risks could lead to material adverse impacts on the company's business, financial condition, and results of operations, potentially resulting in a decline in the net asset value of the shares and loss of investment.","The primary risks include the company's lack of an operating history, potential for significant fluctuations in quarterly results, and the risk of not achieving investment objectives due to market conditions and competition.",4.5,0.6506208933235252,1.0,0.75,1.0
How does the company's status as a non-diversified investment company under the 1940 Act affect its investment strategy?,"The company's status as a non-diversified investment company under the 1940 Act allows it to invest a greater proportion of its assets in securities of a single issuer compared to a diversified investment company. This means the company is not required to limit its investments to 5% of its total assets in securities of any one issuer or 10% of the outstanding voting securities of any one issuer. As a result, the company can concentrate its investments in a smaller number of issuers or within specific industries, which may lead to greater fluctuations in its net asset value in response to changes in the financial condition or market perception of those issuers.","As a non-diversified investment company, the company is not limited in the proportion of assets it may invest in securities of a single issuer, which may increase the volatility of its NAV and make it more susceptible to economic or regulatory occurrences.",5.0,0.8008818964346766,1.0,1.0,1.0
What measures does the company take to mitigate the risk of unrealized losses on its portfolio?,"The company takes measures to mitigate the risk of unrealized losses on its portfolio by securing loans with a security interest in the available assets of its portfolio companies. This includes attempting to obtain and properly perfect liens on these assets to help protect against credit risk. However, there is no assurance that the company will successfully obtain or perfect these liens, and the value of the collateral may fluctuate or be difficult to sell, which can impact the effectiveness of this risk mitigation strategy.","The company values its investments at market value or fair value as determined in good faith by its Board of Trustees, considering various factors such as the estimated enterprise value of a portfolio company, the nature and realizable value of collateral, and the portfolio company’s ability to make payments based on its earnings and cash flow.",3.0,0.4149949009339918,1.0,0.875,1.0
How does the company plan to address the risk of fluctuations in interest rates affecting its cost of capital and net investment income?,"The company may use interest rate risk management techniques to limit its exposure to interest rate fluctuations, including various interest rate hedging activities permitted by the 1940 Act. However, the Investment Advisor does not have significant experience with these techniques and has not implemented them to a significant extent. The company may hedge against the risk of adverse movement in interest rates in its short-term and long-term borrowings relative to its portfolio of assets, but it is not required to do so. If hedging activities are engaged in, they may limit the ability to benefit from lower interest rates on the hedged portfolio, and adverse developments from interest rate changes or hedging transactions could materially affect the business, financial condition, and results of operations.","The company may use interest rate risk management techniques, including various interest rate hedging activities to the extent permitted by the 1940 Act, to limit its exposure to interest rate fluctuations.",4.0,0.8742328197707193,1.0,0.875,1.0
What are the potential consequences if the company fails to maintain its status as a Business Development Company (BDC)?,"If the company fails to maintain its status as a Business Development Company (BDC), it could be subject to regulation as a registered closed-end investment company under the 1940 Act. This would significantly decrease its operating flexibility and could require it to restrict borrowings, reduce leverage, sell securities, and engage in other activities that are permitted under BDC regulations. Additionally, failure to comply with the requirements of the 1940 Act could lead to enforcement actions by the SEC. Such a loss of status would have a material adverse effect on the company's business, financial condition, and results of operations.","If the company fails to maintain its BDC status, it could be regulated as a registered closed-end investment company under the 1940 Act, subjecting it to more regulatory restrictions and potentially decreasing its operating flexibility.",5.0,0.9117590655702147,1.0,1.0,1.0
How does the company manage the risk of default by portfolio companies on their debt obligations?,"The company manages the risk of default by portfolio companies through several strategies. It monitors financial and operating covenants imposed on its investments to detect early signs of distress. In the event of a default, the company may pursue recovery actions or negotiate new terms with the defaulting company. The company also holds secured assets that can be foreclosed upon to mitigate losses. Additionally, it seeks to manage cash flow by avoiding extensions or restructurings of loans unless necessary, as these can negatively impact financial performance. The company acknowledges that due to the illiquid nature of its investments, it may not be able to exit or dispose of its investments quickly if a portfolio company's actions are detrimental. Furthermore, it considers the possibility of bankruptcy-related risks, where a court may recharacterize its debt as subordinated if managerial assistance was provided or based on other circumstances, which could affect recovery.",The company may incur expenses to seek recovery upon default or to negotiate new terms with defaulting portfolio companies. It also relies on the investment expertise and network of business contacts of the Adviser and its affiliates to monitor and service its investments.,4.5,0.6171698888135868,1.0,0.875,1.0
What are the implications of Intec Israel being characterized as a passive foreign investment company (PFIC) for U.S. shareholders?,"If Intec Israel is classified as a passive foreign investment company (PFIC), U.S. shareholders may face adverse U.S. federal income tax consequences. These could include the treatment of all or a portion of any gain on disposition as ordinary income, the application of a deferred interest charge on such gain and on the receipt of certain dividends, and the obligation to comply with certain reporting requirements. Additionally, once classified as a PFIC, the company will continue to be treated as such for all subsequent years in which a U.S. Holder owns shares or American Depositary Shares (ADSs), regardless of whether it continues to meet the PFIC test, unless the U.S. Holder makes a specified election after the company ceases to be a PFIC. The classification is determined annually based on the company’s income and asset composition, and changes in business plans or market conditions may affect its status from year to year.","U.S. shareholders of a PFIC may face adverse tax consequences, including having gains classified as ordinary income, loss of preferential tax rates on dividends, and application of interest charges to distributions and share sales.",4.5,0.7367497978478158,1.0,1.0,1.0
How did the adoption of the Current Expected Credit Loss (CECL) model affect the Company's financial statements in 2020?,"The adoption of the Current Expected Credit Loss (CECL) model in 2020 primarily affected the calculation of expected credit losses on gross customer trade accounts receivable. The transition was implemented using a modified retrospective approach, with the impact of the initial adoption recorded through retained earnings at January 1, 2020, and no restatement of prior periods. This shift from an incurred loss approach to a lifetime expected loss methodology resulted in a change in how the allowance for credit losses was calculated. However, the adoption of ASC 326 and the application of CECL did not have a material impact on the Company's financial statements. The methodology now relies on probability-weighted forecasts incorporating macroeconomic variables and forward-looking projections to estimate lifetime expected credit losses.","Upon adoption of CECL on January 1, 2020, the Company recorded a cumulative effect adjustment to decrease retained earnings by $25,018, with corresponding adjustments to the allowance for credit losses on loans and unfunded commitments.",4.0,0.6291231337287986,1.0,1.0,1.0
What significant mergers and acquisitions did FB Financial Corporation complete in 2020?,"FB Financial Corporation completed the mergers of FNB Financial Corp. on February 14, 2020, and Franklin Financial Network, Inc. on August 15, 2020.","FB Financial Corporation completed mergers with Franklin Financial Network, Inc. on August 15, 2020, and FNB Financial Corp. on February 14, 2020.",5.0,0.9889954882097638,1.0,1.0,1.0
How did the Company's allowance for credit losses change in 2020 due to the acquisitions of Franklin and FNB Financial Corp.?,"The Company's allowance for credit losses increased by $77,653 as of the August 15, 2020 acquisition date due to loans acquired from Franklin and by $4,494 as of the February 14, 2020 acquisition date due to loans acquired from Farmers National.","The acquisitions of Franklin and FNB Financial Corp. increased the allowance for credit losses by $77,653 and $4,494, respectively, as of their acquisition dates.",4.0,0.8125965056604465,1.0,0.875,0.5
"What was the impact of the PPP loans on the Company's loan portfolio as of December 31, 2020?","The PPP loans had a significant impact on the Company's loan portfolio as of December 31, 2020. The Bank actively participated in the Paycheck Protection Program, which led to an increase in loan volumes. A substantial portion of these loans was expected to remain on the balance sheet for up to two years, contributing to higher loan volumes. Additionally, the loans earned interest at a fixed rate of 1 percent and primarily had a two-year term, with a maturity extension to five years for loans disbursed on or after June 5, 2020, or through mutual agreement for earlier loans. The Bank pledged securities to the Federal Reserve's Discount Window to facilitate the funding of these loans, resulting in an increase in pledged securities compared to the previous year. Furthermore, as of December 31, 2020, no allowance for loan losses was necessary for the $6.7 billion in outstanding PPP loans, as they were 100% guaranteed by the SBA. This assurance reduced credit risk related to these loans.","As of December 31, 2020, the Company had $212,645 of loans originated as part of the PPP, which are federally guaranteed and have minimal credit risk associated with them.",4.0,0.6777115960487672,1.0,1.0,1.0
How did the Company's investment in Federal Home Loan Bank (FHLB) stock affect its financial position?,"The Company's investment in Federal Home Loan Bank (FHLB) stock is accounted for at cost because the stock does not have a readily determinable fair value due to restricted ownership and the absence of a market. These investments are evaluated for impairment, but they are not carried at fair value. As a result, changes in the fair value of FHLB stock do not directly impact the Company's financial position through earnings or comprehensive income unless an impairment is identified. The carrying value remains at cost unless impairment is recognized, which would affect the financial position by reducing the value of the investment on the balance sheet.","The Bank accounts for its investments in FHLB stock at cost and evaluates them for impairment. As of December 31, 2020, the investment in FHLB stock was carried at cost and evaluated for impairment.",4.5,0.7042766599485824,1.0,0.75,1.0
What were the quarterly earnings per share (EPS) for FB Financial Corporation in 2020?,The provided context does not contain information about the quarterly earnings per share (EPS) for FB Financial Corporation in 2020.,"The quarterly EPS for FB Financial Corporation in 2020 were as follows: Q1 - $0.71, Q2 - $0.95, Q3 - $1.00, and Q4 - $1.11.",1.0,0.7909793487333123,1.0,0.375,1.0
How does the ongoing COVID-19 pandemic potentially affect the company's operations?,"The ongoing COVID-19 pandemic could disrupt the company's operations by affecting the health and productivity of its employees, potentially leading to reduced efficiency due to remote work arrangements and collaboration challenges. It may also impact third-party partners, suppliers, and regulatory agencies, which could hinder the timely delivery of products or services and the execution of business strategies. Travel restrictions, quarantine measures, and government-imposed shutdowns may interrupt business activities, particularly in regions where the company or its partners operate. Additionally, the pandemic may cause economic disruptions, including recession and high unemployment, which could affect consumer demand and the company's financial performance. While some companies have implemented precautionary measures to mitigate risk, the full extent of the impact remains uncertain and could be material across various aspects of operations.","The COVID-19 pandemic could materially affect the company's operations, including clinical development, sales and marketing efforts, supply chain operations, research and development activities, and fundraising activities, potentially leading to delays or disruptions.",4.5,0.5768690632617127,1.0,1.0,1.0
How does the company's reliance on third-party manufacturers for the production of its product candidates pose risks?,"The company's reliance on third-party manufacturers for the production of its product candidates poses several risks. It increases the likelihood that sufficient quantities of the product candidates may not be available on a timely basis or at all, or that they may not be produced at an acceptable cost or quality, which could delay, prevent, or impair development or commercialization efforts. The company may be unable to establish or maintain agreements with these manufacturers on favorable terms, and even if agreements are in place, there is a risk that manufacturers may breach contracts, fail to comply with regulatory requirements such as cGMP, or fail to produce according to specifications or schedules. Additionally, third-party manufacturers could terminate or not renew agreements at inconvenient times, potentially leading to costly disruptions. There is also a risk of misappropriation or disclosure of proprietary information, including trade secrets and know-how. Furthermore, the company does not have control over the operational stability of these manufacturers, which could be affected by factors such as regulatory enforcement actions, financial distress, or disruptions from events like the COVID-19 pandemic. Lastly, changes to the manufacturing process require prior regulatory approval, adding complexity and potential delays.","Reliance on third-party manufacturers carries risks such as potential breaches of manufacturing agreements, termination of agreements, reliance on the third party for regulatory compliance, quality assurance, and potential supply disruptions.",5.0,0.825457107298316,1.0,1.0,1.0
What are the potential impacts of the company's limited operating history as a pharmaceutical company?,"The company's limited operating history may make it difficult to evaluate its future viability, as it has not demonstrated the ability to complete large-scale clinical trials, obtain marketing approval, manufacture commercial products, or conduct sales and marketing activities. This lack of experience in commercializing pharmaceutical products reduces the accuracy of predictions about its success. Additionally, the company may face unforeseen expenses, difficulties, and delays, such as the unexpected results from its Phase 2a trial, and may struggle to transition from a research-focused entity to one capable of supporting commercial operations, potentially impacting its overall business performance.","The company's limited operating history makes it difficult to evaluate its future success and viability, and it may encounter risks and difficulties frequently experienced by early-stage pharmaceutical companies, which could adversely affect its business, operating results, and financial condition.",5.0,0.7004955516057502,1.0,1.0,1.0
How does the company's status as an emerging growth company and a smaller reporting company affect its disclosure requirements?,"As an emerging growth company and a smaller reporting company, the company is permitted to rely on exemptions from certain disclosure requirements that apply to other public companies that are not in these categories. This includes not being required to comply with auditor attestation requirements under Section 404 of the Sarbanes-Oxley Act, having reduced disclosure obligations regarding executive compensation in annual reports, periodic reports, and proxy statements, and being exempt from holding nonbinding advisory votes on executive compensation or requiring stockholder approval for golden parachute payments not previously approved. Additionally, the company is only required to provide two years of audited financial statements and two years of selected financial data in its annual report. These reduced requirements may make the company's common stock less attractive to some investors.","As an emerging growth company and a smaller reporting company, the company is permitted to rely on exemptions from certain disclosure requirements, which may make its common stock less attractive to investors and could affect the trading price of its stock.",5.0,0.7975340092882545,1.0,0.875,1.0
How did the COVID-19 pandemic impact VF's financial position as of March 2020?,"The COVID-19 pandemic impacted VF's financial position as of March 2020 through several key actions and adjustments. In response to the pandemic, VF elected to draw down $1.0 billion from the Global Credit Facility to strengthen its cash position and support general working capital needs for Fiscal 2021. This borrowing, which had an interest rate of 1.81%, was later repaid in April 2020 using proceeds from the issuance of senior unsecured notes. Additionally, lease concessions related to the effects of the pandemic were accounted for under specific guidance, treated as if enforceable rights and obligations existed, provided they resulted in substantially the same or reduced total payments compared to the original lease contracts. These concessions were reflected within variable rent expense but did not have a material impact on the consolidated financial statements. Furthermore, VF made adjustments to its Global Credit Facility in April 2020, including increasing the consolidated indebtedness to consolidated capitalization ratio covenant to 70% and revising the calculation to net of unrestricted cash, which provided greater flexibility in managing its debt obligations during the uncertain economic environment.",The COVID-19 pandemic led VF to draw down $1.0 billion from its Global Credit Facility to strengthen its cash position and support general working capital needs.,4.0,0.7675232689882466,1.0,0.875,1.0
"What was the total amount of cash flow hedges used by VF as of March 2020, and how much was expected to be reclassified to earnings within the next 12 months?","VF used derivative contracts primarily to hedge a portion of the exchange risk for its forecasted sales, purchases, production costs, operating costs, and intercompany royalties as part of its cash flow hedges. As of March 2020, accumulated other comprehensive income (OCI) included $60.2 million of pre-tax net deferred gains for foreign currency exchange contracts that were expected to be reclassified to earnings within the next 12 months. The actual amount reclassified would depend on exchange rates at the time the outstanding derivative contracts were settled.","VF had $60.2 million of pre-tax net deferred gains for foreign currency exchange contracts in accumulated OCI as of March 2020, of which $60.2 million was expected to be reclassified to earnings within the next 12 months.",5.0,0.8684945182326984,1.0,0.875,1.0
How does the COVID-19 pandemic impact the company's commercial launch of TAZVERIK?,"The COVID-19 pandemic has impacted the company's commercial launch of TAZVERIK in follicular lymphoma (FL) and epithelioid sarcoma (ES) by disrupting marketing and sales efforts, limiting access to healthcare professionals, and reducing in-person outreach opportunities to promote the drug. Additionally, the pandemic may further disrupt the commercialization of TAZVERIK through supply chain challenges, regulatory delays, and other adverse effects on business operations.","The COVID-19 pandemic has limited the company's ability to access accounts and healthcare professionals, negatively impacted patient visits to physicians, and continued to disrupt commercialization efforts, which could result in adverse effects on the business and operations.",4.5,0.7114481460288316,1.0,1.0,1.0
What are the financial implications of the company's reliance on third-party manufacturers for the production of tazemetostat?,"The company's reliance on third-party manufacturers for the production of tazemetostat may lead to financial implications such as the inability to secure manufacturing agreements on a timely basis or on acceptable terms. This could result in delays, prevent or impair development and commercialization efforts, and potentially lead to additional losses and a reduction in potential product revenue. Furthermore, if third-party manufacturers fail to meet quality or regulatory standards, it could result in sanctions, product recalls, or legal penalties, which might also negatively impact financial performance. Additionally, any need to replace manufacturers could incur added costs and delays, further affecting profitability and competitiveness.","Reliance on third-party manufacturers increases the risk of not having sufficient quantities of tazemetostat or such quantities at an acceptable cost or quality, which could delay, prevent, or impair development or commercialization efforts.",5.0,0.720036551173373,1.0,1.0,1.0
How does the company's intellectual property portfolio affect its competitive position?,"The company's intellectual property portfolio plays a significant role in its competitive position, as it helps protect the proprietary technology used in its products and services. This protection is essential because the technology often represents a major portion of the collateral securing investments. The company relies on patent, trade secret, and trademark laws to safeguard its intellectual property. However, these protections are not foolproof, as competitors may misappropriate intellectual property, disputes over ownership may arise, and litigation may be necessary to enforce rights. Such legal actions can lead to high costs and resource diversion. Additionally, if the company is found to infringe on third-party rights, it may face damages, be required to alter products, obtain licenses, or cease certain activities—any of which could negatively impact its ability to service debt and reduce the value of investments. While the company’s intellectual property rights provide a basis for maintaining its competitive advantage, their effectiveness is limited by factors such as the scope of claims, the possibility of invalidation, third-party patents, and the risk of independent development of similar technologies. Thus, while the portfolio supports competitive positioning, its limitations mean it may not fully ensure a lasting advantage.","The company's ability to protect its intellectual property rights is crucial for maintaining a competitive edge. Failure to obtain, maintain, and enforce patent protection could allow competitors to develop and commercialize similar products, adversely affecting the company's business.",4.0,0.39310693607105723,1.0,0.875,1.0
What are the risks associated with the company's reliance on collaborations for product development and commercialization?,"The risks associated with the company's reliance on collaborations for product development and commercialization include the potential for collaborators to have significant discretion in determining the efforts and resources they apply, which may lead to delays, insufficient funding, or abandonment of clinical trials or product candidates. Collaborators may also choose not to pursue development or commercialization based on clinical results, changes in strategic focus, or external factors such as acquisitions. There is a risk that collaborators may independently develop or support competing products, or may not commit adequate resources to marketing and distribution, limiting potential revenue. Disputes with collaborators could result in delays, termination of agreements, or costly litigation. Additionally, collaborators may experience financial difficulties or fail to properly maintain or defend the company's intellectual property. The company may also be required to issue equity, assume liabilities, or expend substantial operational, financial, and management resources. Furthermore, the company may not retain control over the development or commercialization process, and strategic collaborators may design trials or select indications in ways that reduce the likelihood of success.","Risks include collaborators' discretion in determining resource allocation, potential de-emphasis or termination of development programs, and the possibility of disagreements over proprietary rights or contract interpretation, which could adversely affect the company's business.",4.5,0.7804414846340587,1.0,1.0,1.0
What are the four reportable operating segments of Willis Towers Watson?,"The four reportable operating segments of Willis Towers Watson are:

- Human Capital and Benefits (HCB)  
- Corporate Risk and Broking (CRB)  
- Investment, Risk and Reinsurance (IRR)  
- Benefits Delivery and Administration (BDA)","The four reportable operating segments are Human Capital and Benefits (HCB), Corporate Risk and Broking (CRB), Investment, Risk and Reinsurance (IRR), and Benefits Delivery and Administration (BDA).",5.0,0.8771159559372783,1.0,1.0,1.0
What are the key assumptions used in the valuation of Willis Towers Watson's defined benefit pension plans?,"The key assumptions used in the valuation of Willis Towers Watson's defined benefit pension plans include the discount rate, which is determined using a granular approach to service and interest costs. Additionally, the expected rate of return on plan assets is based on the weighted-average yield expected from the anticipated makeup of the plans’ investments. Other material assumptions involve rates of participant mortality, as well as the expected long-term rates of compensation and pension increases. These assumptions are reviewed annually and adjusted as necessary based on economic forecasts, historical trends, portfolio composition, and peer company comparisons.","The key assumptions include discount rates, expected long-term rates of return on plan assets, rates of participant mortality, expected long-term rates of compensation and pension increases.",5.0,0.7160814592144654,1.0,0.875,1.0
How does Willis Towers Watson recognize revenue from broking services?,"Willis Towers Watson recognizes revenue from broking services primarily at a point in time, which is the later of the policy inception date or when the policy placement is complete, as this is considered the point when control is transferred to the client. For employer-sponsored Medicare broking, revenue is recognized over time because the company is obligated to provide ongoing services to place retiree Medicare coverage. In cases where fees are not fixed and are variable, the company estimates the transaction price based on past transactions and applies a constraint to ensure only probable amounts are included. This estimated transaction price is then adjusted over time as confirmation of remuneration is received or additional information becomes available. Additionally, market-derived income, which may be earned from insurance and reinsurance carriers, is included as part of the revenue from broking services.","Revenue from broking services is recognized at the later of the policy inception date or when the policy placement is complete, as this is viewed as the date when control is transferred to the client.",4.5,0.6545357962038005,1.0,1.0,1.0
What are the key risks and uncertainties related to the COVID-19 pandemic that Willis Towers Watson has considered in its financial statements?,The provided context does not include any information about the key risks and uncertainties related to the COVID-19 pandemic that Willis Towers Watson has considered in its financial statements.,"The key risks and uncertainties include the collectability of billed and unbilled receivables, the estimation of revenue, and the fair value of reporting units, tangible and intangible assets, and contingent consideration.",1.0,0.2948096976554705,0.0,0.75,1.0
"What is the total amount of remaining performance obligations as of December 31, 2020, and how is it expected to be recognized in future periods?","As of December 31, 2020, the total amount of remaining performance obligations is approximately $8.4 billion. This amount includes deferred installation revenues and is expected to be recognized in future periods, with the majority recognized over the next 24 months. The recognition timing reflects the satisfaction of performance obligations under contracts, which may include initial terms and renewal periods, as well as the fulfillment of commitments related to fixed minimum levels of service.","As of December 31, 2020, approximately $8.4 billion of total revenues, including deferred installation revenues, are expected to be recognized in future periods, the majority of which will be recognized over the next 24 months.",5.0,0.7100675586639551,1.0,0.875,1.0
"How did the adoption of Topic 842 (Leases) impact the Company's financial results on January 1, 2019?","The adoption of Topic 842 on January 1, 2019, significantly impacted the Company's financial results by requiring the recognition of right-of-use (ROU) assets and lease liabilities on the balance sheet for all operating leases. This change resulted in the de-recognition of existing build-to-suit assets and liabilities, with the cumulative effects of the initial application reflected as an adjustment to the opening balance of retained earnings. The Company applied the alternative transition method, which allowed it to record ROU assets and lease liabilities for all existing leases as of January 1, 2019, without restating comparative periods under the previous guidance. Additionally, the Company elected to apply a package of practical expedients, which included not reassessing existing contracts for lease classification, not separating lease and non-lease components, and not reevaluating initial direct costs. As a result, the financial statements reflected these adjustments, including the recognition of ROU assets and lease liabilities, while comparative information continued to be reported under the prior accounting standards.","On January 1, 2019, the adoption of Topic 842 resulted in the recognition of new ROU assets and liabilities on the balance sheet for all operating leases, and the de-recognition of existing build-to-suit assets and liabilities with a cumulative effect adjustment to retained earnings.",5.0,0.7955554799805639,1.0,1.0,1.0
"What are the key risks and uncertainties that may have a material adverse effect on the company's business, financial condition, or results of operations?","The key risks and uncertainties that may have a material adverse effect on the company's business, financial condition, or results of operations include:

- The impact of the coronavirus (COVID-19) pandemic and subsequent outbreaks, which could lead to an economic downturn, recovery challenges, effects on global trade, and changes in customer behavior and corporate strategy.
- The ability to effectively implement and deliver on business strategies, which may affect operations and relationships with customers, regulators, employees, and other stakeholders.
- Uncertainty regarding future market and economic conditions in the United States and abroad, including changes in interest rates, energy prices, and unemployment levels, a decline in housing prices, availability of credit and liquidity, shifts in consumer confidence and spending behavior, consumer perception about the availability of credit, price competition, and the consequences of unexpected geopolitical events such as trade disputes and developments related to the United Kingdom.","The key risks include uncertainty regarding future revenue and access to funding, potential failure to develop or commercialize drug or biologic product candidates, clinical trial delays, reliance on third parties for management of clinical programs and manufacturing, extensive regulation by government and regulatory agencies, and reliance on intellectual property.",3.0,0.4536607448669709,1.0,0.875,1.0
How does the company plan to address the risk of failing to obtain regulatory approval for its product candidates?,"The company acknowledges that obtaining regulatory approval for its product candidates involves significant risk and depends on various factors beyond its control. To address this risk, the company plans to conduct comprehensive preclinical studies and clinical trials to demonstrate the safety, potency, and purity of its product candidates. These trials are designed to generate the necessary data to support regulatory submissions. The company also plans to seek regulatory approval in key markets such as the United States and the European Union, and potentially in other foreign countries where commercial opportunities exist. In some cases, the company may rely on collaborators or partners to help with the regulatory process, including conducting required activities and submitting applications. Despite these efforts, the company cannot guarantee that regulatory approval will be obtained, as approval may be delayed, limited, or denied based on the interpretation of clinical data by regulatory authorities, which could require additional costly trials. The company recognizes that even successful completion of clinical trials does not ensure approval, and that post-approval requirements may include further clinical studies. Additionally, regulatory approval, if granted, may come with limitations on labeling or approved indications that could affect the product’s commercial potential. The company is prepared for the possibility of failure at any stage of development and understands that a significant number of product candidates do not ultimately receive approval or achieve commercial success.","The company plans to navigate the regulatory approval process by ensuring compliance with all necessary clinical trial designs, data submissions, and regulatory requirements. It also aims to maintain open communication with regulatory authorities to address any issues promptly.",5.0,0.6892665945972352,1.0,0.0,1.0
What are the potential impacts of clinical trial delays on the company's business?,"Clinical trial delays can lead to increased development costs for the company's product candidates, which may cause the value of the company to decline and limit its ability to obtain additional financing. Delays may also result in the abandonment of one or more clinical trials, particularly if there are difficulties in enrolling sufficient patients or volunteers. Additionally, delays in regulatory approvals, clinical site initiation, and patient enrollment—often exacerbated by factors such as the COVID-19 pandemic—can significantly disrupt operations, hinder the timely commercialization of product candidates, and allow competitors to bring similar products to market sooner. These factors collectively pose a material adverse effect on the company’s business, operations, and financial condition.","Clinical trial delays could result in increased costs, delays in advancing product candidates, and potential loss of market opportunities, which could harm the company's competitive position and financial performance.",4.5,0.8323538382738199,1.0,0.875,1.0
How does the company plan to manage the financial risk associated with the need for substantial additional funding?,"The company plans to manage the financial risk associated with the need for substantial additional funding by seeking various sources of capital, including equity or debt financings, government or third-party funding, marketing and distribution arrangements, collaborations, strategic alliances, and licensing agreements. The company may also consider the opportunistic sale of non-core assets and explore alternative financing options. However, the company acknowledges that future financing may not be available on acceptable terms or at all, and the terms of any financing could result in adverse effects such as increased fixed payment obligations, restrictive covenants, dilution of stockholder rights, or a decline in the market price of its shares. The company also recognizes that raising capital may divert management attention from day-to-day operations and may require adjustments to its capital expenditures and development plans depending on the availability of funds and existing financing requirements.","The company plans to manage this risk through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements, and other marketing or distribution arrangements to secure the necessary capital on acceptable terms.",4.5,0.6481426899068309,1.0,1.0,1.0
What are the potential consequences of material weaknesses in the company's internal control over financial reporting?,"Material weaknesses in internal control over financial reporting can lead to a reasonable possibility that material misstatements in financial statements will not be prevented or detected on a timely basis. This may result in inaccurate financial reporting, which can undermine investor confidence in the company’s financial information and potentially lead to a decline in the stock price. Additionally, ineffective controls could hinder the detection of fraud, increase the risk of financial restatements, and result in higher remediation costs. Failure to comply with regulations such as Section 404 of the Sarbanes-Oxley Act may also negatively impact the market price of the company’s common stock. Furthermore, these weaknesses may impair the company’s ability to make distributions and expose shareholders to the risk of losing all or part of their investment.","Material weaknesses could lead to a failure to maintain compliance with securities law requirements, loss of investor confidence, and a decline in the company's share price. It could also result in investigations by regulatory authorities.",4.5,0.6791823592228795,1.0,1.0,1.0
"What was the total purchase price for the acquisition of eNett and Optal by WEX Inc., and how was this amount allocated?","The total purchase price for the acquisition of eNett and Optal by WEX Inc. was $1.3 billion in cash and 2.0 million shares of the Company’s common stock under the Original Purchase Agreement. However, due to a Material Adverse Effect related to the COVID-19 pandemic, the transaction was not completed as initially agreed. 

On December 15, 2020, a Deed of Settlement was executed, resulting in an amended purchase agreement that reduced the aggregate purchase price to $577.5 million (subject to working capital and other adjustments). This led to a total cash payment of $615.4 million upon closing the acquisition.

The purchase price was allocated to various assets, including a customer relationship intangible asset of approximately $168.0 million, which is being amortized over the 13-year term of the Chevron agreement. Additionally, accounts receivable were established at fair value. Transaction costs related to the acquisition were considered insignificant and expensed as incurred.","The total purchase price for the acquisition of eNett and Optal by WEX Inc. was $577.5 million. This amount was allocated to the acquired businesses based on their estimated fair value of $415 million, with the residual value of $162.5 million allocated to the legal settlement.",4.0,0.8591852165521904,1.0,1.0,1.0
What measures did WEX Inc. take in response to the COVID-19 pandemic to safeguard its business and employees?,"WEX Inc. faced operational challenges during the COVID-19 pandemic, particularly in segments such as Travel and Corporate Solutions and Health and Employee Benefit Solutions, due to reduced travel and deferrals of non-essential medical treatments. While the provided information does not detail specific measures taken to safeguard employees, it highlights how the company managed business operations amid these disruptions.

The company reported a decline in purchase volumes in the travel portion of the Travel and Corporate Solutions segment, attributed to the global decline in travel and tourism. In contrast, the corporate payments portion of this segment saw increased purchase volumes, driven by the migration to virtual payments and greater use of accounts payable products. The Health and Employee Benefit Solutions segment experienced challenges in the second quarter of 2020 but showed a slight increase in purchase volumes by the fourth quarter, as pandemic-related restrictions eased.

To mitigate financial risk, WEX Inc. maintained regulatory compliance by adhering to requirements such as deposit reserves with the Federal Reserve Bank. At December 31, 2020, there was no required reserve due to temporarily relaxed regulatory requirements enacted in response to the pandemic. The company also utilized alternative funding sources, including the Promontory Interfinancial Network, LLC’s ICS service, for cost-effective variable-rate funding without collateralization. These actions reflect efforts to maintain liquidity and operational stability during uncertain times.","WEX Inc. took several precautionary measures in response to the COVID-19 pandemic, including restricting business travel, temporarily closing offices, canceling participation in industry events, permanently reducing headcount, and furloughing employees across worldwide offices where necessary.",2.0,0.47300307098683003,1.0,0.75,0.5
What is the primary focus of the company's business?,"The primary focus of the company's business is to identify and complete a business combination, after which it aims to operate the post-transaction business or assets for the long term. The company does not plan to buy businesses or assets with the intent to resell them for profit, nor does it intend to acquire unrelated businesses or act as a passive investor.",The company is a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to transform the lives of patients with cancer by offering better and more durable benefits than currently available immuno-oncology treatments.,2.0,0.3926346753403178,1.0,1.0,1.0
What are the main product candidates currently under development by the company?,"The company has four product candidates currently in clinical development, each of which is still in early-stage clinical trials. The specific names or details of these product candidates are not mentioned in the provided context.","The main product candidates are FS118, a tetravalent mAb2 bispecific antibody targeting PD-L1 and LAG-3; FS120, a dual agonist bispecific antibody stimulating CD137 and OX40; FS222, a bispecific antibody targeting CD137 and PD-L1; and SB 11285, a next-generation cyclic dinucleotide-based STING agonist.",1.0,0.3050892178851578,1.0,0.0,1.0
What are the key challenges and competitive landscape for the company's immuno-oncology therapies?,"The company operates in a highly competitive biotechnology and pharmaceutical market focused on immuno-oncology therapies. Key challenges include competing with established pharmaceutical and biotechnology companies, universities, and research institutions that have significantly greater financial, research, and development resources. Large pharmaceutical companies possess extensive experience in clinical testing, patient recruitment, regulatory approvals, manufacturing, and marketing, giving them a strong competitive edge. Additionally, smaller and early-stage companies can also pose significant competition, especially through partnerships with larger firms. These competitors vie for talent, clinical trial sites, patient enrollment, and complementary technologies necessary for product development.

The competitive landscape features numerous companies developing or commercializing immuno-oncology therapies, including AstraZeneca, BMS, Eli Lilly, MSD, EMD Serono, Novartis, Pfizer, Genentech, Roche, and Sanofi. Many of these firms are pursuing innovations such as combining immuno-oncology antibody therapies to target two cancer pathways simultaneously or developing bispecific antibodies and fusion proteins to enhance the effects of traditional monoclonal antibodies. The field is marked by rapid technological change and innovation, requiring continuous adaptation and advancement to maintain a competitive position.","The company faces potential competition from many sources, including large biotechnology and pharmaceutical companies, academic institutions, government agencies, and other public and private research organizations. The immuno-oncology field is characterized by rapidly advancing technologies and innovation, intense competition, and a strong emphasis on intellectual property.",5.0,0.7310126554822444,1.0,0.75,1.0
What are the regulatory requirements for marketing approval of the company's product candidates in the United States?,"In the United States, marketing approval for the company's product candidates requires submission of an NDA to the FDA. This process involves providing extensive preclinical and clinical data to demonstrate the product candidate’s safety and efficacy for each therapeutic indication. Additionally, information about the product manufacturing process must be submitted, and manufacturing facilities are subject to inspection by the FDA. The approval process is comprehensive, requiring adherence to strict regulatory standards, including recordkeeping, labeling, and quality control requirements.","The regulatory requirements include completing nonclinical laboratory tests and animal studies, submitting an Investigational New Drug (IND) application, conducting adequate and well-controlled human clinical trials, submitting a Biologics License Application (BLA) or New Drug Application (NDA), undergoing FDA pre-approval inspections of manufacturing facilities, and potential FDA audits of clinical trial sites.",4.0,0.6473516790560301,1.0,0.875,1.0
What are the potential environmental risks associated with the Partnership’s operations?,"The Partnership's operations involve the transportation, storage, and use of natural gas and crude oil, which are flammable and combustible. These activities pose potential risks of serious personal injury and significant property damage. As a result, the Partnership may face litigation and claims related to product liability, personal injury, and property damage, some of which may involve actual or punitive damages. The Partnership maintains liability insurance with coverage amounts and deductibles that management considers reasonable and prudent, and which are generally accepted in the industry. Additionally, following the sale of a refinery to PES, the Partnership's subsidiaries retained certain environmental remediation liabilities, which have been funded through a wholly-owned captive insurance company based on actuarial estimates. There may be a need for future additional environmental remediation liabilities depending on the use of the property by the buyer, although management cannot currently estimate these potential future costs.","The Partnership’s operations involve the generation, handling, and disposal of hazardous substances, hydrocarbons, and wastes, which are subject to stringent environmental laws and regulations. Non-compliance with these laws could result in significant penalties, remediation costs, and other liabilities.",4.0,0.6398826265486707,1.0,0.75,1.0
How does the Partnership’s reliance on key customers impact its financial results?,"The Partnership’s reliance on key customers impacts its financial results by creating significant vulnerability to the loss of any major client. A limited number of customers currently represent a substantial majority of the Partnership’s income, and its operating results are contingent on maintaining sales to these customers, which include power utilities, railroad companies, and industrial end-users. The loss of a significant customer could adversely affect the Partnership’s operating results, particularly in the short term, as a substantial majority of its sales are expected to continue coming from a concentrated group of customers. Additionally, the Partnership's revenue is expected to be heavily concentrated in the Caribbean, further tying its financial performance to the stability and operations of specific customers and markets in that region. This reliance also affects the Partnership’s ability to diversify its customer base, potentially limiting growth and increasing financial risk.",The Partnership’s intrastate and interstate transportation and storage operations depend on key customers to transport natural gas through its pipelines. The failure of these major shippers to fulfill their contractual obligations could have a material adverse effect on the Partnership’s cash flow and results of operations.,4.5,0.5434625039419247,1.0,1.0,1.0
What are the major types of revenue within the Partnership's reportable segments?,"The major types of revenue within the Partnership's reportable segments include intrastate transportation and storage, interstate transportation and storage, midstream, NGL and refined products transportation and services, crude oil transportation and services, investment in Sunoco LP, fuel distribution and marketing, all other, investment in USAC, contract operations, and retail parts and services.","The major types of revenue within the Partnership's reportable segments include intrastate transportation and storage, interstate transportation and storage, midstream, NGL and refined products transportation and services, crude oil transportation and services, investment in Sunoco LP, investment in USAC, and all other.",4.0,0.9876920583783105,1.0,1.0,1.0
"What is the total amount of long-term debt as of December 31, 2020?","The total amount of long-term debt as of December 31, 2020, is $30,805 million.","The total amount of long-term debt as of December 31, 2020 was $51.37 billion.",3.0,0.9599536506663331,1.0,0.875,1.0
How does the Partnership determine the fair value of its financial assets and liabilities?,"The Partnership determines the fair value of its financial assets and liabilities using a variety of methods depending on the nature of the asset or liability. For financial assets and liabilities measured on a recurring basis, as well as non-financial assets and liabilities measured on a non-recurring basis, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. 

The Partnership considers the principal or most advantageous market and the assumptions market participants would use, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 820 establishes a fair value hierarchy that prioritizes the use of observable inputs over unobservable ones.

For investment securities, the Partnership determines fair value based on prices obtained from multiple third-party pricing vendors. The fair value is calculated as the average of vendor prices within a cluster pricing tolerance range around the median price, with outliers evaluated for reasonableness. 

For reporting units, the Partnership uses either the discounted cash flow method or the guideline company method, or a combination of both. The discounted cash flow method involves estimating future cash flows, including capital expenditures, and discounting them to present value using a risk-adjusted industry rate. The guideline company method applies valuation multiples from comparable publicly-traded companies to the reporting unit's projected EBITDA. The Partnership also estimates a control premium that reflects the incremental value from majority ownership.

For financial assets and liabilities not measured at fair value on a recurring or non-recurring basis, the Partnership records them at amortized cost. The specific valuation methodologies and primary inputs for assets and liabilities measured at fair value are summarized in the Statement of Condition and reported in Table 15.2. The use of different assumptions in these methods can significantly impact the fair value estimates.","The Partnership determines the fair value of its financial assets and liabilities by using the highest possible “level” of inputs, including observable quotes in an active market for identical assets and liabilities (Level 1), inputs observable for similar assets and liabilities (Level 2), and unobservable inputs (Level 3).",4.0,0.663773990129672,1.0,0.875,1.0
What are the key risks related to the company's financial position as outlined in the financial report?,"The key risks related to the company's financial position include the potential for material adverse effects on business, prospects, financial condition, and results of operations. These risks may negatively impact the trading price of the company's common stock. The risks may include uncertainties related to the company's operations, financial performance, and market conditions. Additionally, there may be risks that are currently unknown or not considered material but could have a significant impact in the future. The company encourages investors to consider these risks in their entirety, along with other information contained in the annual report and public filings with the SEC.","The key risks related to the company's financial position include a history of losses, reliance on a limited number of significant clients, and the need for additional capital to support business growth.",3.0,0.5401167188447074,1.0,0.75,1.0
How does the company's dependence on a few large clients impact its financial stability?,"The company's dependence on a few large clients impacts its financial stability by creating significant risk if these clients were to leave, fail to renew, or reduce their subscriptions. A substantial portion of the company's revenue comes from a limited number of clients, with one client, Anthem, accounting for 21% to 23% of revenue in recent years. Additionally, the top ten clients accounted for 42% to 48% of total revenue over the same period. This concentration makes the company vulnerable to fluctuations in revenue if key clients reduce their engagement or if mergers and acquisitions lead to contract cancellations. The loss of major clients could also harm the company's reputation and its ability to attract new clients, further affecting long-term financial performance. Furthermore, the company relies on these relationships to achieve economies of scale, as the initial investment in client relationships is high and revenue is recognized over time, making it difficult to quickly offset the loss of revenue from key clients.","The company's dependence on a few large clients, such as Anthem, exposes it to significant financial risk if any of these clients were to reduce their business or terminate their contracts, which could materially affect revenue and financial stability.",5.0,0.7324347467866995,1.0,1.0,1.0
What are the potential impacts of rapid technological changes on the company's business?,"Rapid technological changes can significantly impact the company's business in several ways. The company may struggle to keep pace with evolving technology and customer needs, potentially affecting its ability to develop new products or enhance existing ones, which could negatively affect its business and operating results. The emergence of new technologies, techniques, or products could offer better price-performance combinations or better meet customer requirements than the company's current or future offerings. Additionally, the financial services industry, where the company operates, experiences frequent changes in technology, client preferences, and industry standards, which could render the company's existing technology uncompetitive or obsolete. Furthermore, the biopharmaceutical field, in which the company is engaged, is marked by rapid research advancements, and discoveries by others may make the company's products, such as octreotide capsules or future product candidates, uncompetitive or obsolete. Any failure to adapt to these changes could lead to a decline in market share and negatively impact financial performance.","Rapid technological changes pose a risk of obsolescence for the company's current technology and services, requiring continuous investment in research and development to stay competitive and relevant in the market.",4.5,0.5659034346981243,1.0,1.0,1.0
What is the primary risk factor mentioned in the financial report regarding the legality of cannabis under U.S. federal law?,"The primary risk factor mentioned in the financial report is that cannabis remains illegal under U.S. federal law, classified as a Schedule I controlled substance under the Controlled Substances Act. This creates a significant risk because federal enforcement of cannabis laws could change, potentially leading to violations of federal law even in states where cannabis is legal. Such enforcement could negatively impact business operations, prospects, revenue, and financial condition due to the preemption of state laws by federal statutes.","The primary risk factor is that cannabis remains illegal under U.S. federal law, which could lead to enforcement actions by federal authorities and potentially harm the company's business operations and financial condition.",5.0,0.8804874584857049,1.0,1.0,1.0
What are the potential consequences if the company fails to comply with state regulations in the jurisdictions where it operates?,"Failure to comply with state regulations in the jurisdictions where the company operates could result in government-imposed fines or orders requiring changes to business practices, which may adversely affect the business. Additionally, compliance with varying state regulations may necessitate substantial costs or changes to business practices and compliance procedures in ways that are unfavorable to the business. Such non-compliance could also lead to government enforcement actions, civil and/or criminal penalties, private litigation, and negative publicity, all of which could negatively impact operating results and business. In some cases, the company might be restricted in its ability to collect, use, or disclose data, or could even be unable to operate in certain jurisdictions. These consequences could materially adversely affect the company’s business, financial condition, and results of operations.","If the company fails to comply with state regulations, it could face sanctions including revocation or additional conditions on licenses, suspension or expulsion from markets, imposition of fines and censures, and potential material liabilities or revocation of licenses and permits.",4.5,0.7723350932926092,1.0,1.0,1.0
What measures does the company take to mitigate the risk of security breaches and theft in its operations?,"The company engages a security firm to provide security during the transport and movement of large amounts of cash and products. Employees who transport cash and/or products may be escorted by armed guards when requested. The company has implemented security measures at its cultivation, processing, and dispensary facilities and continues to monitor and improve these measures. Additionally, the company has integrated recovery systems, security protocols, network protection mechanisms, and other security measures into its platform, systems, networks, and physical facilities to protect against, detect, and minimize security breaches. While these steps are in place, there is no assurance that all security breaches or theft can be prevented.","The company has implemented security measures at its facilities and engages a security firm for the transport and movement of large amounts of cash and products, including escorting employees by armed guards when necessary.",4.5,0.8635604228211893,1.0,0.0,1.0
What are the potential impacts of a global economic slowdown or financial market disruptions on the company's business?,"A global economic slowdown or financial market disruptions could lead to significant adverse effects on the company's business. These include disruptions and extreme volatility in global financial markets, increased rates of default and bankruptcy, and declining consumer and business confidence, which may result in decreased consumer spending. Such macroeconomic conditions could negatively impact the company's operations, as its business depends on the general economic environment and levels of consumer spending. This could lead to difficulties in maintaining existing customers or attracting new ones, and may necessitate price reductions to remain competitive. 

Additionally, disruptions in credit and financial markets could impair the company's ability to raise additional capital on acceptable terms, and supply chain strain could result from a weak economy affecting suppliers. The company may also be affected by broader economic factors such as inflation, currency fluctuations, trade barriers, and geopolitical instability, which can affect securities prices, investment opportunities, and the value of its investments. Furthermore, the company may face increased costs or operational delays due to trade restrictions, tariffs, or supply chain challenges. Overall, any general or market-specific economic downturn could have a material adverse effect on the company's financial condition, results of operations, and cash flow.","A global economic slowdown or financial market disruptions could lead to decreased consumer spending, reduced demand for the company's products, increased competition, and potentially lower revenues and profitability.",4.5,0.766752546719309,1.0,0.875,1.0
"What critical audit matter was identified in the audit of Evergy, Inc.'s financial statements?","The provided context does not identify any specific critical audit matters related to the audit of Evergy, Inc.'s financial statements.","The critical audit matter identified was the impact of rate regulation on the financial statements, particularly related to the accounting for the economics of rate regulation which impacts multiple financial statement line items and disclosures. This matter involved especially challenging, subjective, or complex judgments due to the high degree of subjectivity involved in assessing the impact of future regulatory orders on the financial statements.",1.0,0.4843474939158935,0.0,0.5,1.0
"What are the key components of Evergy, Inc.'s property, plant, and equipment accounting?","The key components of Evergy, Inc.'s property, plant, and equipment accounting include recording the value at cost, which encompasses contracted services, direct labor, materials, indirect charges for engineering and supervision, and an allowance for funds used during construction (AFUDC). AFUDC reflects the allowed cost of capital for financing utility construction and is calculated using a composite rate on qualified construction work in progress, compounded semi-annually. AFUDC equity funds are included as a non-cash item in other income, while AFUDC borrowed funds reduce interest expense. Additionally, when property units are retired or disposed of, the original cost net of salvage is charged to accumulated depreciation, and repair costs are expensed as incurred, except for deferred maintenance costs related to planned outages at specific facilities.","The key components of Evergy, Inc.'s property, plant, and equipment accounting include recording the value at cost, which includes contracted services, direct labor and materials, indirect charges for engineering and supervision, and an allowance for funds used during construction (AFUDC). Depreciation and amortization are computed using the straight-line method over the estimated lives of depreciable property based on rates approved by state regulatory authorities.",4.5,0.9373298284593549,1.0,1.0,1.0
"How does Evergy, Inc. account for nuclear plant decommissioning costs?","Evergy, Inc. accounts for nuclear plant decommissioning costs by estimating these costs based on either the immediate dismantlement method or the deferred dismantling method as determined by the State Corporation Commission of the State of Kansas (KCC) and the Missouri Public Service Commission (MPSC). These estimates include the costs of decontamination, dismantlement, and site restoration. Evergy Kansas Central and Evergy Metro contribute to a tax-qualified trust fund to fund the decommissioning of Wolf Creek. The related liabilities for decommissioning are recorded as asset retirement obligations (AROs) on the consolidated balance sheets of Evergy, Evergy Kansas Central, and Evergy Metro. Differences between the decommissioning trust fund asset and the related ARO are recorded as regulatory assets or liabilities due to authorized regulatory treatment and related regulatory accounting. Net realized and unrealized gains and losses on the nuclear decommissioning trusts are recorded as regulatory liabilities on the consolidated balance sheets.","Evergy, Inc. accounts for nuclear plant decommissioning costs by contributing to a tax-qualified trust fund to be used to decommission Wolf Creek. Related liabilities for decommissioning are included in asset retirement obligations (AROs) on the consolidated balance sheets. Differences between the decommissioning trust fund asset and the related ARO are recorded as a regulatory asset or liability, reflecting the authorized regulatory treatment and related regulatory accounting.",5.0,0.9160191054290522,1.0,1.0,1.0
How does reliance on third-party manufacturers impact our business?,"Reliance on third-party manufacturers impacts our business in several significant ways. It introduces risks related to regulatory compliance, as we depend on these manufacturers to meet FDA and DEA standards and ensure product quality. There is also a risk of proprietary information being misappropriated, including trade secrets and know-how. Changing suppliers can lead to disruptions, additional regulatory filings, and increased costs. Additionally, third-party agreements may be breached, terminated, or not renewed at inconvenient or costly times, potentially delaying or halting manufacturing.

We face challenges in securing sufficient manufacturing capacity, especially during scale-up, which may result in production delays or quality issues. Establishing new manufacturing arrangements can be difficult due to limited qualified manufacturers, long lead times, and the need for specialized expertise. We may also struggle to negotiate favorable terms or secure the necessary financial capital for these arrangements.

If third-party manufacturers fail to meet agreed-upon timelines, specifications, or logistical requirements, or prioritize other products, our ability to develop, commercialize, and meet market demand is compromised. This can make us less attractive to potential partners, limiting our access to development programs. Furthermore, we may not have redundant supply sources or second manufacturing options, leaving us vulnerable to disruptions from events such as natural disasters, labor disputes, or pandemics like COVID-19.

Overall, these dependencies constrain our operational flexibility, expose us to regulatory and financial risks, and could delay clinical trials, impede regulatory approval, or hinder successful commercialization.","Reliance on third-party manufacturers increases the risk of supply disruptions, quality control issues, and potential delays in product development and commercialization, which could adversely affect our ability to generate revenue.",4.5,0.8226823356909928,1.0,1.0,1.0
"How does KemPharm, Inc. recognize revenue from contracts with customers?","The provided context does not contain information about how KemPharm, Inc. recognizes revenue from contracts with customers.","KemPharm recognizes revenue in accordance with ASC 606, which involves identifying performance obligations, determining the transaction price, allocating the transaction price to each performance obligation, and recognizing revenue when (or as) each performance obligation is satisfied.",1.0,0.6611372580488057,0.0,0.25,1.0
"How has KemPharm, Inc. addressed its liquidity concerns?","KemPharm, Inc. has addressed its liquidity concerns through various financing activities, including a Purchase Agreement dated February 17, 2020, between the company and Lincoln Park Capital Fund, LLC. This agreement likely provided a source of capital to support the company's operations and clinical development initiatives. Additionally, the company's ability to secure funding through such arrangements reflects its strategy to manage liquidity while advancing its product pipeline.","After taking into account the underwritten public offering, debt restructuring with subsequent payoff, and warrant inducement transactions discussed in Note R, the Company's cash and cash equivalents as of the filing date are sufficient to fund the Company's operating expenses and capital expenditure requirements for at least one year from the date the financial statements are issued.",3.0,0.326037775029052,1.0,0.5,1.0
What are the terms of the KP415 License Agreement with Commave Therapeutics SA?,"The KP415 License Agreement with Commave Therapeutics SA includes the following terms:

- Commave was granted an exclusive, worldwide license to develop, manufacture, and commercialize the Company’s product candidates containing serdexmethylphenidate (“SDX”) and d-methylphenidate (“d-MPH”), including AZSTARYS, KP484, and, at Commave’s option, KP879, KP922, or other future product candidates targeting ADHD or other central nervous system disorders.

- Commave paid an upfront payment of $10.0 million.

- Commave agreed to pay milestone payments of up to $63.0 million upon the achievement of specified regulatory milestones related to AZSTARYS and KP484.

- Additionally, Commave agreed to pay up to $420.0 million in U.S. sales milestones upon the achievement of specified sales targets.

- Commave is obligated to pay tiered royalty payments on a product-by-product basis, ranging from a percentage in the high single digits to the mid-twenties of Net Sales in the United States, and from a percentage in the low to mid-single digits of Net Sales in countries outside the United States, subject to certain reductions as defined in the agreement.

- Royalty payments will continue until the expiration of the Royalty Term for each applicable product.","Under the KP415 License Agreement, KemPharm granted Commave an exclusive, worldwide license to develop, manufacture, and commercialize the Company’s product candidates containing serdexmethylphenidate (SDX) and d-methylphenidate (d-MPH), including AZSTARYS, KP484, and optionally KP879, KP922, or any other product candidate developed by the Company containing SDX and developed to treat ADHD or any other central nervous system disorder. Commave paid an upfront payment of $10.0 million and agreed to pay milestone payments, sales milestones, and tiered royalty payments on net sales.",5.0,0.8908970205685418,1.0,1.0,1.0
What was the outcome of the debt restructuring mentioned in the financial report?,"The debt restructuring resulted in no gain on restructuring because the total cash outflows required under the amended agreement exceeded the carrying value of the original agreement. The amendments were classified as a troubled debt restructuring under ASC 470-60, and the changes to the 2021 Notes were treated as a debt modification. A $2.3 million increase in the fair value of the embedded conversion feature was recorded as an increase to additional paid-in capital and as a debt discount, which will be amortized to interest expense using the effective interest method over the remaining term of the notes. Additionally, the Deerfield Facility Agreement and the associated convertible note will continue to be carried net of discount and debt issuance costs, which will be amortized as interest expense.","In anticipation of the Public Offering, the Company restructured the December 2019 Notes and the January 2020 Note in the aggregate principal amount of $60.8 million and the Deerfield Note in the principal amount of $7.5 million. The Company exchanged $31.5 million of the outstanding principal and accrued interest on the Facility Notes for Series B-2 Preferred Stock and Exchange Warrants and made a payment of $30.3 million in partial repayment of the remaining outstanding principal and accrued interest on the Facility Notes.",3.0,0.5181105098287379,1.0,0.875,1.0
What is the role of the Dividend Retention Fund in Chubb's operations?,"The Dividend Retention Fund plays a key role in supporting Century's financial stability by ensuring that a portion of dividends paid by INA Holdings Corporation and INA Financial Corporation is withheld to maintain a principal balance of $50 million. This fund is used to make capital contributions to Century when the XOL Agreement's capacity falls below $200 million on an incurred basis, with the contribution amount being the lesser of the required restoration amount or the fund's balance. These contributions help uphold the financial structure and reinsurance capacity of Century, which is integral to Chubb's operations. Additionally, the fund cannot be terminated without approval from the Pennsylvania Insurance Commissioner, emphasizing its regulatory significance.","The Dividend Retention Fund is used to maintain the statutory capital and surplus of Century Indemnity Company, a subsidiary of Chubb, by replenishing the principal to $50 million from dividends withheld from Chubb Group Holdings.",4.5,0.8191445492738099,1.0,0.875,1.0
How does Chubb manage its foreign currency exposure?,"Chubb manages its foreign currency exposure by using foreign currency forward contracts, which are agreements to exchange specific currencies at a future date. These contracts help minimize the effect of fluctuating foreign currencies. The company's policy is to generally match assets, liabilities, and required capital for each individual jurisdiction in local currency, which includes the use of such derivatives. Chubb does not hedge its net asset non-U.S. dollar capital positions but considers economic hedging for planned cross-border transactions.","Chubb manages its foreign currency exposure by using foreign currency forward contracts to exchange specific currencies at a future date, aiming to minimize the effect of fluctuating foreign currencies.",5.0,0.9133341308670048,1.0,0.875,1.0
What is the impact of the COVID-19 pandemic on Chubb's unpaid losses and loss expenses in 2020?,"The COVID-19 pandemic significantly impacted Chubb's unpaid losses and loss expenses in 2020, primarily driving an increase in both gross and net unpaid losses and loss expenses due to catastrophe losses incurred.","The COVID-19 pandemic led to an increase in Chubb's unpaid losses and loss expenses in 2020, primarily due to catastrophe losses incurred.",5.0,0.9725186259483464,1.0,0.875,1.0
What is the policy for dividend distributions from Chubb Limited?,"Dividend distributions from Chubb Limited are made in U.S. dollars, although they must be stated in Swiss francs under Swiss corporate law. The dividends are issued without withholding tax through distributions from capital contribution reserves and are paid out of free reserves. The Board of Directors determines the record and payment dates for dividends, and it has the discretion to abstain from distributing a dividend. Shareholders have approved annual dividend amounts, which are then paid in quarterly installments.","Chubb Limited issues dividends without subjecting them to withholding tax by way of distributions from capital contribution reserves and payment out of free reserves, with dividends stated in Swiss francs but paid in U.S. dollars.",5.0,0.9057520940209701,1.0,0.875,1.0
What are the principal risk factors associated with investing in the company's securities?,"The principal risk factors associated with investing in the company's securities include the uncertainty regarding the value of the investment portfolio, as it is recorded at fair value with the Board responsible for overseeing, reviewing, and approving the estimate of fair value in good faith. This uncertainty arises because there is typically no public market for the securities of privately held companies in which the company invests, and the valuation may be subject to significant judgment. Additionally, any adverse events could materially and negatively impact the company's business, financial condition, results of operations, and cash flows, potentially leading to a decline in net asset value and the trading price of the securities, resulting in a loss of all or part of the investment.","Investing in the company's securities involves a high degree of risk, including speculative and leveraged investments, potential loss of capital, regulatory restrictions, and exposure to market volatility.",4.0,0.6105454897714322,1.0,0.75,1.0
How does the company's business model depend on referral relationships with venture capital and private equity fund sponsors?,"The company's business model relies significantly on strong referral relationships with intermediaries, financial institutions, investment bankers, commercial bankers, financial advisors, attorneys, accountants, consultants, alliance partners, and other individuals within the networks of its Senior Lending Team and Executive Committee. These relationships are crucial for generating potential investment opportunities. While the specific mention of venture capital and private equity fund sponsors is not included in the provided context, the reliance on referral networks suggests that such relationships—potentially including those with venture capital and private equity fund sponsors—are likely part of the broader network from which investment opportunities are sourced. The failure to maintain or develop these relationships could negatively impact the company’s ability to grow its investment portfolio.",The company's business model significantly relies on strong referral relationships with venture capital and private equity fund sponsors to generate investment opportunities. The inability to maintain or develop these relationships could adversely affect the company's business.,4.0,0.5699198867900592,1.0,1.0,1.0
What are the regulatory risks the company faces as a Business Development Company (BDC)?,"The company faces several regulatory risks as a Business Development Company (BDC). A failure to maintain its qualification as a BDC would significantly reduce its operating flexibility. If it fails to continuously qualify, it might be subject to regulation as a registered closed-end investment company under the 1940 Act, which would require it to restrict borrowings, reduce leverage, sell securities, and engage in activities permitted under that structure. Additionally, failure to comply with the requirements of the 1940 Act could lead to enforcement actions by the SEC. The company is also limited in its ability to acquire non-qualifying assets unless at least 70% of its total assets consist of qualifying assets, with certain exceptions for follow-on investments and distressed companies. This limitation affects its investment strategy and flexibility.","As a BDC, the company is subject to regulatory constraints that may affect its ability to raise additional capital, incur debt, and make certain investments. Non-compliance with BDC regulations could lead to loss of status or enforcement actions.",5.0,0.785375392371771,1.0,0.875,1.0
How does the company's exposure to changes in interest rates affect its profitability?,"The company's profitability is affected by changes in interest rates because a portion of its income depends on the difference between the interest rates it earns on its investments and the rates it pays on its borrowings. Since the company borrows money to make investments and may issue debt securities or preferred stock, its net investment income is influenced by this spread. The company's interest-earning investments typically accrue interest at both variable and fixed rates, while its liabilities generally accrue interest at fixed rates. As a result, changes in interest rates can impact both the yield on its investments and the cost of its debt, potentially leading to operating losses if interest expenses exceed interest income. Additionally, interest rate fluctuations may affect the value of its portfolio, its ability to attract new investments, and the credit risk associated with its borrowers, all of which can have a material adverse effect on its investment objectives and overall rate of return on capital.","Changes in interest rates can impact the company's net investment income, as higher rates may increase borrowing costs and reduce the demand for loans, while lower rates may decrease yields on new investments.",4.5,0.723729320053782,1.0,1.0,1.0
What is the nature of the Company's business and what types of companies does it primarily lend to?,"The company's business involves making debt and equity investments primarily in smaller privately-owned companies. These companies are typically not publicly traded and often lack extensive public information, making it necessary for the company to rely on its internal teams to assess potential investments. The investments are often in the form of debt that is not initially rated by credit agencies, and if rated, would likely be classified as below investment grade, indicating higher risk.","The Company is a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed companies in various technology, life sciences, and sustainable and renewable technology industries.",3.0,0.4972144607591816,1.0,1.0,1.0
"What is the Company's policy regarding the declaration and payment of dividends, and how does it affect its tax status?","The Company has announced its intention to reinstate distributions to common stockholders at an annual rate of $0.40 per share, payable as dividends in arrears on a quarterly basis. The first dividend was declared on October 1, 2020, and paid on October 15, 2020, in a partial amount of $0.04889 per share, covering the period from the Listing Date through September 30, 2020. For the year ended December 31, 2020, the entire dividend of $0.04889 per share was treated as a return of capital for U.S. federal income tax purposes. Dividends declared and paid in subsequent years, such as the one in January 2021, are considered events of that year, with their tax treatment disclosed in the relevant annual reports.

Additionally, if a significant number of shareholders choose to receive cash, the available cash may be insufficient, leading to a portion of the distribution being paid in stock. Shareholders electing to receive cash will not receive less than the lesser of the portion they elected to receive in cash or the product of their total distribution and the percentage limitation on cash available. For U.S. federal income tax purposes, the value of stock distributed as a dividend is treated as equivalent to the cash that could have been received, requiring shareholders to include the dividend amount in income as ordinary income or long-term capital gain, depending on the nature of the distribution. This may result in a tax liability exceeding any cash received. Non-U.S. shareholders may also face U.S. tax withholding on dividends, including those paid in stock. Moreover, a large number of shareholders selling stock to cover taxes could potentially reduce the trading price of the common stock.","The Company's policy is to declare and pay dividends on a quarterly basis, ensuring that it distributes at least 90% of its investment company taxable income to maintain its RIC tax status. This avoids federal income tax on the distributed portion of its taxable income.",3.0,0.5122029550026941,1.0,0.875,1.0
"How does the Company manage its credit risk, and what measures are in place to mitigate potential losses?","The Company manages its credit risk through well-defined underwriting criteria and account administration standards established by management. It employs written credit policies that outline underwriting standards, approval levels, exposure limits, and other necessary controls. Portfolio diversification across obligors, industries, products, and geographic locations is actively managed to reduce concentration risk. An independent credit review process ensures compliance with commercial, real estate, and consumer credit policies, risk ratings, and other critical information. The Company adheres to sound credit principles, evaluating customers’ borrowing needs, repayment capacity, character, and history.

Credit risk is monitored using internal risk management measures within limits approved by authorized personnel, and credit risk management processes are designed to function effectively across all stages of economic and financial cycles, including periods of market volatility. The Company implements early warning indicators and stress testing scenarios based on recent experience, with results incorporated into business planning. Counterparty credit limits are established for certain products and are continually monitored to address changing customer and market conditions.

To mitigate potential losses, the Company maintains reserves for probable and reasonably estimable losses from legal proceedings, investigations, and regulatory matters. However, in many cases, the outcome or financial impact of such matters remains uncertain due to their early stages or the nature of the claims.","The Company manages its credit risk through rigorous credit assessment processes, including obtaining first priority security interests in portfolio companies' assets, which may include intellectual property. It also monitors portfolio companies' financial performance and market conditions to mitigate potential losses.",4.5,0.6113064274496103,1.0,1.0,1.0
What was the impact of the adoption of ASC 606 on the company's revenue recognition?,"The adoption of ASC 606 resulted in accelerated recognition of a portion of original listing fees related to the New York Stock Exchange business, while also causing a deceleration in the recognition of a portion of clearing fee revenues, though the impact on clearing business performance obligations was minimal. Revenue recognition for all other businesses remained unchanged.",The adoption of ASC 606 accelerated the timing of recognition of a portion of original listing fees related to the New York Stock Exchange businesses and decelerated the timing of recognition of a portion of clearing fee revenues.,5.0,0.9673924155161376,1.0,0.875,1.0
How does the company account for stock-based compensation?,"The company accounts for stock-based compensation by recognizing compensation expense over the period during which the recipient is required to provide service in exchange for the award. This expense is measured at the grant date based on the fair value of the award and is recorded net of estimated forfeitures. For awards with service conditions, the expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period. For awards with market or performance conditions, the expense is recognized using a graded-vesting methodology over the required service period for each vesting tranche. The fair value of options is determined using the Black-Scholes option-pricing model, while awards with market conditions are valued using a Monte Carlo simulation model. Shares repurchased under the annual capital plan are used for share issuances under stock-based compensation programs.","The company measures and recognizes compensation expense for share-based payment awards, including employee stock options, restricted stock, and shares purchased under the Employee Stock Purchase Plan, based on estimated fair values on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as stock-based compensation expense over the requisite service period.",5.0,0.7111766228513191,1.0,0.875,1.0
What is the primary function of the Exchanges segment?,"The primary function of the Exchanges segment is to operate regulated marketplaces for the listing, trading, and clearing of a broad array of derivatives contracts and financial securities, including commodities, interest rates, foreign exchange, equities, and exchange-traded funds. It also includes operations such as the New York Stock Exchange, global futures networks, and related data and connectivity services.","The Exchanges segment operates regulated marketplaces for the listing, trading, and clearing of a broad array of derivatives contracts and financial securities.",5.0,0.8945982748201634,1.0,0.875,1.0
What services does the Fixed Income and Data Services segment provide?,"The Fixed Income and Data Services segment provides a range of services including evaluated end-of-day and real-time pricing for fixed income securities, reference data, fixed income analytics, and workflow solutions such as best execution services, liquidity indicators, portfolio analytics, and an ETF Hub. It also offers electronic trading platforms through ICE Bonds, supporting various trading protocols like click-to-trade, request for quotation, and auctions. Additionally, the segment provides clearing services for credit default swaps (CDS), covering both single names and index instruments, and generates revenues from interest income on clearing margin deposits.","This segment provides fixed income pricing, reference data, indices, execution services, global credit default swaps clearing, and multi-asset class data delivery solutions.",4.5,0.8244909075234602,1.0,1.0,1.0
What is the significance of the NYSE in the company's Exchanges segment?,"The NYSE is a key component of the company's Exchanges segment, which includes the New York Stock Exchange and other registered securities exchanges. It contributes to the segment's diversified transaction revenues and recurring data and listings revenues, forming a significant part of the company's marketplace infrastructure for listing, trading, and clearing financial securities.","The NYSE is the global leader in listings, having been the venue of choice for innovators, visionaries, and leaders for over 225 years, and it is the leading listing venue across a range of sectors.",4.5,0.7169799022335278,1.0,0.875,1.0
What measures have been taken to protect the company from clearing member defaults?,"The company has implemented several measures to protect against clearing member defaults. These include contributing its own capital to the front of the guaranty fund of the clearing houses, which can be utilized in the event of a default. Additionally, in 2019, a layer of insurance was added to the clearing member default protection. This default insurance layer operates after and in addition to the 'Skin In The Game' contributions from ICE Clear Credit, ICE Clear Europe, and ICE Clear U.S., but before the guaranty fund contributions from non-defaulting clearing members. The insurance has a three-year term and is subject to renewal. Despite these safeguards, there is no guarantee that the measures will be sufficient to prevent losses in the event of a significant default.",The company has contributed its own cash to the guaranty funds and added a layer of insurance to its clearing member default protection.,5.0,0.8025076045345817,1.0,0.875,1.0
How does the company's data services offerings aim to address market demands?,"The company's data services offerings aim to address market demands by providing subscription-based, recurring revenues through a range of global financial and commodity market solutions. These include pricing and reference data, exchange data, analytics, feeds, index services, desktops, and connectivity solutions. By offering these services, the company seeks to meet the needs of customers across various markets, ensuring accessibility, functionality, and reliability in data delivery. Additionally, the company focuses on enhancing and improving its electronic platforms and proprietary technology to remain competitive and responsive to evolving industry standards and client preferences.","The company's data services offerings aim to address the rising demand for independent, real-time information, which is being driven by regulation, market fragmentation, increasing technology and data demands, and passive investing and indexation.",4.0,0.5623952325647896,1.0,0.75,1.0
How does the company manage cybersecurity risks?,"The company manages cybersecurity risks through a comprehensive approach that includes the implementation of procedures, controls, and information technology tools to identify, monitor, and prevent threats on its networks. It maintains a Cybersecurity Strategy (CSS) that guides its security program, focusing on the nature of its business, ongoing threat intelligence, and targeted risk mitigation. The strategy is ratified by the Risk Committee of the Board of Directors and relevant corporate governance committees.

The company conducts risk management by framing threats around areas such as sabotage, fraud, and asset theft, which are evaluated by senior leadership, including the Board, Chief Risk Officer, and Chief Information Security Officers. Risk assessments inform testing priorities, remediation actions, and validation of improvements. Additionally, the company operates regionally diverse data centers with backup systems and maintains business continuity and disaster recovery plans to ensure service availability during disruptions. Incident and crisis management plans are also in place to respond to events at any global location.

To protect customer data, the company utilizes industry-leading information security infrastructure and strengthens security and authentication measures, including those related to cloud technologies and remote work environments. Despite these efforts, the company acknowledges that cybersecurity incidents may still occur due to evolving threats, and it remains vigilant in assessing and enhancing its protective tools and controls.","The company employs a Cybersecurity Strategy (CSS) that emphasizes ongoing intelligence collection regarding cybersecurity threats and initiatives to address prominent areas of cybersecurity risk, including the deployment of external and internal teams of ethical hackers.",5.0,0.4687459661391397,1.0,1.0,1.0
How does the fair value determination of our portfolio investments impact our financial condition?,"The fair value determination of our portfolio investments impacts our financial condition by introducing uncertainty into the reported value of our assets. Since many of our investments are in privately held companies without a public market, their fair value is based on estimates derived from various inputs, including management assessments, third-party valuation firms, and the audit committee, all under the oversight of our Board. These valuations are inherently subjective and may fluctuate due to external events or changes in assumptions, leading to material differences from the actual values realized upon sale. As a result, the recorded fair value may differ significantly from the actual proceeds, which can affect reported earnings, credit availability, and the amount of cash available for shareholder distributions. Additionally, changes in estimated fair values are directly reflected in our earnings, meaning any overestimation or underestimation can impact our financial performance and the market value of our common shares.","The fair value determination of our portfolio investments is subjective and dependent on a valuation process approved by our Board. Fair value fluctuations may cause our net asset value to materially understate or overstate the value we may ultimately realize on our investments, impacting our financial condition.",5.0,0.6956906561502438,1.0,1.0,1.0
How does the highly competitive market for investment opportunities affect our business?,"The highly competitive market for investment opportunities can reduce returns and lead to losses. It increases competition with other financial institutions, SMB lenders, and alternative investment vehicles like CLOs, which may offer better pricing, more flexible structuring, and greater resources. This competition may force the business to match competitors' terms, potentially resulting in lower returns or higher risks of capital loss. Additionally, competitors may have advantages such as lower costs of capital, greater experience, or fewer regulatory constraints, making it harder to secure favorable investments. If the business cannot source investments effectively, it may be unable to achieve its investment objectives.","The highly competitive market for investment opportunities could reduce returns and result in losses as we may lose investment opportunities to competitors with greater financial, technical, and marketing resources. Competitors may also offer better pricing and more flexible structuring, forcing us to match their terms or forego opportunities.",4.5,0.854363586402683,1.0,1.0,1.0
What measures are in place to manage the risk of material non-public information limiting our investment discretion in portfolio companies?,"We will not enter into any agreements unless and until we are satisfied that doing so will not raise concerns under the 1940 Act or, if such concerns exist, we have taken appropriate actions to seek review and approval by our Board or exemptive relief for such transaction. Our Board will review these procedures on an annual basis.","Members of our Investment Advisor’s investment committee and other investment professionals may serve as directors or in similar capacities in portfolio companies. If material non-public information is obtained, we could be prohibited from purchasing or selling securities of such companies, limiting our investment discretion.",2.0,0.404106718484568,1.0,0.875,1.0
How does the involvement of interested directors in the valuation process create potential conflicts of interest?,"The involvement of interested directors in the valuation process may create conflicts of interest because these directors also serve as directors of or in a similar capacity to portfolio companies in which the entity invests. This dual role could lead to situations where their personal or professional interests in the portfolio companies may influence their judgments when determining the fair value of investments. Additionally, the Investment Advisor’s management fee is based, in part, on the value of gross assets, and its incentive fees are based on realized and unrealized gains, which may incentivize biased valuations to increase compensation. As a result, the decisions made during the valuation process could be influenced by these financial incentives, potentially compromising objectivity and fairness in assessing the value of portfolio investments.","The involvement of interested directors in the valuation process could result in conflicts of interest as the Investment Advisor’s management fee is based on the value of our gross assets, and its incentive fees are based on realized and unrealized gains. This participation could influence the valuation process in a way that may not be in the best interest of all stockholders.",4.5,0.8626949002080821,1.0,0.875,1.0
What are the implications of the terms of the Investment Advisory Agreement and the Administration Agreement not being negotiated on an arm’s length basis?,"The terms of the Investment Advisory Agreement and the Administration Agreement not being negotiated on an arm’s length basis may result in terms that are less favorable to the entity compared to what could have been achieved through negotiations with an unaffiliated third party. This includes a potential incentive fee structure that could encourage the Investment Advisor to pursue speculative investments and use leverage, even when it may not be prudent. As a result, the terms, including fees, may not be optimized for the entity’s best interests.","The non-arm’s length negotiation of these agreements may result in terms that are not as favorable to us as if they had been negotiated with an unaffiliated third-party. This could include higher fees and less favorable incentive fee structures, which may induce the Investment Advisor to pursue speculative investments or use leverage when it may not be advisable.",5.0,0.892678720753915,1.0,1.0,1.0
How does the potential for PIK interest payments affect our assets under management and the fees payable to Capitala Investment Advisors?,"PIK interest payments increase the size of the loan balance, which in turn increases assets under management. This leads to higher base management fees and incentive fees payable to Capitala Investment Advisors. Additionally, the higher loan balance results in more interest accrual, further increasing pre-incentive fee net investment income and, consequently, incentive fees.","PIK interest payments increase the size of the loan balance, thereby increasing our assets under management. This results in an increase in the base management fee payable to the Investment Advisor. Additionally, the accrual of interest on the higher loan balance increases our pre-incentive fee net investment income, leading to an increase in incentive fees.",5.0,0.9324430472219478,1.0,1.0,1.0
What are the primary risks associated with the commercial success of our products in the U.S.?,"The primary risks associated with the commercial success of products in the U.S. include the inability to establish effective commercialization capabilities, either independently or through partnerships, which could hinder the successful launch of approved products. Even if a product receives marketing approval, it may fail to achieve sufficient market acceptance among physicians, patients, and healthcare payors. Additionally, commercial success depends on factors such as reimbursement levels from government agencies and third-party payors, pricing competitiveness, physician and patient adoption, and the effectiveness and safety of the product compared to alternatives. Regulatory approvals may also limit the approved uses of a product, affecting its market viability. Furthermore, the presence of superior competing products or proprietary rights held by others could prevent successful market entry. Ongoing compliance with regulatory requirements is also critical, as failure to meet these may result in the loss of approvals or suspension of sales. Finally, the commercial performance of a product could be limited by smaller-than-expected addressable patient populations, narrower indications than anticipated, or competition influencing treatment guidelines and physician preferences.","The primary risks include the inability to meet sales expectations, attain profitability and positive cash-flow from operations, and the dependency on the effectiveness of sales, managed markets, marketing efforts, and support for our products.",4.5,0.5924284944941016,1.0,1.0,1.0
What are the potential consequences of failing to comply with cGMP regulations in our manufacturing processes?,"Failure to comply with cGMP regulations can lead to a range of consequences, including delays or failures in obtaining regulatory approval for product candidates. The FDA may issue warning letters, withdraw approvals, or take regulatory or legal actions such as recalls, seizures, suspension of production, or suspension of clinical trials. Additionally, there could be refusal to approve pending applications, detention of products, restrictions on import or export, injunctions, civil and criminal penalties, and potential exclusion from federal health care programs. Such non-compliance could also result in debarment, license revocation, adverse publicity, and significant disruptions to manufacturing and supply chains, potentially leading to market disruption or the need to secure alternative suppliers.","Failure to comply with cGMP regulations could result in product seizures, recalls, or withdrawals, suspension or withdrawal of marketing approvals, fines, and criminal prosecutions, which could significantly harm our business.",5.0,0.8790372100721537,1.0,1.0,1.0
What are the key provisions in our loan agreement that could restrict our operations?,"The loan agreement includes several key provisions that could restrict operations. These include limitations on selling, transferring, or disposing of business or property, making changes to the organizational structure, consolidating or merging with other entities, acquiring other entities, incurring additional debt, creating liens on assets, paying dividends (except in common stock), repurchasing stock, repaying subordinated debt, and making certain investments. Additionally, the agreement contains operating covenants and default clauses that may restrict financing, business activities, and strategic expansion. A breach of these covenants could result in a default, leading to the immediate repayment of all outstanding debt.","The loan agreement contains negative covenants that restrict our ability to sell or dispose of assets, amend certain material agreements, consolidate or merge, incur additional indebtedness, incur additional liens, pay dividends or make certain payments, and make payments of certain subordinated indebtedness.",5.0,0.7922308711856608,1.0,1.0,1.0
How does the classification of our board of directors into two classes affect our corporate governance?,"The context provided does not mention a classification of the board of directors into two classes. Instead, it consistently describes a classification into three classes—Class I, Class II, and Class III—with staggered three-year terms. This structure is intended to delay the ability of stockholders to change the majority of the board's membership, thereby affecting corporate governance by potentially slowing down or preventing changes in management or control. The provided information does not include any details about a two-class board structure or its implications.","The classification of our board of directors into two classes, with one class elected each year, may make it more difficult for a third party to acquire control of us or effect a change in our board of directors and management, potentially deterring hostile takeovers or changes in control.",2.0,0.43563659256474113,1.0,1.0,1.0
What are the potential impacts of Brexit on our international operations?,"Brexit, specifically the United Kingdom's withdrawal from the European Union, may negatively affect global economic conditions, financial markets, and the company's business. This could disrupt international operations by introducing regulatory and compliance complexities, impacting trade relationships, and creating uncertainty in financial markets. Additionally, changes in trade policies, tariffs, and customs regulations may increase operational costs and affect the company's ability to operate efficiently across international markets. Exchange rate fluctuations between the pound sterling, euro, and U.S. dollar may also influence financial performance, particularly since the company's subsidiaries in the UK and Austria operate in different currencies. The uncertainty surrounding the UK-EU Trade and Cooperation Agreement further adds to the potential risks in international trade and market penetration.","Brexit could lead to legal uncertainty and divergent national laws and regulations, new regulatory costs and challenges, potential restrictions on direct investments by foreign entities and trade restrictions, and changes in tax laws and tariffs, which could adversely affect our operations.",4.5,0.5418836883761872,1.0,0.875,1.0
How does the company plan to manage the transition from a research and development focus to commercial activities?,"The company does not outline a specific plan for managing the transition from a research and development focus to commercial activities. Instead, it acknowledges that such a transition will be necessary and emphasizes that it may not be successful. The company recognizes that this shift could involve unforeseen expenses, difficulties, complications, and delays, and that it may not be able to effectively support commercial operations. There is no mention of strategies, organizational changes, or preparations to facilitate this transition.","The company may encounter unforeseen expenses, difficulties, complications, delays, and other known and unknown obstacles during this transition. It may not be successful in this transition, which could adversely affect its business.",5.0,0.5235113331191704,1.0,0.75,1.0
What are the potential consequences if the company is unable to raise additional funding when needed?,"If the company is unable to raise additional funding when needed, it may be forced to delay, reduce, or cease its research and development programs, as well as its future commercialization efforts. The company may also need to discontinue development activities on its product candidates or even cease operations altogether. Additionally, any delay in obtaining capital or failure to complete strategic transactions could further hinder its ability to pursue business objectives. The inability to secure funding could also result in a decline in the company's stock price, making future financing more difficult. Moreover, reliance on future financings that may not be available or may come on unfavorable terms could lead to dilution of stockholders' holdings or adverse changes in their rights.","If the company is unable to raise capital when needed, it could be forced to delay, reduce, or eliminate its product development programs or commercialization efforts, which would significantly impact its ability to develop and market its products.",4.5,0.8117126456554389,1.0,1.0,1.0
How does the company's reliance on third-party manufacturers impact its operations?,"The company's reliance on third-party manufacturers introduces several operational risks. It depends on these manufacturers for regulatory compliance and quality assurance, and there is a risk that they may fail to synthesize or manufacture products according to specifications, potentially leading to breaches of agreements. These third parties may also terminate or choose not to renew contracts based on their own business priorities, which could be costly or damaging to the company. Additionally, the company faces challenges in scaling manufacturing capacity, managing quality issues during scale-up or commercial production, and responding to disruptions such as contamination, natural disasters, or public health crises. Since the company does not have redundant supply or second-source arrangements for bulk drug substances, it may experience delays or failures in product development, clinical trials, or commercialization if manufacturers cannot perform as expected. Furthermore, regulatory requirements such as cGMP compliance necessitate ongoing investments in quality control and inspections, and any changes to manufacturing processes require prior approval, adding complexity and potential delays. This dependence may also affect the company’s profitability and ability to bring products to market competitively.","The company's reliance on third-party manufacturers for the manufacture of its product candidates and related raw materials may expose it to risks such as unforeseen expenses, difficulties, complications, delays, and other known and unknown obstacles. If these third-party manufacturers fail to comply with regulatory requirements or meet contractual obligations, it could delay or prevent the company's ability to develop or commercialize its product candidates.",5.0,0.7312089019941421,1.0,1.0,1.0
What are the key risks related to the company's intellectual property?,"The key risks related to the company's intellectual property include the inability to protect its rights or the inadequacy of those rights to safeguard its technology and product candidates. This could allow competitors to develop and commercialize similar technologies or drugs, potentially harming the company's competitive position. The company relies on a combination of trade secrets, patents, copyrights, trademarks, and confidentiality agreements, which provide only limited protection. Patent prosecution is costly and time-consuming, and the company may lack control over the filing and enforcement of patents, particularly when licensed to third parties. There is also a risk that patentable aspects of inventions may not be identified in time, and defects in patent applications—such as issues with priority claims, inventorship, claim scope, or patent term adjustments—may arise. Additionally, the company may face challenges such as not being the first to file for certain patents, independent development of similar technologies by others, or the failure of pending applications to result in issued patents. Even if patents are granted, they may be invalidated or deemed unenforceable due to legal challenges. Competitors could conduct research in jurisdictions where the company lacks patent protection and use that knowledge to create competing products. The company may also struggle to maintain exclusive market advantages or avoid infringing on others' patents. Furthermore, the company may not develop additional patentable technologies, face issues with trademark protection, or risk that third parties could patent technology the company chooses to keep as trade secrets. Any of these issues could have a material adverse effect on the business, financial condition, and results of operations.","The key risks include the inability to obtain, maintain, or adequately protect intellectual property rights, potential infringement claims from third parties, and the uncertainty of patent litigation outcomes. Additionally, the company may face challenges in enforcing its patents and may not be able to prevent competitors from using similar technologies.",5.0,0.7996887913250079,1.0,1.0,1.0
What is the primary risk associated with investing in the company's common stock?,"The primary risk associated with investing in the company's common stock is the high degree of risk involved, which may include significant volatility, potential loss of principal, and the possibility of the stock price declining. Additionally, the company's common stock may trade below its net asset value, which could restrict the ability to sell additional shares publicly without stockholder and director approval. Stockholders also bear the expenses of borrowings, and debt holders have senior rights to repayment, which may not align with the interests of common stockholders. Furthermore, the stock price could be adversely affected by securities litigation, stockholder activism, and the impact of events such as the COVID-19 pandemic.","Investing in the company's common stock involves a high degree of risk, including the potential for significant losses if the market price of the stock declines.",4.0,0.7126662792651243,1.0,1.0,1.0
What is the potential impact of the COVID-19 pandemic on the company's business?,"The COVID-19 pandemic poses significant risks to the company's business operations, including potential disruptions due to the spread of the virus among employees, suppliers, and partners, as well as government-mandated shutdowns. These disruptions could limit the company's ability to conduct business at full capacity for an indefinite period. The pandemic has already led to adverse impacts on global economic conditions, which could affect the company's financial condition and ability to secure financing on acceptable terms. The company has implemented precautionary measures such as remote work and reduced in-person meetings, which may negatively affect operational efficiency. The full extent of the impact remains uncertain and depends on factors such as the duration and severity of the outbreak, the effectiveness of containment measures, and the availability and distribution of vaccines. Potential consequences include delays in clinical development and regulatory efforts, reduced access to capital, and negative effects on liquidity, business performance, and stock value. Additionally, the pandemic may exacerbate existing risks and uncertainties, and its continued evolution presents ongoing challenges to the company’s operations, financial performance, and growth prospects.","The COVID-19 pandemic has adversely impacted and may continue to adversely impact the company's business, including its preclinical studies and clinical trials, and finances, by causing disruptions in operations, delays in clinical trials, and financial market volatility.",5.0,0.6216875187498186,1.0,1.0,1.0
What are the risks related to the company's reliance on third-party manufacturers?,"The risks related to the company's reliance on third-party manufacturers include dependency on these partners for FDA and DEA regulatory compliance and quality assurance, the potential for misappropriation of proprietary information such as trade secrets, and disruptions and costs associated with changing suppliers, including additional regulatory filings. There is also the risk of third-party breach, termination, or nonrenewal of agreements at inconvenient or costly times, delays or inability to procure or expand manufacturing capacity, and issues related to scale-up of manufacturing. Additionally, the company faces costs and validation requirements for new equipment and facilities needed for scale-up, difficulties in negotiating manufacturing agreements under commercially reasonable terms, and the risk of being reliant on a limited number of sources, including single sources, for critical product components. This reliance can lead to carrier disruptions or increased costs beyond the company’s control. Any of these risks could result in clinical trial delays, failure to obtain regulatory approval, or impaired ability to commercialize products. Further risks include the potential for third-party failure to synthesize or manufacture products according to specifications, the requirement to maintain cGMP compliance, and the need for prior regulatory approval for changes to manufacturing processes. Unannounced inspections by regulatory authorities and reporting requirements also add to the operational burden.","Risks include the potential for not having sufficient quantities of product candidates, failure of third-party manufacturers to comply with regulatory requirements, and the inability to control the quality and timeliness of manufacturing processes.",4.5,0.7574304361839528,1.0,1.0,1.0
What are the potential consequences of the company's inability to protect its intellectual property rights?,"The company may face challenges in enforcing its intellectual property rights, which could harm its ability to compete and reduce demand for its products. It might also incur higher costs and divert management’s attention in protecting its rights. Legal actions to enforce these rights could lead to unpredictable outcomes, including the invalidation or unenforceability of its intellectual property. Additionally, litigation could result in significant expenses and distract technical and management personnel, potentially affecting stock prices. If the company is found to infringe on third-party intellectual property, it could be forced to stop developing, manufacturing, or commercializing certain products, or it may need to obtain licenses under potentially unfavorable terms. This could lead to financial damages, including treble damages and legal fees in cases of willful infringement. Misappropriation claims could similarly harm the business, financial condition, and operations. Furthermore, the company may be unable to detect or prevent unauthorized use, which could negatively impact its reputation and competitive position.","Inability to protect intellectual property rights could lead to competitors developing and commercializing similar products, which could harm the company's business, financial condition, and competitive position.",4.5,0.6928747210808566,1.0,1.0,1.0
How does the company's reliance on third-party manufacturers impact its business operations?,"The company's reliance on third-party manufacturers impacts its business operations by introducing several risks. These include the potential for manufacturers to fail to increase production capacity in a timely or cost-effective manner, as well as the possibility of quality issues during scale-up or commercial activities. Contaminations in product candidates or manufacturing facilities could lead to facility closures, causing delays. Performance failures by manufacturers could delay clinical development or marketing approval. The company does not currently have arrangements for redundant supply or a second source for bulk drug substance, meaning it may face significant delays or costs if a manufacturer cannot meet agreed-upon terms. The company may incur added expenses and time in identifying and qualifying replacement manufacturers, and may be unable to reach agreements with alternatives on a timely basis. Additionally, disruptions such as natural disasters, labor disputes, political instability, or public health crises like the COVID-19 pandemic could hinder manufacturing or shipping. The dependence on third parties also exposes the company to risks related to regulatory compliance, quality assurance, and the possibility of contract termination or nonrenewal. Furthermore, any changes to the manufacturing process require regulatory approval, and noncompliance with cGMP standards could lead to inspections, reporting requirements, and potential market entry delays. This reliance may ultimately affect the company's ability to commercialize products efficiently and competitively, as well as impact future profit margins.","The company's reliance on third-party manufacturers for the production of its product candidates increases the risk of supply chain disruptions, quality control issues, and potential delays in the development and commercialization of its products.",5.0,0.791155385193629,1.0,1.0,1.0
How does the company's financial position and need for capital affect its ability to pursue its business objectives?,"The company's financial position and its need for capital significantly impact its ability to pursue business objectives. While the company is currently well capitalized, it may use its available funds more quickly than anticipated due to changes in operational plans or unexpected demands. The company expects to require additional capital to expand development efforts, obtain regulatory approvals, and commercialize its products. This need for capital may arise sooner than planned and could be sourced through equity or debt financings, collaborations, or other arrangements. However, the company cannot guarantee that such financing will be available on acceptable terms or at all. Securing additional funding may divert management attention, potentially affecting day-to-day operations and progress in developing and commercializing its products. Moreover, any future financings could result in the issuance of additional securities, which may dilute existing stockholders and potentially lower the market price of the company’s shares. In addition, reliance on debt could introduce increased financial obligations and restrictive covenants that limit operational flexibility. Therefore, the company’s ability to achieve its business goals, including commercialization and growth, is contingent upon its ability to access capital under favorable conditions.","The company's need for substantial additional funding to pursue its business objectives may limit its ability to conduct research and development, initiate clinical trials, and seek marketing approval for its product candidates, potentially delaying or preventing the achievement of its goals.",5.0,0.5164632975599172,1.0,1.0,1.0
What are the implications of the company's dual-class stock structure for minority shareholders?,"The dual-class stock structure limits minority shareholders' ability to influence corporate decisions, as voting power is concentrated in the hands of a smaller group of shareholders. In this structure, Class B shares carry significantly more voting power per share compared to Class A shares, allowing key individuals, such as founders or executives, to maintain substantial control over the company. This can result in decisions being made that may not align with the interests of minority shareholders, including those related to mergers, acquisitions, or changes in leadership. Additionally, the existence of non-voting common stock may further diminish the influence of regular shareholders, especially if these non-voting shares are converted into voting shares, altering the balance of voting power. Such a structure may delay or deter changes in control, potentially limiting the ability of minority shareholders to benefit from premium offers during a sale of the company. This concentrated control may also affect the market price of the common stock due to potential investor concerns about reduced governance transparency and the possibility of restricted inclusion in certain market indexes.","The dual-class stock structure may limit the ability of minority shareholders to influence corporate matters and could result in decisions that are not aligned with their best interests, as the majority of voting power is concentrated among a few significant stockholders.",5.0,0.7692980059112656,1.0,1.0,1.0
How does Prelude Therapeutics design its clinical trials?,Prelude Therapeutics designs its clinical trials to leverage the broad utility of its compounds with a focus on efficient regulatory pathways. This approach aims to enable their potentially transformative medicines to reach patients with high unmet medical need more quickly.,Prelude Therapeutics designs its clinical trials to leverage the broad utility of its compounds with a focus on efficient regulatory pathways to enable potentially transformative medicines to quickly reach patients with high unmet medical need.,5.0,0.9802201454548024,1.0,0.625,0.5
How does Prelude Therapeutics protect its intellectual property?,"Prelude Therapeutics protects its intellectual property through the use of patents, trademarks, and other proprietary rights. The company seeks to develop proprietary prodrug formulations that do not infringe on the intellectual property rights of others. It also holds common law trademarks for its name, logo, and product names. Additionally, the company may pursue patents for its technologies and product candidates, though there are risks that these patents may not be issued, may not provide competitive advantages, or could be invalidated or held unenforceable. The company may also engage in legal actions to protect or enforce its patents and other intellectual property rights if they are infringed. However, protection is not guaranteed, as third parties may develop similar technologies independently or through research conducted in jurisdictions with different legal safeguards.","Prelude Therapeutics protects its intellectual property by seeking and maintaining patent protection for compositions of matter, methods of use, and other inventions important to its business. It also relies on know-how and continuing technological innovation to maintain its proprietary position.",4.0,0.6575922496980898,1.0,1.0,1.0
What was the primary reason for the decrease in income tax expense in 2020?,The primary reason for the decrease in income tax expense in 2020 was lower earnings before income taxes.,"The decrease in income tax expense in 2020 was primarily due to the decrease in total income before tax, which was mainly caused by lower crude oil prices, partially offset by lower impairment and write-off charges.",4.0,0.8441015900105933,1.0,1.0,1.0
How did Chevron respond to market conditions and the COVID-19 pandemic during 2020?,"Chevron responded to market conditions and the COVID-19 pandemic during 2020 by taking swift action to protect its long-term health and value. The company lowered its capital expenditures by 35 percent and reduced its operating expenses, excluding non-recurring severance costs, by $1.4 billion compared to 2019. It also completed an enterprise-wide transformation aimed at capturing additional cost efficiencies. Additionally, Chevron suspended its stock repurchase program in March 2020. These measures were taken in response to reduced demand for its products and falling commodity prices caused by travel restrictions and economic activity constraints related to the pandemic. The company entered the crisis well positioned with a strong balance sheet, flexible capital program, and low cash flow breakeven price.","Chevron responded to market conditions and the COVID-19 pandemic by swiftly adjusting controllable items, such as lowering capital expenditures by 35% and reducing operating expenses by $1.4 billion compared to 2019. Additionally, the company suspended its stock repurchase program in March 2020 to protect the dividend and maintain a strong balance sheet.",5.0,0.9480524261251282,1.0,1.0,1.0
What were the key factors affecting Chevron's upstream segment earnings in 2020?,"Chevron's upstream segment earnings in 2020 were impacted by several key factors. These included lower refined product, crude oil, and natural gas prices, as well as reduced refined product volumes, which led to a decrease in sales and other operating revenues. Additionally, income from equity affiliates declined due to the full impairment of Petropiar and Petroboscan in Venezuela, along with lower upstream-related earnings from Tengizchevroil in Kazakhstan. Exploratory expenses increased, primarily due to higher charges for well write-offs. Despite these challenges, depreciation, depletion, and amortization expenses decreased, mainly due to lower impairments. Overall, the combination of reduced commodity prices, operational impairments, and fluctuating exploration costs contributed to the financial performance of the upstream segment.","The key factors affecting Chevron's upstream segment earnings in 2020 included lower crude oil and natural gas realizations, higher impairment and write-off charges, and lower crude oil sales volumes. These factors were influenced by external market conditions, including the impact of the COVID-19 pandemic and lower commodity prices.",4.5,0.8691089281077724,1.0,0.875,1.0
What were the major impairments and write-offs recorded by Chevron in 2020?,"Chevron recorded a full impairment of its investments in Venezuela, totaling $2.6 billion, due to significant uncertainties regarding the recovery of its investment. This resulted from the deteriorating operating environment in the country and the conclusion that an other than temporary loss of value had occurred. As part of this impairment, the company removed approximately 160 million barrels of proved reserves and changed its accounting treatment from the equity method to a non-equity method. Additionally, exploration expenses in 2020 increased due to higher charges for well write-offs, and depreciation, depletion, and amortization expenses decreased primarily due to lower impairments.","In 2020, Chevron recorded major impairments and write-offs primarily due to downward revisions to its oil and gas price outlook. The company fully impaired its investments in Petropiar and Petroboscan in Venezuela, resulting in a total impairment of $2.6 billion.",4.5,0.8443054397202693,1.0,0.875,1.0
What was the impact of the Noble Energy acquisition on Chevron's financial position?,"The acquisition of Noble Energy, Inc. on October 5, 2020, had a significant impact on Chevron's financial position. The aggregate purchase price was $4,109, with approximately 58 million shares of Chevron common stock issued as consideration, representing about 3% of shares outstanding after the acquisition. As part of the transaction, Chevron recognized long-term debt and finance leases with a fair value of $9,231. The acquisition was accounted for as a business combination under ASC 805, requiring assets and liabilities to be measured at their acquisition-date fair values. Provisional fair value measurements were made, with potential adjustments possible within the first year as further analysis was completed. Oil and gas properties were valued using a discounted cash flow approach incorporating internally generated assumptions, while assumed debt was valued using observable market prices. This transaction expanded Chevron’s portfolio with low-cost proved reserves, undeveloped resources, and cash-generating assets in key regions including the U.S., the Eastern Mediterranean, and West Africa. Additionally, the company assumed $9,400 in total debt, including senior notes and finance lease obligations, which were subject to refinancing and restructuring efforts in the following months.","The acquisition of Noble Energy added $7.7 billion in assets sales proceeds and increased Chevron's debt by assuming total debt, including finance lease obligations, with a fair value of approximately $9.4 billion. This acquisition provided Chevron with low-cost proved reserves and attractive undeveloped resources.",4.5,0.7557727045858064,1.0,1.0,1.0
What are the potential impacts of changes in tax laws or regulations on the company's financial condition?,"Changes in tax laws or regulations could have a material adverse effect on the company's business, cash flow, financial condition, and results of operations. New tax laws or changes to existing ones, including those related to corporate tax rates, deferred tax assets, foreign earnings taxation, and expense deductibility, could increase the company's future U.S. tax expense, result in significant one-time charges, or reduce the value of deferred tax assets. Additionally, the application of new or existing tax laws in an adverse manner, or retroactive changes, could increase tax liability for the company or its stockholders. The potential for future legislation to repeal or modify aspects of laws such as the Tax Cuts and Jobs Act, along with uncertainties regarding state conformity with federal changes, adds to the risk. These factors could collectively negatively impact the company's financial condition and operations.","Changes in tax laws or regulations, such as the Tax Cuts and Jobs Act of 2017 and the California Consumer Privacy Act (CCPA), could increase the company's compliance burdens and costs, potentially impacting its financial condition and results of operations.",4.5,0.6670404569021751,1.0,1.0,1.0
"What is the current status of the Company's investment in Oak Therapeutics, Inc.?","The Company no longer has an investment in Oak Therapeutics, Inc. As of April 15, 2019, the Company entered into a Termination and Release Agreement with Oak, surrendering all of its Oak shares and terminating all contractual relationships, including rights related to the investment. The investment was written off in the Company’s consolidated financial statements for the year ended December 31, 2019, and was reflected at a value of zero.","On April 15, 2019, the Company entered into a Termination and Release Agreement with Oak Therapeutics to surrender all of its Oak shares to Oak and terminate any rights the Company might have to acquire additional shares or interest in Oak. The parties terminated all contractual relationships between them. As of the date of deconsolidation, Oak had a negative net asset, which resulted in a gain of $0.08 million.",5.0,0.8859771645656893,1.0,1.0,1.0
How does the Company assess the recoverability of its long-lived assets?,"The Company assesses the recoverability of its long-lived assets by comparing the carrying amount of the assets to the estimated future net cash flows. If the estimated future net cash flows are less than the carrying amount, an impairment expense is recorded to reduce the carrying amount to fair value. Fair value is determined using a discounted cash flow approach or, when available, comparable market values. Long-lived assets to be disposed of are reported at the lower of their carrying amount or fair value less costs to sell. The Company groups these assets at the lowest level for which identifiable cash flows are largely independent and uses a fair value discounted cash flow model or a market approach method to measure potential impairment if the carrying amount may not be recoverable.","The Company assesses the carrying value of its long-lived asset groups when indicators of impairment exist and recognizes an impairment loss when the carrying amount of a long-lived asset is not recoverable when compared to undiscounted cash flows expected to result from the use and eventual disposition of the asset. Indicators of impairment include significant underperformance relative to historical or projected future operating results, significant changes in the Company’s use of the assets or in its business strategy, loss of or changes in customer relationships, and significant negative industry or economic trends.",4.5,0.7320293768963921,1.0,1.0,1.0
How does our dependence on Merck for collaboration affect our business and financial condition?,"Our dependence on Merck for collaboration significantly impacts our business and financial condition. All of our recent revenue has been derived from this single partnership, and we currently have no other agreements that could provide material, ongoing future revenue. This reliance creates financial vulnerability, as any changes in Merck’s strategic decisions or funding commitments could disrupt our ability to fund research and development. Under the current agreement, Merck provides reimbursement for research and development activities up to specified funding caps during the research phase. If expenses exceed these caps, we must use our own financial resources or risk pausing or suspending development, which could hinder progress on key product candidates. Additionally, we cannot predict whether Merck will extend the research phase or agree to modified terms, and any such changes are expected to result in reduced annual research support. If we fail to reach agreement on modified terms, Merck may not extend the collaboration, potentially halting development of certain product candidates after the current phase ends. Furthermore, while we may seek other collaborators for non-Merck product candidates, these arrangements would likely offer limited control over resource allocation and could impact our ability to generate revenue. Overall, the reliance on Merck introduces substantial risks to our financial stability and long-term growth.","Our dependence on Merck involves risks such as Merck potentially not extending the research phase of the collaboration, deciding not to proceed with certain product candidates, or terminating the collaboration, which could delay or preclude our ability to complete research and development programs and materially adversely affect our business and financial condition.",5.0,0.7046585163883198,1.0,0.875,1.0
"What are the potential impacts of disease outbreaks, epidemics, and pandemics, such as COVID-19, on our business operations?","Disease outbreaks, epidemics, and pandemics such as COVID-19 can significantly disrupt business operations by affecting the health and productivity of employees, causing delays in content delivery, and impeding the ability to execute business strategies. They can also impact third-party partners and regulatory agencies, leading to inefficiencies in collaboration and operational challenges. Remote work implementations may reduce productivity due to difficulties in communication and teamwork. Additionally, such events can hinder recruitment efforts, reduce consumer demand, and negatively affect sales of virtual items or events, as seen in the cancellation of scheduled activities. Economic downturns, high unemployment, and global supply chain disruptions resulting from pandemics can further strain financial performance and affect the company’s ability to secure financing. Furthermore, clinical development timelines may be delayed due to disruptions in clinical trial operations, with reliance on contract research organizations potentially being compromised. These factors collectively pose substantial risks to business continuity, results of operations, cash flows, and overall financial health.","Disease outbreaks like COVID-19 can disrupt our operations, delay clinical trials, impact patient enrollment, and increase costs. They can also affect our ability to obtain regulatory approvals and commercialize our product candidates, thereby harming our business, financial condition, and results of operations.",5.0,0.6097222582264517,1.0,1.0,1.0
What are the risks associated with our international operations and expansion plans?,"The risks associated with international operations and expansion include the inability to obtain timely regulatory or pricing approvals, uncertainties in collecting accounts receivable, and exposure to foreign currency exchange rate fluctuations that can impact revenues and net income. Additionally, there are challenges in staffing and managing international operations, potential governmental controls, and less favorable intellectual property laws. Compliance with foreign laws and regulations can be complex and may conflict with U.S. regulations. There are also risks related to anti-bribery and anti-corruption legislation, such as the U.K.'s laws. Expanding internationally involves multiple conflicting and changing laws, including privacy, tax, export, and employment regulations, as well as difficulties in obtaining and enforcing intellectual property rights. Other risks include managing multiple reimbursement systems, financial risks from longer payment cycles and regional financial crises, and exposure to natural disasters, political instability, and economic disruptions. The costs of international operations, including travel, translation, and insurance, can also increase expenses. Finally, the United Kingdom’s withdrawal from the European Union may negatively affect global economic conditions and financial markets, potentially impacting business operations.","Risks include compliance with varying regulatory requirements, potential difficulties in obtaining and maintaining regulatory approvals, challenges in managing foreign operations, and exposure to financial risks such as currency exchange rate fluctuations and longer payment cycles.",5.0,0.7326753559741205,1.0,1.0,1.0
What is the potential impact if the company fails to complete its initial business combination by the deadline?,"If the company fails to complete its initial business combination by the deadline, it will cease all operations except for winding up, redeem the public shares at a per-share price based on the trust account balance (which may result in receiving less than $10.00 per share), and dissolve and liquidate. In this scenario, the public stockholders may receive less than $10.00 per share, and the warrants will expire worthless. Additionally, the company may face reduced ability to conduct due diligence, limited time to negotiate terms, and insufficient working capital to pursue alternative targets, which could lead to unfavorable business combination terms. Third parties may also bring claims against the company, potentially reducing the liquidation proceeds available to stockholders.","If the company fails to complete its initial business combination by the deadline, it will cease all operations except for winding up, redeem public shares, and dissolve, resulting in shareholders receiving only their pro rata portion of the funds in the trust account, which may be less than $10.10 per share, and the warrants will expire worthless.",4.5,0.9318124095156187,1.0,1.0,1.0
What are the key components of the decoupling mechanism for the Utilities?,"The key components of the decoupling mechanism for the Utilities include:

1. Monthly revenue balancing account (RBA) revenues or refunds for the difference between PUC-approved target revenues and recorded adjusted revenues, which delinks revenues from kWh sales.  
2. Rate adjustment mechanism (RAM) revenues to account for escalations in certain O&M expenses and rate base changes.  
3. MPIR component.  
4. Performance incentive mechanisms (PIMs).  
5. An earnings sharing mechanism that reduces revenues between rate cases if the utility exceeds the return on average common equity (ROACE) allowed in its most recent rate case.","The key components of the decoupling mechanism for the Utilities include monthly revenue balancing account (RBA) revenues or refunds, rate adjustment mechanism (RAM) revenues, major project interim recovery (MPIR), performance incentive mechanisms (PIMs), and an earnings sharing mechanism (ESM).",5.0,0.939781365166661,1.0,1.0,1.0
How does HEI manage its investment securities portfolio?,"HEI manages its investment securities portfolio by classifying debt securities as held-to-maturity (HTM), trading, or available-for-sale (AFS) at the time of purchase. Securities intended to be held to maturity are reported at amortized cost. Marketable debt securities held for short-term resale are classified as trading and reported at fair value, with unrealized gains and losses included in earnings. Other marketable debt securities are classified as AFS and reported at fair value, with unrealized gains and losses excluded from earnings and recorded in accumulated other comprehensive income until realized. Interest income is recorded on an accrual basis, with discounts and premiums on securities accreted or amortized using the interest method over the remaining contractual or estimated lives of the securities, adjusted for anticipated prepayments. The effective yield is determined based on actual and projected prepayment experience.","HEI manages its investment securities portfolio by classifying investments as held-to-maturity (HTM), trading, or available-for-sale (AFS), and by using fair value estimates obtained from independent third-party pricing services or brokers.",5.0,0.8578022803479595,1.0,0.875,1.0
What is the significance of the performance-based regulation (PBR) framework approved by the PUC?,"The performance-based regulation (PBR) framework approved by the PUC is significant because it builds upon the existing decoupling mechanism to provide financial stability for utilities while supporting Hawaii’s transition to a clean energy economy and meeting its renewable portfolio standards. It allows utilities to continue using current cost recovery mechanisms like the Energy Cost Recovery Clause and Purchased Power Adjustment Clause, while also introducing modifications that include financial incentives for exemplary performance through Performance Incentive Mechanisms and Shared Savings Mechanisms. The framework incorporates tools such as Scorecards, Reported Metrics, and an expedited Pilot Process to monitor and encourage performance. It also includes safeguards like a symmetric Earnings Sharing Mechanism and a Re-Opener mechanism to ensure fairness by protecting both utilities and customers from excessive earnings or losses and allowing for adjustments when necessary. This structure promotes accountability, innovation, and alignment with state energy goals.","The PBR framework approved by the PUC provides a new regulatory model that aims to provide financial stability to the Utilities and facilitate the transition to a clean energy economy. It includes mechanisms such as the annual revenue adjustment (ARA), earnings sharing mechanism (ESM), and performance incentive mechanisms (PIMs) to ensure efficient and effective operations.",5.0,0.770708604270989,1.0,0.875,1.0
How does HEI manage its short-term borrowings?,"HEI manages its short-term borrowings through a combination of commercial paper, a term loan, and unsecured senior notes. On April 20, 2020, HEI closed on a $65 million 364-day term loan, which was used to reduce the balance on the HEI Facility, thereby increasing its available borrowing capacity. This term loan bears interest at a floating rate, chosen by HEI, based on either an alternate base rate or an adjusted London interbank offered rate plus a margin, and matures on April 19, 2021. The term loan can be prepaid without penalty at any time, but proceeds from debt capital market transactions exceeding $50 million must first be used to pay down the term loan. In December 2020, HEI drew $50 million in unsecured senior notes, using the proceeds to pay down $50 million of the term loan. On January 29, 2021, the remaining $15 million balance of the term loan was repaid. As of December 31, 2020, HEI had $65 million in commercial paper outstanding, compared to $97 million in 2019. Interest on the term loan was 1.9% as of December 31, 2020, while the weighted-average interest rate on commercial paper was 0.8% as of the same date. HEI also uses the proceeds from its notes for general corporate purposes, including the paydown of commercial paper balances.","HEI manages its short-term borrowings through commercial paper and bank term loans. As of December 31, 2020, HEI had $65 million of commercial paper outstanding and a $65 million 364-day term loan from a syndicate of two banks. HEI also maintains credit facilities to support its short-term commercial paper program and working capital needs.",4.0,0.87138206803098,1.0,1.0,1.0
How does HEI manage its long-term debt?,"HEI manages its long-term debt through a combination of term loans, senior notes, and commercial paper. It utilizes short-term financing instruments such as a $65 million 364-day term loan, which was used to reduce the balance on the HEI Facility and increase available borrowing capacity. The term loan is subject to floating interest rates and may be prepaid without penalty, though proceeds from debt capital market transactions exceeding $50 million must first be applied to repay the loan. HEI also issues unsecured senior notes through private placement agreements, such as the $50 million HEI Series 2020A and the $75 million HEI Series 2020B and 2020C agreements, to secure additional funding. These instruments are backed by customary covenants, including financial ratios consistent with those in its existing credit agreements, and include provisions for prepayment in the event of a change of control or certain asset dispositions. Furthermore, HEI manages its debt by repaying outstanding obligations promptly, as evidenced by the full repayment of the $65 million term loan by January 29, 2021, using proceeds from senior note issuances. Additionally, HEI employs commercial paper, with a weighted-average interest rate of 0.8% as of December 31, 2020, to maintain liquidity and manage short-term funding needs.",HEI manages its long-term debt by issuing unsecured senior notes through private placements and maintaining credit facilities to support its short-term commercial paper program and working capital needs. HEI also ensures compliance with financial covenants and customary conditions in its debt agreements.,5.0,0.8218717503477758,1.0,1.0,1.0
What are the unique properties of CSN therapeutics?,"CSN therapeutics are unique due to their ability to enhance cellular bioenergetic efficiency through multiple mechanisms. They act by improving the cellular bioenergetic state, reducing oxidative stress, and stimulating protein homeostasis within central nervous system cells, all simultaneously and independently. Each nanocrystal can exchange thousands of electrons per second, addressing energy deficits in diseased cells without further depleting their internal energy stores. This supports cells by providing the fundamental energy components needed for normal function. Additionally, the nanocatalytic activities of CSN therapeutics are determined by the shape, faceting, size, and chemical composition of the nanocrystals, allowing for flexibility and tunability in their application.","CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystalline form, possess unusually high, unique catalytic activities not present in those same elements in bulk form. These nanocatalytic activities drive, support, and maintain beneficial metabolic and energetic intercellular reactions within diseased, stressed, and damaged cells.",4.5,0.7739162231787294,1.0,1.0,1.0
What is the patent-protected position of Clene?,"Clene holds a patent-protected position with granted patents in the EPO, India, Korea, Mexico, and New Zealand, with two patents granted in New Zealand. Additionally, there are pending patent applications in Canada, China, India, Israel, Japan, and Singapore. The patents are set to expire in 2033 in the U.S. and applicable foreign jurisdictions, though this does not include potential patent extensions. There have been no known proceedings or claims of infringement involving Clene’s intellectual property to date.",Clene's patent-protected position affords it the potential to develop a broad and deep pipeline of novel CSN therapeutics to address a range of diseases with high impact on human health.,4.0,0.6215825570641409,1.0,0.875,1.0
What is the Clene Approach to drug development?,"The Clene Approach to drug development is innovation focused and scientifically driven. It involves the innovation of highly active therapeutic nanocatalysts with novel mechanisms of action, resulting from proprietary advances in nanotechnology, plasma and quantum physics, biochemistry, and materials science. This platform allows for the creation of new drug modalities targeting diseases that have been difficult to address with traditional small molecule or monoclonal antibody approaches. The approach is also scientifically driven, emphasizing clear scientific rationale and sound experimental design from basic science to clinical trials. Clene has developed expertise in producing concentrated, stable, highly active, clean-surfaced nanocrystal suspensions using efficient, green, and scalable processes, positioning it as a leader in therapeutic catalytic nanocrystals and establishing new classes of nanomedicines.","The Clene approach to drug development is innovation-focused and scientifically driven, involving the creation of highly active therapeutic nanocatalysts with novel mechanisms of action resulting from proprietary advances in nanotechnology, plasma and quantum physics, biochemistry, and materials science.",5.0,0.8559610549211604,1.0,1.0,1.0
What is the market opportunity for CSN therapeutics in neurodegenerative diseases?,"The market opportunity for CSN therapeutics in neurodegenerative diseases is significant due to the substantial unmet medical needs in conditions such as multiple sclerosis (MS), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). There are currently no approved therapies that promote remyelination or have been shown to improve function in people with non-active, progressive MS, which accounts for about one-third of all MS cases. Additionally, existing treatments for ALS have limited disease-modifying effects, and there are no disease-modifying therapies for PD, with current options providing only symptomatic relief. The absence of treatments that can prevent or slow the loss of dopaminergic neurons in PD further underscores the need for effective interventions. Given the urgent demand for safe and effective treatments, the potential commercial sales of CSN therapeutics, particularly CNM-Au8, are high if clinical studies confirm remyelination or improved neurological function. Furthermore, with no approved MS drug demonstrating remyelination or neuroprotection, CNM-Au8's ability to address these aspects provides a unique first-mover advantage in the global market.","Despite the urgent demand for treatments and the tremendous market opportunities for neurodegenerative disease therapeutics, effective treatments are limited. If the clinical studies underway provide evidence of remyelination or demonstrate improved neurological function, CSN therapeutics will have significant commercial sales potential in treating MS, PD, or ALS.",4.5,0.7620549287653983,1.0,0.875,1.0
What is the primary responsibility of the management of the Federal Home Loan Bank of Boston regarding internal control over financial reporting?,The primary responsibility of the management of the Federal Home Loan Bank of Boston is to establish and maintain adequate internal control over financial reporting. This includes ensuring that the process provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with accounting principles generally accepted in the United States of America.,The management of the Federal Home Loan Bank of Boston is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America.,5.0,0.9288659255385394,1.0,1.0,1.0
How does the Federal Home Loan Bank of Boston manage its credit risk exposure from advances?,"The Federal Home Loan Bank of Boston manages its credit risk exposure from advances through an integrated approach that includes establishing credit limits for each borrower and conducting ongoing reviews of each borrower's financial condition. The bank also employs collateral and lending policies designed to limit the risk of loss while meeting the funding needs of borrowers. Additionally, the bank is required to obtain sufficient collateral to fully secure credit products up to the counterparty’s total outstanding credit obligations plus unused credit lines. Acceptable collateral includes first-mortgage loans on improved residential property, securities issued or guaranteed by the U.S. government or its agencies, cash or deposits in a collateral account, and other real-estate-related collateral with a readily ascertainable value and where the bank can perfect its security interest. In the case of community financial institutions, secured loans for small business and agriculture or securities representing a whole interest in such loans may also be accepted as collateral.","The Federal Home Loan Bank of Boston manages its credit risk exposure from advances through an integrated approach that includes establishing credit limits for each borrower, ongoing review of each borrower's financial condition, and collateral and lending policies that limit risk of loss while balancing borrowers' needs for a reliable source of funding.",5.0,0.8662893127760232,1.0,1.0,1.0
What are the key features of the Mortgage Partnership Finance® (MPF®) program through which the Federal Home Loan Bank of Boston invests in mortgage loans?,"The Mortgage Partnership Finance® (MPF®) program allows the Federal Home Loan Bank of Boston to invest in mortgage loans by purchasing conventional and government-insured or -guaranteed residential fixed-rate mortgage loans from participating financial institutions. These loans are typically originated and credit-enhanced by the institutions that sell them and are held for portfolio. The majority of the loans are serviced by the originating institution or an affiliate, though some are sold servicing-released and serviced by third parties. The program includes credit-enhancements such as primary and supplemental mortgage insurance or other forms of protection, which are factored into the allowance for credit losses. Loans are recorded at amortized cost, with periodic assessments for expected credit losses conducted quarterly, and the program enables the bank to fulfill its mission of supporting affordable housing.",The MPF program allows the Federal Home Loan Bank of Boston to invest in conventional and government-insured or -guaranteed residential fixed-rate mortgage loans purchased from participating financial institutions. These loans are either guaranteed or insured by federal agencies or credit-enhanced by the related entity that sold the loan.,4.5,0.829335555665958,1.0,0.875,1.0
How does the company's significant indebtedness affect its financial flexibility?,"The company's significant indebtedness reduces its financial flexibility by requiring a substantial portion of cash flow from operations to be used for principal and interest payments, limiting funds available for working capital, capital expenditures, and other corporate purposes. It also increases vulnerability to economic downturns, interest rate fluctuations, and competitive pressures, while restricting the ability to pursue business opportunities or obtain additional financing. Additionally, restrictive covenants in credit agreements limit strategic activities, and the risk of default could lead to accelerated debt repayment, further constraining financial options.","Significant indebtedness increases the risk of loss, reduces cash available for distributions, and may limit the company's ability to refinance debt or pursue new investments, potentially affecting its financial condition and results of operations.",5.0,0.705298037055907,1.0,1.0,1.0
How does the lack of liquidity in the company's investments affect its business?,"The lack of liquidity in the company's investments may adversely affect its business because the securities in which it invests are not publicly traded and are subject to restrictions on resale, making them less liquid than publicly traded securities. There is no established trading market for these securities, which can make it difficult to sell them when desired. If the company is required to liquidate all or a portion of its portfolio quickly, it may realize significantly less than the value at which the investments were previously recorded. Additionally, the company does not expect to achieve liquidity in its investments in the near-term and may face further restrictions on liquidation if it possesses material non-public information about a portfolio company.","The lack of liquidity in the company's investments makes it difficult to sell assets quickly if needed, which could limit its ability to respond to changes in economic conditions or meet financial obligations.",5.0,0.7919164131583267,1.0,1.0,1.0
"What was the outcome of Rayonier Inc.'s management assessment of internal control over financial reporting as of December 31, 2020?","Rayonier Inc.'s management concluded that the internal control over financial reporting was effective as of December 31, 2020.","Based on their evaluation under the criteria set forth in the Internal Control - Integrated Framework, management concluded that their internal control over financial reporting was effective as of December 31, 2020.",5.0,0.6973363640128796,1.0,1.0,1.0
What are the inherent limitations of internal control over financial reporting?,"Internal control over financial reporting may not prevent or detect misstatements due to its inherent limitations. These limitations include the possibility that controls may become inadequate over time because of changes in conditions or a deterioration in the degree of compliance with policies and procedures. Additionally, projections of effectiveness to future periods are subject to the risk that controls may no longer be effective.","The inherent limitations of internal control over financial reporting include the possibility of misstatements due to error or fraud not being prevented or detected on a timely basis. Additionally, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.",5.0,0.9455272622234323,1.0,1.0,1.0
What are the reportable business segments of Rayonier Inc. after the merger with Pope Resources?,"The reportable business segments of Rayonier Inc. after the merger with Pope Resources include the addition of a new segment, Timber Funds, as part of a revision to their business segments.","After the merger with Pope Resources, Rayonier Inc. operates in six reportable segments: Southern Timber, Pacific Northwest Timber, New Zealand Timber, Timber Funds, Real Estate, and Trading.",3.0,0.9089999925709035,1.0,0.875,1.0
What is the nature of the environmental remediation liabilities assumed by Rayonier Inc. in the merger with Pope Resources?,"The environmental remediation liabilities assumed by Rayonier Inc. in the merger with Pope Resources relate to potential liability associated with environmental contamination and Natural Resource Damages (NRD) in Port Gamble, Washington. These liabilities are considered part of the non-cancellable commitments and are based on preliminary estimates of fair value as of December 31, 2020.","In the merger with Pope Resources, Rayonier Inc. assumed environmental remediation liabilities related to potential liability associated with environmental contamination and Natural Resource Damages (NRD) in Port Gamble, Washington.",5.0,0.9357324629846879,1.0,0.75,1.0
How does Rayonier Inc. account for its investments in marketable equity securities?,"Rayonier Inc. accounts for its investments in marketable equity securities in accordance with the accounting policies described in Note 1 - Summary of Significant Accounting Policies. As of December 31, 2019, these investments consisted entirely of 114,400 limited partnership units of Pope Resources, which were originally purchased in an open-market transaction at $65.90 per unit. These units were included as consideration transferred in the merger with Pope Resources. The specific accounting treatment for these investments is detailed in Note 1, with additional context provided in Note 2 - Merger with Pope Resources.","Rayonier Inc. accounts for its investments in marketable equity securities at fair value based on quoted prices in their active market, with both the realized and unrealized gains and losses reported in “Interest and other miscellaneous income, net.”",2.5,0.672382019653412,1.0,0.75,1.0
"What is the primary focus of Starwood Property Trust, Inc.?","Starwood Property Trust, Inc. is primarily focused on originating, acquiring, financing, and managing mortgage loans and other real estate investments in both the United States and Europe.","Starwood Property Trust, Inc. is primarily focused on originating, acquiring, financing, and managing mortgage loans and other real estate investments in both the United States and Europe.",5.0,1.0,1.0,1.0,1.0
How has the adoption of Accounting Standards Codification Topic 326 affected the Company's accounting for expected credit losses?,"The adoption of Accounting Standards Codification Topic 326 has resulted in the Company using a forward-looking ""expected loss"" model for measuring credit losses on financial instruments, including trade receivables and off-balance sheet credit exposures. This approach, known as the Current Expected Credit Loss (CECL) model, requires the recognition of an allowance for credit losses based on expected losses over the life of the financial assets, incorporating historical experience, current conditions, and reasonable and supportable forecasts. The adoption was applied using the modified-retrospective method, which did not require restatement of prior period financial statements. As a result, the Company now estimates credit losses on its accounts receivable using both quantitative and qualitative components. The quantitative component is derived from an analytic model based on historical loss rates, while the qualitative component considers recent trends in economic indicators and other relevant factors that may impact loss rates. This change has led to an earlier recognition of credit loss provisions compared to the previous incurred loss model.","The adoption of ASC 326, effective January 1, 2020, changed the Company's method of accounting for expected credit losses to a current expected credit loss model (CECL), which requires the consideration of possible credit losses over the life of an instrument, as opposed to only upon the occurrence of a discrete loss event.",5.0,0.6928662881328356,1.0,1.0,1.0
How does the Company manage its exposure to interest rate risk?,"The Company manages its exposure to interest rate risk primarily through the use of natural on-balance-sheet hedges, which involve offsetting interest rate exposures from loans and investment securities with deposits and other interest-bearing liabilities. The investment securities portfolio is specifically utilized to manage interest rate exposure and sensitivity within the guidelines established by the ALCO. The Company employs natural and offsetting economic hedges to minimize the need for off-balance-sheet derivative financial instruments. Additionally, the Company considers expected movements in interest rates when managing risk and may use different techniques as rates change. Derivative instruments, such as interest rate swaps and caps, are used to hedge cash flow risks and stabilize interest expense, although their use is generally limited. The Company also conducts simulation analyses to formulate strategies that achieve a desired risk profile while adhering to capital and liquidity guidelines.","The Company manages its exposure to interest rate risk by using derivative financial instruments such as interest rate swaps, which are designed to economically hedge certain risks. These derivatives are not designated for hedge accounting and changes in their fair value are recorded in earnings.",4.0,0.7152814846001562,1.0,1.0,1.0
What is the significance of the fair value option election for certain financial assets and liabilities?,"The fair value option election allows entities to measure certain eligible financial assets and liabilities at fair value, both initially and subsequently. This election is made on an instrument-by-instrument basis and is irrevocable once chosen. It enables entities to report unrealized gains and losses on these items in earnings, providing transparency in financial reporting. The election is particularly significant for mitigating accounting mismatches between the carrying value of instruments and related assets and liabilities consolidated at fair value. It also ensures consistency across financial instruments, such as residential loans, and is appropriate for items with short-term holding periods, such as loans held-for-sale. Additionally, fair value measurements are required to be reported separately in the consolidated balance sheets from instruments measured using other accounting methods.","The fair value option election allows the Company to make an irrevocable election to measure certain eligible financial assets and liabilities at fair value. Unrealized gains and losses on items for which the fair value option has been elected are reported in earnings, which helps to mitigate accounting mismatches between the carrying value of the instruments and the related assets and liabilities that the Company consolidates at fair value.",4.5,0.8284832772138669,1.0,0.875,1.0
How does the Company account for acquisitions of real estate with in-place leases?,"The Company accounts for acquisitions of real estate with in-place leases by applying the asset acquisition provisions of ASC 805 when substantially all of the fair value of the assets acquired is concentrated in a single identifiable asset or group of similar assets. In such cases, the acquired properties are recognized at their purchase price, including acquisition costs, which are capitalized. For all other acquisitions of real estate with in-place leases, the business combination provisions of ASC 805 are applied. Additionally, the asset acquisition provisions of ASC 805 are used for acquired real estate assets where a lease is entered into concurrently with the acquisition, such as in sale-leaseback transactions.","For acquisitions of real estate with in-place leases where substantially all of the fair value of the assets acquired is concentrated in either a single identifiable asset or group of similar identifiable assets, the Company applies the asset acquisition provisions of ASC 805, resulting in the acquired properties being recognized initially at their purchase price inclusive of acquisition costs.",4.5,0.9081894865889154,1.0,0.875,1.0
What is the Company's approach to managing credit risk in its investment portfolio?,"The Company manages credit risk in its investment portfolio by using bond ratings published by independent agencies to measure risk. The investment securities portfolio consists of U.S. government-sponsored entity securities, tax-free securities, or other securities with ratings from “AAA” to “Not Rated.” All securities, except those not rated, are rated by at least one nationally recognized statistical rating organization.","The Company manages credit risk by regularly evaluating the extent and impact of any credit deterioration associated with the performance and/or value of the underlying collateral, the financial and operating capability of the borrower, and the overall economic environment. It utilizes third-party database services to provide industry losses as benchmarks for determining expected credit losses.",3.0,0.5468515164608625,1.0,0.875,1.0
How has Stifel Financial Corp. adopted new accounting standards for credit losses?,"Stifel Financial Corp. adopted the new accounting standard for credit losses, ASU 2016-13 Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, by changing its method for accounting for the Allowance for Credit Losses in the year ending December 31, 2020. This change was implemented in accordance with the updated standards, and auditing the Company’s Allowance for Credit Losses was identified as a critical audit matter.","Stifel Financial Corp. adopted the new accounting standard for credit losses on January 1, 2020, which requires the measurement of the allowance for credit losses to be based on management’s best estimate of lifetime expected credit losses inherent in the Company’s relevant financial assets.",4.5,0.8785497755720766,1.0,0.0,1.0
How does Stifel Financial Corp. manage its off-balance sheet credit risk?,"Stifel Financial Corp. manages its off-balance sheet credit risk through various financial instruments and activities that are not reflected on its balance sheet, such as commitments, contingent liabilities, and derivative instruments. These include investment banking activities, securities trading, and lending practices, which expose the company to credit risk in the form of potential losses if counterparties fail to meet their obligations. The company mitigates this risk by employing risk management practices, such as credit assessments of counterparties, monitoring and controlling exposure limits, and using hedging strategies to offset potential losses. Additionally, Stifel Financial Corp. may utilize collateral, netting agreements, and other credit enhancement techniques to reduce the likelihood of default by counterparties. While the provided documents do not detail specific policies, it is standard practice for financial institutions to manage off-balance sheet credit risk through rigorous credit risk assessment and monitoring frameworks, which are likely in place at Stifel Financial Corp.","Stifel Financial Corp. manages its off-balance sheet credit risk through various strategies, including position and credit limits, continuous monitoring of collateral, requiring additional collateral when appropriate, and using interest rate derivative contracts to manage exposures arising from business activities.",4.0,0.7256351104065852,1.0,0.375,1.0
What are the key factors considered in the valuation of Stifel Financial Corp.'s financial instruments?,"The key factors considered in the valuation of Stifel Financial Corp.'s financial instruments include judgments, assumptions, and estimates related to market conditions, credit risk, liquidity, and the expected future cash flows. These elements significantly influence the reported amounts and are subject to change, potentially affecting the accuracy of the valuation.","The key factors considered in the valuation of Stifel Financial Corp.'s financial instruments include observable market prices, contractual terms, market parameters, credit ratings, and the value of underlying collateral. The valuation techniques used vary depending on the level of pricing observability.",3.0,0.861375521113368,1.0,0.75,1.0
How does Stifel Financial Corp. report its quarterly financial information?,"Stifel Financial Corp. reports its quarterly financial information in its consolidated financial statements, which include the company and its wholly owned subsidiaries. The financial statements are prepared in conformity with U.S. generally accepted accounting principles and include significant estimates and assumptions that affect the reported amounts. These statements are accompanied by notes that provide further details on items such as accounting changes, cash flows, and other financial data.","Stifel Financial Corp. reports its quarterly financial information in a summarized format, providing key financial metrics such as revenues, net income, and earnings per share for each quarter of the fiscal year.",4.0,0.8298698751036394,1.0,0.75,1.0
What is the primary method used to evaluate the effectiveness of the Partnership’s internal control over financial reporting?,"The primary method used to evaluate the effectiveness of the Partnership’s internal control over financial reporting involves obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk.",The Partnership uses the framework set forth in the report entitled “Internal Control-Integrated Framework” (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).,3.0,0.5804302934745766,1.0,1.0,1.0
What is the purpose of the commercial paper program maintained by the Partnership?,"The commercial paper program maintained by the Partnership is used to issue privately placed, unsecured commercial paper notes up to an aggregate of $3.0 billion. These notes are backstopped by the senior unsecured revolving credit facility and the senior secured hedged inventory facility, meaning borrowings under the commercial paper program reduce the available capacity under these facilities. The program supports short-term financing needs, with proceeds used to fund acquisitions, investments, repurchase common stock, and for general corporate purposes. Additionally, the program allows the Partnership to manage its liquidity efficiently by leveraging market conditions and interest rates.","The commercial paper program allows the Partnership to issue up to $3.0 billion in privately placed, unsecured commercial paper notes, which are primarily used for short-term financing needs such as working capital.",4.5,0.9149866475552861,1.0,1.0,1.0
How does the Partnership allocate net income for partners’ capital presentation purposes?,"The Partnership allocates net income for partners’ capital presentation purposes entirely to the Limited Partners. This is because, following the Energy Transfer Merger, the general partner holds a non-economic interest in the Partnership, resulting in all net income being allocated to the Limited Partners for capital account and statement of operations presentation.",Net income is allocated 100% to common unitholders after giving effect to income allocations for cash distributions to Series A preferred unitholders and guaranteed payments attributable to Series B preferred unitholders.,3.0,0.649184566934664,1.0,1.0,1.0
"How did Loews Corporation assess the effectiveness of its internal control over financial reporting as of December 31, 2020?","Loews Corporation assessed the effectiveness of its internal control over financial reporting as of December 31, 2020, based on criteria established in the Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. This assessment was performed by the Company’s management, and the independent registered public accounting firm, Deloitte & Touche LLP, audited the internal control over financial reporting in accordance with the standards of the Public Company Accounting Oversight Board (United States). The audit resulted in an unqualified opinion on the Company's internal control over financial reporting.",Loews Corporation's management assessed the effectiveness of its internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control - Integrated Framework (2013).,5.0,0.852758665629764,1.0,0.75,1.0
"What significant accounting changes did Loews Corporation adopt on January 1, 2020?","The provided context does not contain any information about significant accounting changes adopted by Loews Corporation on January 1, 2020.","On January 1, 2020, Loews Corporation adopted ASU 2016-13, ""Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,"" which required changes to the recognition of credit losses on financial instruments not accounted for at fair value through net income.",1.0,0.628764863754572,0.0,0.75,1.0
How did the adoption of ASU 2016-13 affect Loews Corporation's financial statements?,The provided context does not contain information about the adoption of ASU 2016-13 or its impact on Loews Corporation's financial statements.,"The adoption of ASU 2016-13 resulted in a $5 million decrease in Retained earnings, after tax and noncontrolling interests, and the establishment of an allowance for credit losses of $6 million for available-for-sale fixed maturity securities that were purchased with credit deterioration.",1.0,0.3258582866654043,0.0,0.375,1.0
"What was the impact of Diamond Offshore's deconsolidation on Loews Corporation's financial statements for the year ended December 31, 2020?","The deconsolidation of Diamond Offshore from Loews Corporation's financial statements resulted in the recognition of a loss of $1.2 billion ($957 million after tax) during the year ended December 31, 2020. This loss was reported within Investment gains (losses) on the Consolidated Statements of Operations and represented the difference between the carrying value and the estimated fair value of Loews Corporation's investment in equity securities of Diamond Offshore as of the Filing Date.","The deconsolidation of Diamond Offshore resulted in the recognition of a loss of $1.2 billion ($957 million after tax) during the year ended December 31, 2020, which is reported within Investment gains (losses) on the Consolidated Statements of Operations.",5.0,0.886904162543208,1.0,1.0,1.0
How did Boardwalk Pipelines' acquisition of common units affect its financial position?,"The acquisition of common units in Boardwalk Pipelines by Boardwalk GP, LP, a subsidiary of Loews Corporation, resulted in the purchase of all outstanding limited partnership interests not already owned by the General Partner or its affiliates. This transaction, completed on July 18, 2018, for approximately $1.5 billion at $12.06 per unit, led to a situation where the purchase price was lower than the carrying value of the noncontrolling interests. As a result, the financial impact included an increase in Additional paid-in capital by $658 million, an increase in deferred income tax liabilities by $213 million, and a decrease in AOCI (Accumulated Other Comprehensive Income) by $29 million. Following the transaction, Boardwalk Pipelines Holding Corp., a wholly owned subsidiary of Loews Corporation, held all limited partnership interests in Boardwalk Pipelines.","Boardwalk Pipelines' acquisition of common units resulted in an increase to Additional paid-in capital of $658 million, an increase to deferred income tax liabilities of $213 million, and a decrease to AOCI of $29 million.",5.0,0.7525572864801814,1.0,0.875,1.0
What are the potential risks associated with relying on third-party manufacturers for the supply of our product candidates?,"Relying on third-party manufacturers for the supply of product candidates involves several potential risks. These include dependence on the third party for compliance with regulatory requirements such as FDA and DEA standards, as well as for quality assurance. There is also a risk of misappropriation of proprietary information, including trade secrets and know-how. Additionally, disruptions may occur when changing suppliers, which can involve significant costs and regulatory filings. There is a risk that the third party may breach, terminate, or choose not to renew manufacturing agreements at a time that is costly or inconvenient for the company. Delays or an inability to secure or scale up manufacturing capacity could impact development timelines. Furthermore, scaling up production may lead to quality issues and require investment in new equipment and facilities. The inability to negotiate agreements on commercially reasonable terms or to secure alternative manufacturers in a timely manner could hinder development or commercialization efforts. Reliance on a limited number of sources, or even single sources, for critical components may result in supply shortages. Finally, external factors such as carrier disruptions or increased costs beyond the company's control could affect supply chain reliability. Any of these risks could lead to clinical trial delays, failure to obtain regulatory approval, or challenges in successfully commercializing products, potentially resulting in FDA actions such as injunctions, recalls, or production suspensions.","Relying on third-party manufacturers exposes us to risks including potential delays in product supply, quality control issues, and dependency on the manufacturers' compliance with regulatory requirements. Any failure by these manufacturers could delay our product development and commercialization efforts.",5.0,0.8151367120942089,1.0,1.0,1.0
How does the COVID-19 pandemic potentially impact the company's business operations?,"The COVID-19 pandemic may disrupt the company's business operations by affecting the health and productivity of employees, impairing the ability of third-party partners and regulatory agencies to support operations, and leading to remote work arrangements that reduce collaboration efficiency. It could also hinder recruitment efforts, impact consumer health and spending, and cause cancellations or reduced attendance at events. Additionally, economic downturns, high unemployment, and supply chain disruptions resulting from the pandemic may negatively affect overall business performance. The pandemic's effects on global economic conditions may also impact the company's ability to secure financing. While the extent of these impacts remains uncertain, they could be material across various business aspects.","The COVID-19 pandemic could have a material adverse impact on the company's business, financial condition, and results of operations, including disruptions to clinical trials, manufacturing, supply chain, and commercialization efforts, as well as potential delays in regulatory approvals and market introduction of products.",4.5,0.6484526020496594,1.0,1.0,1.0
How does the company's reliance on third-party manufacturers affect its operations?,"The company's reliance on third-party manufacturers introduces several operational risks. The inability of these manufacturers to scale production efficiently or maintain quality control can lead to delays in clinical development or marketing approval. In the event of performance failures, the company may need to replace manufacturers, which could result in added costs, delays, and challenges in identifying and qualifying alternative suppliers. Additionally, the lack of redundant supply or a second source for bulk drug substance increases vulnerability to disruptions caused by factors such as natural disasters, public health crises, or supply chain issues. The company is also dependent on third parties for regulatory compliance and adherence to cGMP standards, with potential consequences including unannounced inspections, mandatory reporting of deviations, and the need for prior regulatory approval for manufacturing changes. Any termination or nonrenewal of manufacturing agreements by third parties could be costly and damaging, further impacting the company’s ability to commercialize products effectively and maintain competitive market timing.","The company's reliance on third-party manufacturers for the production of octreotide capsules exposes it to risks such as potential supply disruptions, quality control issues, and regulatory compliance challenges. Any failure by these manufacturers to meet quality standards or regulatory requirements could delay product development and commercialization, leading to increased costs and potential loss of market opportunities.",5.0,0.7272220008283189,1.0,1.0,1.0
"What are the financial implications of the company's Revenue Interest Financing Agreement with Healthcare Royalty Partners IV, L.P.?","The company received $25.0 million in April 2020, an additional $25.0 million in July 2020, and $15.0 million in September 2020, with an entitlement to an additional $10.0 million in early 2022, subject to certain conditions. In exchange, the company agreed to make tiered quarterly royalty payments in the low double digits on worldwide net revenues of MYCAPSSA and any other future products, with step-downs upon reaching certain annual revenue thresholds. The agreement expires upon the first to occur of April 7, 2030, the Maturity Date, or when HCR has received aggregate payments equal to 195% of the total amount funded by HCR, known as the Hard Cap. If HCR has not reached the Hard Cap by the Maturity Date and no event of default has occurred, the company must pay HCR a specified amount based on the total funded amount as of that date. An event of default, such as the withdrawal, suspension, or other termination of the FDA approval of MYCAPSSA for acromegaly that continues for sixty days and prevents marketing, allows HCR to accelerate payments up to the Hard Cap. Additionally, in the event of certain material adverse events or material breaches of representations and warranties (not considered events of default), HCR may terminate the agreement and require the company to pay the funded portion of the investment, minus payments received, plus a specified annual rate of return. The agreement may restrict the company’s ability to commercialize MYCAPSSA, limit cash flow for operations, and expose the company to risks that could adversely affect its business, financial condition, and results of operations.","The Revenue Interest Financing Agreement imposes significant financial obligations on the company, including tiered quarterly royalty payments based on product revenues, potential gross-up payments, and restrictions on incurring additional indebtedness. These obligations could limit the company's financial flexibility and increase its operating costs, potentially impacting its ability to invest in growth initiatives and maintain profitability.",5.0,0.4298086287854781,1.0,1.0,1.0
How does the company plan to address the risk of product liability lawsuits?,"The company plans to address the risk of product liability lawsuits by carrying product liability insurance and intending to acquire additional insurance coverage for commercial products if marketing approval is obtained. However, there is no assurance that the current or future insurance will be sufficient to cover all potential expenses or losses, as coverage may be inadequate or become unavailable at reasonable costs. The company also faces the risk that even successful defense of such claims could result in significant financial and management resources being diverted from core business activities.","The company maintains product liability insurance coverage to mitigate the financial impact of potential product liability claims. However, it recognizes that insurance coverage may not be sufficient to cover all costs and liabilities that could arise from such claims, and it may face significant legal expenses, reputational damage, and potential financial losses if it is unable to defend against or settle these claims successfully.",5.0,0.813967014670347,1.0,1.0,1.0
How does the company's dependence on a limited group of suppliers and manufacturers impact its business?,"The company's dependence on a limited group of suppliers and manufacturers poses significant risks to its business. If any key supplier is lost or experiences disruptions, it could lead to delays in product development and material delivery, potentially impacting sales. The company may face challenges in finding replacement sources quickly, especially for components that involve unique technology or are subject to stringent regulatory requirements, which could result in additional costs and operational setbacks. Furthermore, the lack of long-term contracts with some suppliers means there is no guarantee of continued supply or adherence to specifications, which could lead to quality issues or production interruptions. This reliance may also reduce the company’s negotiating power, as smaller firms often receive lower priority compared to larger competitors. Additionally, the company's substantial indebtedness could cause suppliers to refuse credit or offer less favorable terms, further disrupting the supply chain. Overall, these factors could negatively affect the company's revenue, market share, and financial condition, and may also damage its reputation and ability to meet customer demand.","The company may incur significant product development costs or experience material delivery delays if there is an interruption in supply from any one of these suppliers or manufacturers, which could materially impact sales of its products.",4.5,0.6234034016182037,1.0,1.0,1.0
"What are the implications of the company being a ""controlled company"" under Nasdaq rules?","The company being classified as a ""controlled company"" under Nasdaq rules means it qualifies for exemptions from certain corporate governance requirements. These exemptions include not being required to have a majority of independent directors on its board, not needing a governance committee composed entirely of independent directors with a written charter, and not being required to have a compensation committee made up entirely of independent directors with a written charter. Additionally, the company is not obligated to have the compensation committee consider independence factors when hiring legal counsel or other advisors, nor is it required to conduct annual performance evaluations of its governance and compensation committees. As a result, stockholders may not have the same protections as those afforded to shareholders of companies that comply with all of Nasdaq's corporate governance standards. The company may also choose to rely on these exemptions in the future, which could affect the level of independence and oversight in its governance structure.","As a controlled company, the company qualifies for exemptions from certain corporate governance requirements, which may limit the protections afforded to shareholders and could impact the company's stock price and trading volume.",5.0,0.7371688799540493,1.0,1.0,1.0
What is the primary risk factor mentioned regarding investment in the company's shares?,"The primary risk factor mentioned regarding investment in the company's shares is that investing in the company's shares involves a high degree of risk, including potential substantial dilution in shareholders' ownership percentage or interests in underlying assets, and the possibility of significant fluctuations in the net asset value (NAV) of the shares due to various factors beyond the company's control. Additionally, the company's shares may be subject to volatility or loss of principal due to the speculative nature of its investments.","The primary risk factor mentioned is that an investment in the company's shares involves a high degree of risk, and the occurrence of any of the risks listed could have a material adverse effect on the company's business, financial condition, results of operations, and future growth prospects.",4.0,0.7962083339218116,1.0,0.0,1.0
How has the COVID-19 pandemic impacted the company's business operations and clinical development timelines?,"The COVID-19 pandemic has negatively impacted the company's business operations and clinical development timelines. Government-imposed measures such as quarantines, shelter-in-place orders, and travel restrictions led to business closures, work stoppages, and delays, which disrupted normal operations. The company implemented a work-from-home policy for all employees, which remains in effect, and may take further operational changes as needed. These measures, along with ongoing uncertainty about the evolving situation, have affected productivity and caused disruptions.

Additionally, clinical development timelines have been adversely affected, particularly due to the pandemic's impact on patient recruitment, enrollment, and follow-up visits at clinical trial sites. The company relies on contract research organizations and other third parties to conduct clinical trials, and there is no guarantee that these partners will continue to perform their duties timely and satisfactorily. The pandemic has also affected operations in regions where the company has concentrations of clinical trial sites or other business activities, and could cause significant disruptions in the services provided by CROs and manufacturers.","The COVID-19 pandemic has affected the company's business operations and clinical development timelines by impacting patient recruitment, enrollment, and follow-up visits at clinical sites. Government orders and restrictions to control the spread of the disease have also caused delays and uncertainties in the company's operations.",4.5,0.8413560245960142,1.0,0.875,1.0
What measures has the company taken to protect its intellectual property rights?,"The company has taken several measures to protect its intellectual property rights. These include relying on patents, copyrights, trade secrets, trademarks, and unfair competition laws. Additionally, the company uses license agreements and other contractual provisions to safeguard its intellectual property. To further protect its proprietary technology, the company enters into confidentiality agreements and intellectual property assignment agreements with employees, consultants, corporate partners, and advisors. Suppliers are also bound by confidentiality provisions under their agreements with the company. Despite these measures, the company acknowledges that its intellectual property rights could still be challenged, invalidated, circumvented, or misappropriated.","The company seeks to protect its intellectual property rights by filing patent applications in the United States and abroad, entering into confidentiality agreements with parties who have access to its proprietary information, and maintaining physical and electronic security of its information technology systems.",5.0,0.6396988127659305,1.0,1.0,1.0
What are the risks associated with the company's reliance on third-party manufacturers for the production of its product candidates?,"The risks associated with the company's reliance on third-party manufacturers include the possibility of not having sufficient quantities of product candidates available on a timely basis or at all, or that such quantities may not be available at an acceptable cost or quality, which could delay, prevent, or impair development or commercialization efforts. There is also a risk that the company may be unable to establish agreements with third-party manufacturers on acceptable terms or at all. Even if agreements are established, reliance on third parties entails additional risks such as failure to comply with regulatory requirements and maintain quality assurance, breach of manufacturing agreements, failure to manufacture according to specifications or schedule, misappropriation or disclosure of proprietary information, and termination or nonrenewal of agreements at times that are costly or inconvenient. Additionally, third-party manufacturers must comply with cGMP regulations and similar foreign standards, and changes to the manufacturing process require prior regulatory approval. The company also faces risks related to regulatory inspections, deviations from cGMP, and reporting and documentation requirements, which require ongoing investment in production and quality control. Furthermore, the company has not secured alternate suppliers, meaning it could face significant challenges in continuing development or commercialization if the current manufacturer cannot meet demand or if problems arise.","The risks include the inability to meet product specifications and quality requirements consistently, delays in obtaining sufficient manufacturing capacity, potential non-compliance with regulatory requirements, and the possibility of increased costs and operational challenges if the company needs to find alternative manufacturers.",5.0,0.7461090999458264,1.0,1.0,1.0
"What was the opinion of KPMG LLP on the Company's internal control over financial reporting as of December 31, 2020?","There is no mention of KPMG LLP in the provided context. The independent registered public accounting firms mentioned are Ernst & Young LLP and PricewaterhouseCoopers LLP. Therefore, it is not possible to determine KPMG LLP's opinion on the Company's internal control over financial reporting as of December 31, 2020.","In their opinion, KPMG LLP stated that the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on the COSO framework.",1.0,0.4737146700565563,1.0,0.875,1.0
How did the Company support its liquidity and capital resources during the crisis in March 2020?,The Company supported its liquidity and capital resources during the crisis in March 2020 by issuing four series of senior notes totaling ¥57.0 billion.,The Company supported its liquidity and capital resources by issuing four series of senior notes totaling ¥57.0 billion and issuing $1.0 billion in senior notes through public debt offerings under its U.S. shelf registration statement. The Company also has available liquidity in its unsecured revolving credit facilities of $1.0 billion and ¥100.0 billion and currently has no borrowings under either of these facilities.,4.0,0.767788151754334,1.0,1.0,1.0
What are the significant accounting policies of Aflac Incorporated?,"The significant accounting policies of Aflac Incorporated include the description of its business, which primarily involves selling supplemental health and life insurance in the United States and Japan. The company operates through American Family Life Assurance Company of Columbus (Aflac) in the U.S. and Aflac Life Insurance Japan Ltd. (ALIJ) in Japan, effective April 1, 2018. Prior to that date, the insurance business in Japan was operated as a branch of Aflac. The company's operations are divided into two reportable business segments: Aflac U.S., including Aflac, and Aflac Japan, including ALIJ. American Family Life Assurance Company of New York (Aflac New York) is a wholly owned subsidiary of Aflac. Most policies are individually underwritten and marketed through independent agents, with group products marketed and administered through Continental American Insurance Company (CAIC), branded as Aflac Group Insurance. Aflac Japan's revenues, including realized gains and losses on its investment portfolio, accounted for a significant portion of the company's total revenues, with 68% in 2020, compared to 69% in 2019 and 70% in 2018.","The significant accounting policies of Aflac Incorporated include foreign currency translation, insurance revenue and expense recognition, cash and cash equivalents, investments, deferred policy acquisition costs, goodwill, policy liabilities, reinsurance, income taxes, treasury stock, share-based compensation, earnings per share, and reclassifications.",2.0,0.7568798970195815,1.0,0.625,0.5
How does the Company account for foreign currency translation?,"The Company translates the financial position of foreign subsidiaries using exchange rates as of the balance sheet date for assets and liabilities, and average exchange rates for income and expense accounts during the period. Translation adjustments are reflected as a separate component of other comprehensive income. Gains or losses from foreign currency transactions are recorded in net income in the period incurred and are included in other income (expense). Certain inter-company balances designated as long-term investment-type loans result in exchange gains and losses that are recorded as a component of other comprehensive income, along with translation adjustments.","The functional currency of Aflac Japan is the Japanese yen. The Company translates its yen-denominated financial statement accounts into U.S. dollars as follows: assets and liabilities are translated at end-of-period exchange rates, realized gains and losses on security transactions are translated at the exchange rate on the trade date, and other revenues, expenses, and cash flows are translated using average exchange rates for the period. The resulting currency translation adjustments are reported in accumulated other comprehensive income.",4.5,0.5433698175943706,1.0,1.0,1.0
What is the basis for KPMG LLP's opinion on the consolidated financial statements?,"The basis for KPMG LLP's opinion on the consolidated financial statements is their audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (PCAOB). This audit included assessing the risks of material misstatement, examining evidence related to the amounts and disclosures, evaluating accounting principles and significant estimates, and assessing the overall presentation of the financial statements. The audit was performed to obtain reasonable assurance that the financial statements are free of material misstatement, whether due to error or fraud.","KPMG LLP's opinion on the consolidated financial statements is based on their audits conducted in accordance with the standards of the PCAOB. Those standards require that they plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.",5.0,0.8715335709718487,1.0,1.0,1.0
How did the Company support its liquidity and capital resources during the crisis in March 2020?,"The Company supported its liquidity and capital resources during the crisis in March 2020 by issuing four series of senior notes totaling ¥57.0 billion. Additionally, it utilized its unsecured revolving credit facilities, which provided $1.0 billion and ¥100.0 billion in available liquidity, though no borrowings were made under these facilities at that time.",The Company supported its liquidity and capital resources by issuing four series of senior notes totaling ¥57.0 billion and issuing $1.0 billion in senior notes through public debt offerings under its U.S. shelf registration statement. The Company also has available liquidity in its unsecured revolving credit facilities of $1.0 billion and ¥100.0 billion and currently has no borrowings under either of these facilities.,4.5,0.8382268999913827,1.0,1.0,1.0
What are the significant accounting policies of Aflac Incorporated?,"Aflac Incorporated and its subsidiaries primarily sell supplemental health and life insurance in the United States and Japan. The company's insurance business is marketed and administered through American Family Life Assurance Company of Columbus in the U.S. and through Aflac Life Insurance Japan Ltd. in Japan, effective April 1, 2018. Prior to that date, the business in Japan was operated as a branch of Aflac. The company operates in two reportable business segments: Aflac U.S., which includes Aflac, and Aflac Japan, which includes ALIJ. American Family Life Assurance Company of New York is a wholly owned subsidiary of Aflac. Most of Aflac's policies are individually underwritten and marketed through independent agents. Additionally, Aflac U.S. markets and administers group products through Continental American Insurance Company, branded as Aflac Group Insurance. The company's insurance operations in the U.S. and Japan serve the two markets for its insurance business. Aflac Japan's revenues, including realized gains and losses on its investment portfolio, accounted for 68% of the company's total revenues in 2020, compared to 69% in 2019 and 70% in 2018.","The significant accounting policies of Aflac Incorporated include foreign currency translation, insurance revenue and expense recognition, cash and cash equivalents, investments, deferred policy acquisition costs, goodwill, policy liabilities, reinsurance, income taxes, treasury stock, share-based compensation, earnings per share, and reclassifications.",1.0,0.6591095990943018,1.0,0.75,0.0
How does the Company account for foreign currency translation?,"The Company translates the financial position of foreign subsidiaries using exchange rates at the balance sheet date for assets and liabilities, and average exchange rates for income and expense items. Translation adjustments are reflected as a separate component of other comprehensive income. For foreign operations, the local currency is considered the functional currency, and translation into U.S. dollars is performed accordingly. Gains or losses from translation are included in other comprehensive income, while net gains and losses from foreign currency transactions are recorded in net income in the period incurred. Additionally, certain intercompany balances designated as long-term investments result in exchange gains or losses that are recorded as a component of other comprehensive income.","The functional currency of Aflac Japan is the Japanese yen. The Company translates its yen-denominated financial statement accounts into U.S. dollars as follows: assets and liabilities are translated at end-of-period exchange rates, realized gains and losses on security transactions are translated at the exchange rate on the trade date, and other revenues, expenses, and cash flows are translated using average exchange rates for the period. The resulting currency translation adjustments are reported in accumulated other comprehensive income.",5.0,0.5686641775336856,1.0,1.0,1.0
What was the outcome of the PJM Transmission Enhancement Settlement for DP&L?,"The PJM Transmission Enhancement Settlement resulted in a reduction of DP&L’s transmission costs through PJM beginning in August 2018. This included credits to reimburse DP&L for amounts overcharged in prior years. DP&L estimated the prior overcharge by PJM to be $40.8 million, with approximately $32.1 million repaid by December 31, 2020. Additionally, $1.7 million was classified as current in ""Accounts receivable, net"" and $7.0 million as non-current in ""Other non-current assets"" on the accompanying Consolidated Balance Sheet. Refunds received are returned to customers via the transmission cost rider.","The PJM Transmission Enhancement Settlement resulted in a reduction of DP&L’s transmission costs through PJM, including credits to reimburse DP&L for amounts overcharged in prior years, which will be passed to customers through the TCRR.",4.5,0.8653348728925284,1.0,1.0,1.0
What was the impact of the adoption of ASC 326 on DP&L's financial statements in 2020?,"The adoption of ASC 326, ""Financial Instruments - Credit Losses,"" in 2020 impacted DP&L's financial statements by requiring the use of the Current Expected Credit Loss (CECL) model for financial assets measured at amortized cost. This change resulted in the earlier recognition of an allowance for credit losses, primarily affecting the calculation of expected credit losses in gross customer trade accounts receivable. The transition to ASC 326 was applied using the modified retrospective method, which involved applying the transition provisions starting at the date of adoption, January 1, 2020. As a result, the financial statements reflected an earlier recognition of credit loss allowances, which influenced the reported amounts of allowances for receivables and related earnings.","The adoption of ASC 326, which updates the impairment model for financial assets, did not have a material impact on DP&L's Consolidated Financial Statements in 2020.",3.0,0.7415274724264513,1.0,1.0,1.0
What methods were used to determine the fair value of the acquired intangible assets in the Caesars Entertainment Corporation acquisition?,"The fair value of the acquired intangible assets was determined using various income approaches. These approaches required significant assumptions and estimates related to expected cash flows and projected financial results, including revenues and EBITDA, as well as the selection of appropriate discount rates.","The fair value of acquired intangible assets was determined using various income approaches, including the relief from royalty method and excess earnings method.",4.0,0.8256101785950956,1.0,0.75,1.0
What were the key terms of the CEI Revolving Credit Facility?,"The CEI Revolving Credit Facility, established on July 20, 2020, provides for a five-year credit agreement with an aggregate principal amount of $1.2 billion, maturing in 2025. It includes a letter of credit sub-facility of $250 million. The interest rate is based on the Company’s election between LIBOR adjusted with a 0% floor or a base rate determined by the highest of the federal funds rate plus 0.50%, the prime rate as set by JPMorgan Chase Bank, N.A., or the one-month adjusted LIBOR rate plus 1.00%, each plus an applicable margin. The margin is 3.25% per annum for LIBOR loans and 2.25% per annum for base rate loans, with potential reductions of 0.25% each based on the Company’s total leverage ratio. A commitment fee of 0.50% on unused commitments is required, which may step down to 0.375% depending on the leverage ratio.","The CEI Revolving Credit Facility provided for a five-year senior secured revolving credit facility in an aggregate principal amount of $1.2 billion, with interest rates based on LIBOR or a base rate plus an applicable margin, and a commitment fee on unused commitments.",4.5,0.8222249418889003,1.0,1.0,1.0
How did the Company's annual goodwill and indefinite-lived intangible asset impairment analysis result in 2020?,"The Company performed its annual goodwill and indefinite-lived intangible asset impairment analysis as of October 1, 2020. As of that date, the fair value of the Former Caesars reporting units and indefinite-lived intangible assets did not significantly exceed their respective carrying values. Additionally, two other reporting units in the Regional Segment had fair values that did not significantly exceed their carrying values. For the year ended December 31, 2020, the Company recorded $100 million of goodwill impairments related to five reporting units in the Regional Segment and $22 million of indefinite-lived intangible asset impairments related to tradenames.","The Company recognized impairment charges in the Regional segment related to goodwill and trade names totaling $100 million and $16 million, respectively, due to declines in recent performance and the expected impact on future cash flows as a result of COVID-19.",4.5,0.6746968712684066,1.0,1.0,1.0
What was the nature of the litigation involving Harrah’s New Orleans and the Department of Revenue?,"The litigation involved a dispute over whether Harrah’s New Orleans was required to pay state sales taxes, as well as district and New Orleans occupancy taxes, on discounted or complimentary rooms provided to patrons or guests at its own hotel and certain third-party hotels. The Department of Revenue sought to collect these taxes, and the courts initially ruled in its favor, requiring the company to pay taxes on complimentary rooms at Harrah’s New Orleans and certain third-party hotels. Harrah’s appealed the decision, and while the Louisiana Supreme Court upheld the requirement to pay taxes on complimentary rooms at Harrah’s New Orleans, it overturned the ruling regarding third-party hotels. The matter is now proceeding to trial to determine the amount of taxes due based on the Supreme Court’s decision.","Harrah’s New Orleans was involved in litigation with the Department of Revenue related to sales taxes on hotel rooms, parking, and entertainment complimentaries for the periods from 2004 through 2016. The litigation is ongoing, and the Company has accrued contingent liabilities of $43 million as of December 31, 2020.",4.5,0.7410082912022108,1.0,1.0,1.0
What were the key terms of the Golf Course Use Agreement with VICI Properties L.P.?,"The Golf Course Use Agreement with VICI Properties L.P. had a 35-year term, inclusive of all renewal periods. Under the agreement, affiliates of the Company agreed to pay an annual payment of $10 million, subject to escalation, an annual use fee of $3 million, subject to escalation beginning in the second year, and certain per-round fees. The term of the agreement was extended so that 15 years remain until the expiration of the initial term.","The Golf Course Use Agreement with VICI Properties L.P. provided for an annual payment of $10 million, an annual use fee of $3 million, and certain per-round fees, with a 35-year term inclusive of all renewal periods.",5.0,0.9718071128484306,1.0,1.0,1.0
What is the primary responsibility of Meredith management as stated in the financial report?,"The primary responsibility of Meredith management, as stated in the financial report, is the preparation, integrity, and objectivity of the financial information included in the Annual Report on Form 10-K for the year ended June 30, 2020.","Meredith management is responsible for the preparation, integrity, and objectivity of the financial information included in the Annual Report on Form 10-K for the year ended June 30, 2020.",5.0,0.931630814695611,1.0,1.0,1.0
How are the consolidated financial statements of Meredith prepared?,"The consolidated financial statements of Meredith are prepared by including the accounts of Meredith and its wholly-owned and majority-owned subsidiaries, after eliminating all significant intercompany balances and transactions.",The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and include amounts based on informed judgments and estimates.,4.0,0.6123472693563375,1.0,0.75,1.0
Who audits the consolidated financial statements of Meredith Corporation?,The consolidated financial statements of Meredith Corporation are audited by KPMG LLP.,The consolidated financial statements and the effectiveness of the Company’s internal control over financial reporting have been audited by an independent registered public accounting firm in accordance with the standards of the Public Company Accounting Oversight Board (United States).,4.0,0.5902096964017808,1.0,1.0,1.0
How did the adoption of the new leasing standard affect Meredith's financial statements?,"The adoption of the new leasing standard resulted in the recognition of right-of-use assets and lease liabilities on the balance sheet for leases with terms longer than twelve months. This change was made in accordance with the Company's historical accounting policies, and prior years' amounts were not restated. Lease expenses are generally recognized on a straight-line basis over the lease term. The Company uses its incremental borrowing rate to determine the present value of lease payments unless the implicit rate is readily determinable. Lease agreements may include various terms such as rent escalation clauses, renewal options, and variable payments based on inflation or consumption. However, leases with an initial term of twelve months or less are exempt from balance sheet recognition, and lease and non-lease components are not separated for any asset classes in the current portfolio.","Upon adoption, $509.9 million and $541.0 million were recorded for operating lease assets and liabilities, respectively, which included the impact to previously recorded liabilities associated with deferred rent and exit or disposal costs, and impairments of certain operating lease assets related to conditions that existed prior to adoption, which resulted in a decrease of $5.8 million to retained earnings as of July 1, 2019.",3.0,0.44505782708437364,1.0,0.75,1.0
"What was the total amount of long-term debt for Meredith Corporation as of June 30, 2020?","The provided context does not contain information about the total amount of long-term debt for Meredith Corporation as of June 30, 2020.","The total amount of long-term debt for Meredith Corporation as of June 30, 2020, was $2.5 billion.",1.0,0.8186608185732329,1.0,0.25,1.0
"What was the total comprehensive income (loss) for Meredith Corporation for the year ended June 30, 2020?","The provided context does not include the specific amount of comprehensive income (loss) for Meredith Corporation for the year ended June 30, 2020. While the context mentions that the consolidated financial statements were audited and that an unqualified opinion was expressed on those statements, it does not contain the actual financial figures. Therefore, the total comprehensive income (loss) cannot be determined from the given information.","The total comprehensive income (loss) for Meredith Corporation for the year ended June 30, 2020, was a loss of $252.3 million.",1.0,0.6889365490270238,1.0,0.75,1.0
"What was the total amount of cash and cash equivalents for Meredith Corporation as of June 30, 2020?","The provided context information does not include specific financial figures such as the total amount of cash and cash equivalents for Meredith Corporation as of June 30, 2020. The documents only describe the basis of presentation, use of estimates, reclassifications, and the definition of cash and cash equivalents, but do not provide the actual monetary amount.","The total amount of cash and cash equivalents for Meredith Corporation as of June 30, 2020, was $122.3 million.",1.0,0.7030770142340818,1.0,0.75,1.0
"What is the primary objective of New York City REIT, Inc.'s use of derivative financial instruments?","The primary objective of New York City REIT, Inc.'s use of derivative financial instruments is to minimize the risks and costs associated with its operating and financial structure, as well as to hedge specific anticipated transactions.","The primary objective of using derivative financial instruments is to hedge all or a portion of the interest rate risk associated with its borrowings, to minimize risks and costs associated with the Company’s operating and financial structure, and to hedge specific anticipated transactions.",4.5,0.7175605731989784,1.0,1.0,1.0
What measures did the Company take to address potential breaches of debt service coverage and debt yield covenants?,"The Company addressed potential breaches of debt service coverage and debt yield covenants by entering into cash management periods for certain properties, such as 9 Times Square, where all rents and other revenue were held in a segregated account as additional collateral. For the 1140 Avenue of the Americas property, breaches of debt service coverage and reserve fund provisions required excess cash to be held in a segregated account as collateral, which could be released after two consecutive quarters of maintaining the required coverage. The covenants could be cured after achieving two consecutive quarters of compliance, and the Company could remain in breach for up to four consecutive quarters without immediate default. Additionally, the Company was in discussions with lenders and evaluating options under loan contracts and alternative property-related strategies. To manage near-term financial needs, the Company anticipated funding interest shortfalls from cash on hand.","The Company is currently in breach of a debt service coverage provision and a reserve fund reserve provision under its non-recourse mortgage secured by the 1140 Avenue of the Americas property, requiring excess cash to be held in a segregated account as additional collateral under the loan. The Company is also evaluating options under the loan pursuant to the contract and other alternative options associated with the property.",4.5,0.7770846190662509,1.0,0.875,1.0
"What accounting principle did i3 Verticals, Inc. adopt on October 1, 2019, and how did it affect revenue recognition?","i3 Verticals, Inc. adopted Accounting Standards Codification Topic 606, ""Revenue from Contracts with Customers,"" on October 1, 2019. This change affected revenue recognition by implementing a new model that requires revenue to be recognized when control of goods or services is transferred to customers in an amount that reflects the consideration the company expects to receive. The company used the modified retrospective adoption method, which means prior periods were not restated, but the cumulative effect was recorded in retained earnings as of the adoption date. This resulted in a change in the timing and presentation of revenue recognition, aligning it with the new standard's requirements for identifying performance obligations and determining the transaction price.","i3 Verticals, Inc. adopted Accounting Standards Codification Topic 606, ""Revenue from Contracts with Customers,"" which changed the timing of certain revenue and expenses recognition under various arrangement types. Revenue is now recognized as each performance obligation is satisfied, and more judgment and estimates are required when applying the requirements of the new standard.",5.0,0.8268882647571655,1.0,0.875,1.0
"How does i3 Verticals, Inc. account for the costs to obtain and fulfill a contract?","i3 Verticals, Inc. capitalizes incremental costs to obtain new contracts and contract renewals, amortizing these costs on a straight-line basis over the benefit period, which is generally the contract term. However, if a commensurate payment is not expected at renewal, the costs are not capitalized. The company expenses sales commissions as incurred for sales commission plans that are paid on recurring monthly revenues, portfolios of existing clients, or have a substantive stay requirement prior to payment. As of September 30, 2020, the company had $3,140 of capitalized contract costs related to commissions paid to obtain new sales, included within “Prepaid expenses and other current assets” and “Other assets” on the consolidated balance sheets. The company recorded commissions expense related to these costs of $398 for the year ended September 30, 2020.","i3 Verticals, Inc. capitalizes incremental costs to obtain new contracts and contract renewals and amortizes these costs on a straight-line basis as an expense over the benefit period, which is generally the contract term. These costs include commissions paid to obtain new sales.",4.5,0.9417784738307724,1.0,1.0,1.0
"What is the impact of the Tax Receivable Agreement (TRA) on i3 Verticals, Inc.'s financial position?","The Tax Receivable Agreement (TRA) has resulted in an increase to i3 Verticals, Inc.'s net deferred tax assets and corresponding liabilities. During the year ended September 30, 2019, the Company recognized an increase in net deferred tax assets of $25,776 and a corresponding TRA liability of $22,413, representing 85% of the tax benefits due to the Continuing Equity Owners. This brought the deferred tax asset and TRA liability balances to $26,736 and $23,229, respectively, as of September 30, 2019. In the following year, during the year ended September 30, 2020, the Company recognized an additional increase in net deferred tax assets of $6,307 and a corresponding TRA liability of $5,361, raising the balances to $31,626 and $27,565, respectively. The TRA also creates an obligation to make future payments to the Continuing Equity Owners, with annual payments expected to range from $0 to $2,460 over the next 25 years. These amounts represent estimates of expected tax savings and are subject to change based on the Company's U.S. federal and state income tax returns. The Company expects to benefit from the remaining 15% of the tax benefits, if any, that are not allocated to the Continuing Equity Owners.","The Tax Receivable Agreement (TRA) requires i3 Verticals, Inc. to pay 85% of certain tax benefits to the Continuing Equity Owners. This has resulted in the recognition of deferred tax assets and corresponding liabilities, which affect the company's financial position by increasing its deferred tax assets and liabilities.",5.0,0.9015586018142631,1.0,1.0,1.0
"What are the quarterly trends in i3 Verticals, Inc.'s revenue and net income for the years ended September 30, 2020 and 2019?","The provided context does not contain specific quarterly revenue or net income figures for i3 Verticals, Inc. for the years ended September 30, 2020 and 2019. While the documents reference quarterly information and financial statements, they do not include the detailed quarterly revenue or net income data required to determine trends. Therefore, the query cannot be answered based on the given context.","For the year ended September 30, 2020, quarterly revenue trends showed an increase from $49,431 in Q1 to $57,606 in Q4, with net income ranging from $2,151 to $6,031. For the year ended September 30, 2019, quarterly revenue increased from $42,222 in Q1 to $50,851 in Q4, with net income ranging from $1,403 to $4,585.",1.0,0.668840902688545,1.0,0.75,1.0
"How did the adoption of ASC 842 impact the Company's balance sheet as of April 1, 2019?","The adoption of ASC 842 on April 1, 2019, resulted in the recognition of operating lease liabilities and corresponding right-of-use assets on the Company's balance sheet, reflecting the present value of remaining lease payments for existing operating leases. This led to a derecognition of existing property and equipment for certain properties that did not qualify for sale accounting during the construction phase and lacked sale-leaseback accounting upon completion. The adjustments also included changes to prepaid rent, deferred rent, lease intangible assets/liabilities, and closed property reserves, with the cumulative effects of adoption recorded as an adjustment to retained earnings.",The adoption of ASC 842 resulted in the recording of $13.3 million of additional lease liabilities and right-of-use assets to the beginning balance of the Company’s Consolidated Balance Sheet.,4.0,0.8183679201816608,1.0,1.0,1.0
"What was the impact of the Redomestication on Global Indemnity Group, LLC's class A common shares?","At the Effective Time, Global Indemnity Group, LLC’s class A common shares were deemed to be registered under Section 12(b) of the Exchange Act pursuant to Rule 12g-3(a) under the Exchange Act. The issuance of the class A common shares by Global Indemnity Group, LLC in the Redomestication was exempt from registration under the Securities Act of 1933, as amended, by virtue of Section 3(a)(10) of the Securities Act. The Company’s class A common shares began trading on Nasdaq under the symbol ""GBLI,"" the same symbol under which the Global Indemnity Limited ordinary shares previously traded, at the commencement of trading on Nasdaq on August 28, 2020.","The Redomestication resulted in the shareholders of Global Indemnity Limited becoming the holders of all of the issued and outstanding common shares of Global Indemnity Group, LLC. The class A common shares of Global Indemnity Group, LLC began trading on Nasdaq under the symbol ""GBLI"" at the commencement of trading on August 28, 2020.",4.0,0.8818371096778579,1.0,1.0,1.0
What are the principal terms of the 7.875% Subordinated Notes due 2047 issued by Global Indemnity Limited?,"The 7.875% Subordinated Notes due 2047 were issued by Global Indemnity Limited on March 23, 2017, through an underwritten public offering, with an initial aggregate principal amount of $120.0 million. The underwriters exercised an over-allotment option on March 30, 2017, increasing the total principal amount to $130.0 million. The notes bear interest at an annual rate of 7.875%, payable quarterly in arrears on January 15, April 15, July 15, and October 15 of each year, beginning July 15, 2017. The notes mature on April 15, 2047. The notes do not restrict the Company from incurring additional indebtedness, including senior indebtedness, and there is no right to accelerate the maturity of the notes in the case of default except in the event of the Company’s bankruptcy, insolvency, or reorganization. Deferred issuance costs of $4.2 million were incurred and are being amortized over the term of the notes. Interest expense, including amortization of these costs, was $10.4 million for each of the years ended December 31, 2020, 2019, and 2018.","The principal terms of the 7.875% Subordinated Notes due 2047 include:
   - Annual interest rate of 7.875%, payable quarterly.
   - Maturity date of April 15, 2047.
   - The Company has the right to redeem the notes in whole or in part on or after April 15, 2022, at a redemption price equal to 100% of the principal amount plus accrued and unpaid interest.",4.5,0.7287357519973046,1.0,1.0,1.0
How is Berkshire Hathaway Energy's operations organized?,"Berkshire Hathaway Energy's operations are organized into eight business segments: PacifiCorp, MidAmerican Funding (which primarily consists of MidAmerican Energy), NV Energy (which primarily consists of Nevada Power and Sierra Pacific), Northern Powergrid (which primarily consists of Northern Powergrid (Northeast) plc and Northern Powergrid (Yorkshire) plc), BHE Pipeline Group (which primarily consists of BHE GT&S, Northern Natural Gas and Kern River), BHE Transmission (which consists of BHE Canada (which primarily consists of AltaLink) and BHE U.S. Transmission), BHE Renewables and HomeServices.","BHE's operations are organized into eight business segments: PacifiCorp, MidAmerican Funding, NV Energy, Northern Powergrid, BHE Pipeline Group, BHE Transmission, BHE Renewables, and HomeServices.",5.0,0.8903626809394136,1.0,1.0,1.0
How many miles of transmission lines does BHE own?,"BHE U.S. Transmission indirectly owns a 50% interest in ETT, which has approximately 1,900 miles of transmission lines, and also owns a 25% interest in Prairie Wind Transmission, which is a 108-mile transmission project. Additionally, BHE U.S. Transmission acquired interests in MATL LLP, which includes 132 line miles in the U.S. of a 214-mile line. However, since BHE does not own the entirety of these assets, the exact total miles of transmission lines directly owned by BHE cannot be determined from the information provided.","BHE owns approximately 36,000 miles of transmission lines.",3.0,0.6437731881375316,1.0,0.875,1.0
What is the total natural gas mains and service lines length for MidAmerican Energy?,"24,100 miles","The natural gas distribution facilities of MidAmerican Energy included 24,100 miles of natural gas main and service lines as of December 31, 2020.",4.0,0.47174544605536517,1.0,1.0,1.0
How does NV Energy manage its energy supply function?,"NV Energy manages its energy supply function through an approach that includes three primary elements. First, it follows management guidelines for procuring and optimizing its supply portfolio, aligning with the requirements of a load-serving entity with a full requirements obligation and adapting to the growth of private generation serving some customers with partial requirements. Second, it employs an energy risk management and control framework that ensures a clear separation between day-to-day risk management and compliance monitoring, as well as a distinction between policy setting and execution. Third, it maintains ongoing regulatory involvement and seeks acknowledgment of its resource portfolio management plans. Additionally, NV Energy relies on long-term power purchase contracts with suppliers using renewable resources, natural gas, and coal to support its energy supply.","NV Energy manages its energy supply function through four key components: IRPs, ESPs, DRPs, and action plans, which are filed with the PUCN for approval and operate in conjunction with the PUCN-approved 20-year IRP.",4.0,0.7154619707466907,1.0,1.0,1.0
What is the Emissions Reduction and Capacity Replacement Plan for Nevada Power?,"The Emissions Reduction and Capacity Replacement Plan (ERCR Plan) for Nevada Power, filed in May 2014, outlines the retirement or elimination of coal-fueled generating capacity over several years. Specifically, it includes the retirement of 300 MWs by December 31, 2014, an additional 250 MWs by December 31, 2017, and another 250 MWs by December 31, 2019. The plan also involves replacing this retired capacity with a combination of constructed, acquired, or contracted renewable and non-technology specific generating units. Additionally, the plan details the expected timeline and costs for decommissioning the retiring coal-fueled units. The Public Utilities Commission of Nevada (PUCN) has the authority to approve or modify the plan, and variations may be approved relative to the requirements under Senate Bill No. 123. As part of the plan, Nevada Power retired 255 MWs of coal-fueled generation in 2019 and an additional 557 MWs in 2017. Between 2014 and 2016, the company acquired 536 MWs of natural gas generating resources, executed long-term power purchase agreements for 200 MWs of renewable energy capacity, and constructed a 15-MW solar photovoltaic facility. Nevada Power also retains the option to acquire an additional 35 MWs of renewable energy capacity in the future, subject to PUCN approval.","The ERCR Plan includes the retirement of 255 MWs of coal-fueled generation in 2019, acquisition of 536 MWs of natural gas generating resources, execution of long-term power purchase agreements for 200 MWs of nameplate renewable energy capacity, and construction of a 15-MW solar photovoltaic facility.",4.5,0.7338350417482231,1.0,1.0,1.0
What is the role of the Northern Powergrid Distribution Companies?,"The Northern Powergrid Distribution Companies are responsible for building, maintaining, and operating the electricity distribution network in their service area, which includes the north-east of England. They receive electricity from the national grid transmission system and from generators connected to the distribution network, then distribute it to end-users' premises using transformers, switchgear, and distribution lines and cables. They charge fees to electricity suppliers for the use of their distribution systems.","The Northern Powergrid Distribution Companies build, maintain, and operate the electricity distribution network through which end-users receive a supply of electricity. They charge fees for the use of their distribution systems to the suppliers of electricity.",5.0,0.9172519331504345,1.0,1.0,1.0
What is the market area design capacity of Northern Natural Gas?,The market area design capacity of Northern Natural Gas is 6.3 Bcf per day.,Northern Natural Gas' pipeline system has a Market Area design capacity of 6.3 Bcf per day.,5.0,0.9096115800490552,1.0,1.0,1.0
What is the transmission system of the Nevada Utilities part of?,"The transmission system of the Nevada Utilities is part of the Western Interconnection, a regional grid in the United States.","The Nevada Utilities' transmission system is part of the Western Interconnection, a regional grid in the United States that includes the interconnected transmission systems of 14 western states, two Canadian provinces, and parts of Mexico.",4.0,0.9646658755983885,1.0,0.875,1.0
What are the key components of the energy supply planning process for the Nevada Utilities?,"The key components of the energy supply planning process for the Nevada Utilities include Integrated Resource Plans (IRPs), Energy Supply Plans (ESP), and Distributed Resource Plans (DRP). IRPs are filed every three years and cover a 20-year period, focusing on a comprehensive, integrated plan to meet customer energy requirements while balancing cost and volatility. ESPs have a one- to three-year planning horizon and serve as intermediate-term resource procurement and risk management plans, requiring PUCN approval for contracts longer than three years. DRPs are designed to facilitate the cost-effective integration of distributed resources into the distribution and transmission systems of the Nevada Utilities.","The key components are IRPs, ESPs, DRPs, and action plans, which are filed with the PUCN for approval and operate in conjunction with the PUCN-approved 20-year IRP.",4.5,0.730975271114562,1.0,1.0,1.0
What is the impact of California Senate Bill 100 on California's RPS?,"California Senate Bill 100, also known as the 100 Percent Clean Energy Act of 2018, increased the Renewable Portfolio Standard (RPS) target to 60% by 2030 and established a long-term goal for 100% of total California retail sales to come from eligible renewable energy resources and zero-carbon resources by December 31, 2045.","California Senate Bill 100 increased the RPS target to 60% by 2030 and enabled a longer-term planning target for 100% of total California retail sales to come from eligible renewable energy resources and zero-carbon resources by December 31, 2045.",5.0,0.9384042162702582,1.0,0.875,1.0
What is the role of the AESO in Alberta's electricity industry?,"The AESO is responsible for assessing both current and future needs of Alberta's interconnected electrical system. It operates the power pool, forecasts load and generation through the 2019 Long-term Outlook, and uses this information to guide the planning of Alberta's transmission system. The AESO's mandate is defined in the Electric Utilities Act (Alberta) and its regulations.","The AESO's mandate is defined in the Electric Utilities Act (Alberta) and requires the AESO to assess both current and future needs of Alberta's interconnected electrical system. The AESO uses the 2019 Long-term Outlook, which is the AESO's forecast of Alberta's load and generation over the next 20 years, as one input to guide the AESO in planning Alberta's transmission system.",5.0,0.9496358971578901,1.0,0.875,1.0
What is the regulatory framework for BHE's regulated subsidiaries and certain affiliates?,"BHE's regulated subsidiaries and certain affiliates are subject to comprehensive governmental regulation that significantly influences their operating environment, pricing, capital structure, costs, and ability to recover costs and earn a reasonable return on invested capital. These entities are regulated by various state, federal, and local agencies, with a primary focus on state regulatory commissions. These commissions typically set retail electric and natural gas rates on a cost-of-service basis, allowing utilities to recover reasonable costs and earn a fair return on investments. The cost of service includes components such as cost of sales, operating expenses, depreciation, taxes, and is adjusted for wholesale revenue and other factors. State regulatory commissions have the authority to review and modify rates, either on their own initiative or at the request of the utility, customers, or customer advocacy groups. The framework also permits adjustments based on changes in investment levels, income tax laws, and periodic reviews of revenue and expenses over a defined test period.","BHE's regulated subsidiaries and certain affiliates are subject to comprehensive governmental regulation, which significantly influences their operating environment, prices charged to customers, capital structure, costs, and ultimately their ability to recover costs and earn a reasonable return on invested capital.",5.0,0.7475543028141611,1.0,0.875,1.0
How has the COVID-19 pandemic affected the company's financial performance in 2020?,"The COVID-19 pandemic did not have a material adverse impact on the company's overall financial results during 2020. However, it negatively impacted revenue growth, particularly in businesses that are discretionary in nature. The company regularly assessed the impact of the pandemic on its operations, considering factors such as business resilience, financial modeling, and stress testing of liquidity and financial resources. The effects on revenue were primarily driven by changes in client behavior and economic conditions, with continued impacts expected through much of 2021 until vaccination rates increased and social-distancing measures were eased. Additionally, the pandemic influenced financial estimates and assumptions, including the collectability of receivables and the fair value of assets and contingent consideration.","The COVID-19 pandemic significantly impacted the company's financial performance in 2020, leading to a decrease in net income by $98.6 million or 35%, primarily due to a $107.9 million increase in the provision for credit losses and a $37.7 million decrease in net interest income.",2.5,0.5717784590279017,1.0,0.875,1.0
"How has the Hawaii economy been impacted by COVID-19, and what are the implications for the company?","The Hawaii economy has been significantly impacted by the COVID-19 pandemic, resulting in a notable decrease in commercial activity both within the state and nationally. This decline has led to financial difficulties for customers, including businesses and individuals, as well as vendors and counterparties, who may struggle to meet their payment obligations. The tourism industry, a vital component of the local economy, has been particularly affected, with the recovery of air travel and tourism highly uncertain. Recovery depends on factors such as declining case numbers globally and within Hawaii, visitor acceptance of new pre-travel testing requirements, the absence of subsequent infection waves, and the availability of vaccines, treatments, and testing capabilities.

For the company, these economic challenges have resulted in increased credit risk, leading to higher allowances for credit losses as borrowers may face difficulties maintaining loan and lease payments. The company is also adapting its business practices to changing consumer behaviors driven by the pandemic. Despite these challenges, the company continues to provide service to all customers and operate across Hawaii, Guam, and Saipan, while emphasizing remote work and safety measures for essential employees. The company remains committed to servicing its customers during this uncertain period.","The Hawaii economy has been significantly impacted by COVID-19, with a 75.2% decrease in visitor arrivals and a 9.3% unemployment rate in December 2020. This has affected the company's operations and customer base, leading to increased credit risk and potential decreases in non-interest income.",4.5,0.6552532210489159,1.0,1.0,1.0
What are the key factors that could impact the company's profitability in future reporting periods?,"Key factors that could impact the company's profitability in future reporting periods include changes in interest rates, housing market conditions, unemployment levels, market volatility, energy prices, and the ability to attract and retain loans and deposits from customers. These factors can affect trading and other revenue, net interest income, loan volume, loss provisions, and ultimately the results of operations. Additionally, the successful implementation of business strategies will also play a significant role in determining financial performance.","Key factors that could impact the company's profitability include continued adverse economic conditions due to the COVID-19 pandemic, changes in interest rates, increased credit risk, and potential decreases in non-interest income.",4.0,0.6835785097832623,1.0,0.875,1.0
How has the company's investment in high-grade investment securities evolved during 2020?,"The company's investment in high-grade investment securities increased significantly during 2020. The total fair value of the investment securities portfolio grew to $6.1 billion as of December 31, 2020, representing an increase of $2.0 billion or 49% compared to December 31, 2019. This growth was primarily driven by redeploying excess balance sheet liquidity and strategic purchases, including the merger with CSFL, which added $1.2 billion of investment securities. Additionally, the company acquired $2.4 billion in new securities during the year, partially offset by maturities, calls, paydowns, and sales totaling $1.1 billion. The portfolio primarily consisted of collateralized mortgage obligations issued by Ginnie Mae, Fannie Mae, and Freddie Mac.","The company increased its investment in high-grade investment securities, primarily collateralized mortgage obligations, with the total fair value of the investment securities portfolio rising by 49% to $6.1 billion as of December 31, 2020.",5.0,0.8141534018230028,1.0,1.0,1.0
"What is the primary purpose of the allowance for credit losses (ACL) at First Hawaiian, Inc.?","The primary purpose of the allowance for credit losses (ACL) at First Hawaiian, Inc. is to estimate and reserve for expected credit losses on financial assets, ensuring that the company's financial statements reflect the potential losses from borrowers who may default on their obligations. This provision helps maintain accurate and reliable financial reporting by accounting for credit risk in accordance with accounting principles generally accepted in the United States of America.","The primary purpose of the ACL is to estimate and reserve for expected credit losses on loans and leases, ensuring that the net carrying value of these assets reflects the amount expected to be collected.",5.0,0.7500953506994029,1.0,0.75,1.0
"How did the adoption of the Current Expected Credit Losses (CECL) model impact First Hawaiian, Inc.'s financial statements in 2020?","The adoption of the Current Expected Credit Losses (CECL) model in 2020 resulted in a change in First Hawaiian, Inc.'s method of accounting for its allowance for credit losses. This change was implemented as a result of the adoption of Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. The financial statements for the periods presented were audited and found to present fairly, in all material respects, the financial position and results of operations and cash flows of the Company in conformity with accounting principles generally accepted in the United States of America. This includes the impact of the new accounting method on the allowance for credit losses.","The adoption of CECL in 2020 required a cumulative effect adjustment to retained earnings as of January 1, 2020, reflecting changes in the allowance for credit losses and the reserve for unfunded commitments.",3.0,0.6300090960337348,1.0,0.75,1.0
"How does First Hawaiian, Inc. manage its interest rate risk?","First Hawaiian, Inc. manages its interest rate risk through a combination of strategies including the use of financial instruments such as interest rate swaps and caps to hedge against potential fluctuations in interest rates. The company monitors its exposure to interest rate changes and employs risk management policies designed to mitigate the impact of interest rate volatility on its financial performance and position. These practices help ensure that the company maintains stability in its earnings and capital structure amid changing market conditions.","First Hawaiian, Inc. manages interest rate risk through the use of interest rate swaps designated as either fair value hedges or cash flow hedges, which help to offset potential adverse impacts on interest expense and net interest margin.",4.0,0.8918411229055129,1.0,0.375,1.0
"What was the impact of the Visa Class B restricted shares on First Hawaiian, Inc.'s financial statements in 2020?","The impact of the Visa Class B restricted shares on First Hawaiian, Inc.'s financial statements in 2020 was not directly through unrealized losses or gains related to the securities themselves, as the Company had the intent and ability to hold the remaining securities in an unrealized loss position as of December 31, 2020. There were no credit losses recognized on these securities during the year ended December 31, 2020. However, the Company had entered into an agreement with a buyer related to the sale of 274,000 shares in 2016, which required payments to the buyer if Visa reduced the conversion rate of Class B shares to unrestricted Class A common shares. While specific payments related to rate reductions occurred in 2018 and 2019, there is no mention of a new payment or impact in 2020. Thus, the direct financial impact in 2020 was minimal, and no new significant adjustments were reported for that year.","The Visa Class B restricted shares resulted in a revaluation adjustment, leading to losses in other noninterest income of $4.8 million in 2020, as the Company made monthly payments based on changes in Visa's conversion rate.",3.0,0.44881269389658757,1.0,1.0,1.0
"What are the regulatory capital requirements for First Hawaiian, Inc., and how did the company perform against these requirements as of December 31, 2020?","The provided context does not contain information about the regulatory capital requirements for First Hawaiian, Inc. or the company's performance against these requirements as of December 31, 2020.","First Hawaiian, Inc. is required to maintain minimum amounts and ratios of Common Equity Tier 1 (CET1) capital, Tier 1 capital, and total capital to risk-weighted assets, as well as a minimum leverage ratio. As of December 31, 2020, the Company was classified as well-capitalized and exceeded the capital conservation buffer.",1.0,0.5910104074082719,1.0,0.75,1.0
"What measures has First Hawaiian, Inc. taken in response to the COVID-19 pandemic, particularly concerning loan modifications and troubled debt restructurings (TDRs)?","First Hawaiian, Inc. implemented loan modifications in its MML and TRE portfolios during the year ended December 31, 2020, in response to the COVID-19 pandemic. These modifications were primarily aimed at providing relief to borrowers affected by economic hardship. The nature of the modifications varied, with a small portion qualifying as troubled debt restructurings (TDRs), which are defined as concessions granted to borrowers facing financial difficulties that the company would not otherwise consider. The company continued to accrue interest income on loans with deferred payments, in accordance with the FASB's guidance on COVID-19. 

The company applied relief under Section 4013 of the CARES Act, as extended by the Consolidated Appropriations Act, 2021 (CAA), and the Interagency Statement on Loan Modifications. This allowed the suspension of TDR accounting and reporting requirements for qualifying loan modifications made between March 1, 2020, and the earlier of January 1, 2022, or 60 days after the termination of the national emergency. As of December 31, 2020, the impact of these modifications on the company’s results of operations was immaterial, and the amortized cost of modified loans under the CARES Act or Interagency statement was also immaterial. 

Additionally, the company designated nonaccrual status for nonperforming debt securities or loans not generating their stated interest rate, applying the cash basis method for payments received on such assets. Interest accrual resumes when borrowers make contractual payments or resolve delinquencies (less than 30 days overdue). For certain TDRs, loan modifications included write-offs due to principal forgiveness.","In response to the COVID-19 pandemic, First Hawaiian, Inc. adopted provisions of the CARES Act and Interagency Statements, which allowed for temporary relief from TDR reporting for certain loan modifications made on a good faith basis in response to borrower impacts from COVID-19.",4.5,0.7225704192244646,1.0,1.0,1.0
What are the potential risks associated with the company's reliance on third-party manufacturers for Oxbryta and its product candidates?,"The potential risks associated with the company's reliance on third-party manufacturers for Oxbryta and its product candidates include the possibility that these manufacturers may fail to perform their obligations, leading to delays or disruptions in supply. This could force the company to manufacture materials itself, which it lacks the capability or resources to do, or to find alternative manufacturers on reasonable terms and timelines, which may not be feasible. Any significant delay or discontinuity in the supply of product candidates or raw materials could delay clinical development and regulatory approval. Additionally, third-party manufacturers are engaged with other companies, exposing them to regulatory and market risks, which could affect their ability to produce materials for the company. Competition for manufacturing facilities may result in performance failures, further delaying development, approval, or commercialization. The company also faces risks related to regulatory compliance, quality assurance, potential breaches or terminations of agreements, inability to meet ordering requirements in terms of quality, quantity, or price, and the possibility of misappropriation of proprietary information. Furthermore, for inclacumab, there are additional risks related to technology transfer from Roche and the need for FDA approval of an IND for a new manufacturing site. The company's lack of experience with biologic product manufacturing increases its reliance on third-party expertise, adding to the overall risk.","Risks include reliance on the third party for regulatory compliance and quality assurance, potential breach or termination of the manufacturing agreement, inability to satisfy ordering requirements as to quality, quantity, and price, and the unwillingness of the third party to extend or renew terms with the company.",5.0,0.704675634878583,1.0,1.0,1.0
How does the company plan to manage its intellectual property risks?,"The company plans to manage its intellectual property risks by seeking patent protection for its product candidates, compositions, methods of use, and manufacturing processes, as well as other commercially important inventions. It relies on trade secret, patent, copyright, and trademark laws, along with confidentiality agreements with employees and third parties, to protect its technology and products. The company also intends to enforce its intellectual property rights through litigation when necessary, although it acknowledges the potential need to forgo enforcement in certain situations based on strategic considerations. Additionally, the company works to identify and secure patentable aspects of its innovations early in development and may collaborate with licensors and licensees, though it may have limited control over the prosecution and maintenance of certain patents. The company further acknowledges the risk of third-party infringement claims and plans to either obtain licenses, redesign products, or face potential lawsuits and damages if infringement is found.","The company seeks to protect its proprietary position by filing patent applications in the United States and abroad related to Oxbryta and its product candidates. However, it acknowledges the uncertainty and complexity involved in obtaining and enforcing biopharmaceutical patents.",5.0,0.4144964978837413,1.0,1.0,1.0
What are the potential risks associated with the company's international operations?,"Potential risks associated with the company's international operations include multiple, conflicting, and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, and regulatory requirements. There is also the risk of failing to obtain and maintain regulatory approvals for product use in various countries, encountering additional third-party patent rights, and facing complexities in protecting and enforcing intellectual property. Managing foreign operations may present difficulties in staffing and overseeing multiple payor reimbursement regimes, government payors, or patient self-pay systems. The company may also face limitations in market penetration, financial risks like longer payment cycles, challenges in collecting accounts receivable, and exposure to foreign currency exchange rate fluctuations. Additionally, there are risks related to natural disasters, political and economic instability, including wars, terrorism, political unrest, and disease outbreaks. Expenses such as travel, translation, and insurance may also increase. Regulatory and compliance risks involve adhering to the U.S. Foreign Corrupt Practices Act and other anti-bribery and anti-corruption laws. The United Kingdom's withdrawal from the European Union could negatively impact global economic conditions, financial markets, and the business.","Risks include compliance with complex and changing laws and regulations, difficulties in obtaining and maintaining regulatory approvals for sales or use of products in various countries, complexities in enforcing intellectual property rights, and financial risks such as longer payment cycles and exposure to foreign currency exchange rate fluctuations.",5.0,0.7525718866869822,1.0,1.0,1.0
What are the financial implications of the Orphan Drug Designation for Oxbryta in the United States?,"The financial implications of the Orphan Drug Designation for Oxbryta in the United States include the potential for marketing exclusivity and other commercial benefits, which could help support the product's commercialization. However, these benefits are not guaranteed, as the designation may not confer effective protection from competition, especially if another drug is deemed clinically superior or if the FDA approves a competitor for a different indication. Additionally, the success of Oxbryta's commercialization depends on adequate pricing, which must cover development and manufacturing costs, and on the availability of government and private insurance coverage. The list price in the U.S. is $125,000 per year, making reimbursement from federal and state programs like Medicare and Medicaid critical for patient access and sales success. If reimbursement is limited or unavailable, the financial viability of the product could be compromised.","The Orphan Drug Designation for Oxbryta in the United States provides several financial incentives, including tax credits for qualifying clinical trials, exemption from the PDUFA application fee, and a substantial period of regulatory market exclusivity, which will expire on November 25, 2026.",4.0,0.6324926638306856,1.0,0.875,1.0
How does the company's dependence on a limited number of customers affect its operating results?,"The company's dependence on a limited number of customers affects its operating results because these customers currently represent a substantial majority of its income. As a result, the company's performance is heavily reliant on maintaining sales of LNG, natural gas, steam, and power to these key customers. The loss of a significant customer could adversely impact operating results, especially in the short term when sales are expected to remain concentrated among a few customers. Additionally, since a substantial portion of revenue is expected to come from customers in the Caribbean and specific projects like the Sergipe Terminal and Sergipe Power Plant, the company is exposed to risks associated with those customers and their operating environments, which could further affect business and financial outcomes.","The company's operating results are contingent on maintaining LNG, natural gas, steam, and power sales to these customers. The loss of a significant customer could adversely affect operating results.",4.5,0.8032959339978365,1.0,1.0,1.0
How does the company's limited operating history impact its ability to evaluate business prospects?,"The company's limited operating history makes it difficult to evaluate the prospects for its future viability. This is because the company has not yet demonstrated the ability to successfully complete large-scale, pivotal clinical trials, obtain marketing approvals, manufacture commercial-scale products, or conduct sales and marketing activities necessary for successful product commercialization. As a result, predictions about its future success or viability may not be as accurate as they could be if the company had a longer operating history or a track record of successfully developing and commercializing pharmaceutical products.","The limited operating history provides a less reliable basis for evaluating business prospects, as the company continues to develop policies and procedures and build its team.",4.0,0.7480692115081098,1.0,1.0,1.0
How did the acquisition of MBT Financial Corp. affect First Merchants Corporation's balance sheet?,"The acquisition of MBT Financial Corp. on September 1, 2019, resulted in several key impacts on First Merchants Corporation's balance sheet. The transaction led to the issuance of approximately 6.4 million shares of common stock, valued at about $229.9 million, which increased the equity section of the balance sheet. Additionally, the acquisition contributed $98,563,000 in goodwill, reflecting the expected synergies and economies of scale, which was recorded as an intangible asset. The merger also added $21,664,000 to premises and equipment, increasing the property and equipment line item on the balance sheet. Furthermore, the acquisition included the integration of MBT’s subsidiary, Monroe Bank & Trust, which expanded the corporation's asset base and branch network. These changes reflect the overall growth in both tangible and intangible assets, along with an increase in equity, as a result of the acquisition.","The acquisition of MBT Financial Corp. resulted in the addition of $98,563,000 of goodwill and $16,527,000 of core deposit intangibles to First Merchants Corporation's balance sheet.",4.5,0.8155500053008018,1.0,0.875,1.0
What are the key components of First Merchants Corporation's defined-benefit pension plans?,"The key components of First Merchants Corporation's defined-benefit pension plans include coverage for approximately 10 percent of the Corporation’s employees, with provisions for non-qualified plans for certain employees, former employees, and former non-employee directors. Benefits are primarily based on years of service and employees’ pay near retirement. Contributions are made to cover benefits for service-to-date as well as those expected to be earned in the future. In 2005, the Board of Directors approved a curtailment of the accumulation of defined benefits for future services for certain participants, meaning no additional pension benefits have been earned by employees who had not attained both the age of 55 and accrued at least 10 years of vesting service as of March 1, 2005.","The key components include service costs, interest costs, expected return on plan assets, amortization of prior service costs, and actuarial gains/losses.",2.0,0.3842229893909761,1.0,0.75,1.0
How does First Merchants Corporation manage its exposure to credit risk in financial instruments?,"First Merchants Corporation manages its exposure to credit risk in financial instruments primarily through the use of collateral. The Bank's loans are generally secured by specific items of collateral, including real property, consumer assets, and business assets. This collateral serves as a form of protection against potential losses in the event of borrower default. Additionally, the determination of the allowance for loan losses, which is a critical estimate in assessing credit risk, is based on evaluating the credit quality of the loan portfolio and incorporating relevant risk factors. The Corporation's internal management of credit risk is further supported by policies and procedures that monitor and manage credit exposure, although specific details of these policies are not included in the provided context.","First Merchants Corporation manages its exposure to credit risk by maintaining an allowance for loan losses, conducting regular credit quality reviews, and implementing credit policies and underwriting criteria for all loans.",4.0,0.7368499301322288,1.0,0.375,1.0
What is the primary purpose of the funds held in the trust account?,"The primary purpose of the funds held in the trust account is to be used for the completion of an initial business combination or to be returned to public shareholders if such combination is not completed within the specified timeframe. These funds are intended to be held in a restricted account and are not to be used for any other purpose, ensuring they are available for the benefit of public stockholders under specific conditions.","The primary purpose of the funds held in the trust account is to be used for completing an initial business combination with a target business. If a business combination is not completed within the specified time frame, the funds are to be distributed to public stockholders.",5.0,0.8965277686443479,1.0,0.875,1.0
What are the potential risks associated with the ability of public stockholders to redeem their shares for cash?,"Public stockholders face several potential risks related to the redemption of their shares for cash. If a stockholder does not receive the tender offer or proxy materials, they may miss the opportunity to redeem their shares. Additionally, strict procedures must be followed to validly tender or submit shares for redemption, such as delivering share certificates or electronic delivery to the transfer agent by specified deadlines. Failure to comply with these procedures, whether due to oversight or timing issues, could result in the shares not being redeemed. Furthermore, stockholders do not have rights to funds in the trust account except under limited circumstances, meaning that if redemption is not successfully completed, they may be forced to sell their shares or warrants in the open market, potentially at a loss. In some cases, redemption rights are also tied to specific events, such as the completion of a business combination or a shareholder vote to amend the company's charter, and not all shareholders may be eligible for cash distributions under all conditions.","The potential risks include making the company's financial condition unattractive to potential business combination targets, difficulty in entering into an initial business combination with a target, and the possibility of not meeting certain closing conditions if too many public stockholders exercise their redemption rights.",3.0,0.6039746835204537,1.0,0.875,1.0
What are the implications of the company being deemed an investment company under the Investment Company Act?,"Being deemed an investment company under the Investment Company Act would impose significant regulatory burdens and operational restrictions. The company could be required to register as an investment company, which would subject it to substantial regulation regarding its capital structure, including limitations on leverage. It would also be subject to restrictions on its investment activities, such as limits on the types of investments it can make, restrictions on transactions with affiliated persons, and requirements related to portfolio diversification and industry concentration. Additionally, the company would be required to comply with extensive reporting, record-keeping, voting, proxy disclosure, and other rules and regulations. These requirements would likely increase operating expenses and could make it more difficult to complete an initial business combination.

Furthermore, if the company or one of its subsidiaries is required to register as an investment company, it could breach covenants in financing arrangements, leading to defaults, accelerated debt obligations, or termination of agreements. This could also result in civil or criminal actions, regulatory proceedings, or the appointment of a court receiver to liquidate the business. The loss of investment company exemptions could lead to the termination of key management and loan servicing agreements, potentially disrupting operations and requiring the company to secure services independently, which may not be feasible on favorable terms. Overall, such a designation would have a material adverse effect on the company’s financial condition, liquidity, results of operations, and ability to distribute returns to shareholders.","If the company is deemed an investment company, it may be subject to burdensome compliance requirements, restrictions on the nature of its investments, and limitations on the issuance of securities, which could make it difficult to complete an initial business combination and could result in its liquidation.",5.0,0.808942897458889,1.0,1.0,1.0
What is the primary responsibility of KeyCorp's management in relation to the financial statements?,"The primary responsibility of KeyCorp's management is to maintain effective internal control over financial reporting and to assess the effectiveness of that internal control, as included in the accompanying financial statements.","KeyCorp's management is responsible for the preparation, content, and integrity of the financial statements and other statistical data compiled for the annual report.",4.0,0.8115120917945318,1.0,1.0,1.0
What is the role of the Audit Committee in KeyCorp's financial reporting process?,"The role of the Audit Committee in KeyCorp's financial reporting process is not explicitly mentioned in the provided context. The documents primarily focus on the responsibilities of KeyCorp’s management and the external auditors in relation to internal control over financial reporting and the audit process. The Audit Committee's role is typically oversight of financial reporting, internal controls, and the audit process, but specific details about its role in KeyCorp are not included in the context.","The Audit Committee meets regularly with Management, internal audit, and the independent registered public accounting firm to review the scope of their audits and discuss the evaluation of internal accounting controls and financial reporting matters.",3.0,0.4027375204173389,1.0,0.5,1.0
How does KeyCorp assess the effectiveness of its internal control over financial reporting?,"KeyCorp assesses the effectiveness of its internal control over financial reporting by conducting an evaluation based on the criteria established in the Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), commonly referred to as the COSO criteria. This assessment is performed annually and results in a conclusion regarding the effectiveness of internal controls as of December 31, 2020. The assessment is supported by the independent audit conducted by Ernst & Young LLP, which provides an unqualified opinion on the effectiveness of internal control over financial reporting as of that date.","KeyCorp assesses the effectiveness of its internal control over financial reporting using criteria described in ""Internal Control - Integrated Framework"" issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework).",5.0,0.8683809915587434,1.0,0.75,1.0
What was the impact of adopting ASU 2016-13 on KeyCorp's financial statements?,"The adoption of ASU 2016-13, which relates to the measurement of credit losses on financial instruments, resulted in a change in KeyCorp's method of accounting for credit losses in 2020. This change was significant enough to be identified as a critical audit matter, particularly impacting the allowance for loan and lease losses (ALLL). The adoption required an assessment of the potential for credit losses across the financial instruments portfolio, influencing the valuation and disclosure of credit risk. The financial statements reflect the impact of this adoption, as noted in the notes to the consolidated financial statements.","The adoption of ASU 2016-13 resulted in a $230 million decrease in retained earnings as of January 1, 2020, net of deferred taxes of $71 million, for the cumulative effect of adopting the new accounting standard for expected credit losses.",3.0,0.5428687139506481,1.0,0.875,1.0
What is the significance of the allowance for loan and lease losses (ALLL) in KeyCorp's financial statements?,"The allowance for loan and lease losses (ALLL) is significant in KeyCorp's financial statements as it represents management’s current estimate of lifetime credit losses inherent in the loan portfolio at the balance sheet date. This allowance is a critical measure of credit risk and is determined using a combination of asset-specific reserves, quantitative models such as probability of default and loss given default, and qualitative adjustments that reflect economic conditions and other relevant factors. The ALLL totaled $1.6 billion as of December 31, 2020, on a loan and lease portfolio of $101.2 billion, indicating its substantial role in assessing and disclosing potential losses. The process of estimating the ALLL involves a high degree of subjectivity and judgment, particularly in evaluating economic forecasts and qualitative adjustments, making it a complex and important component of the financial reporting and audit process.","The ALLL represents KeyCorp's current estimate of lifetime credit losses inherent in the loan portfolio at the balance sheet date, which is a critical component in reflecting the expected credit losses in the financial statements.",5.0,0.7026197295176696,1.0,1.0,1.0
How does KeyCorp manage its exposure to credit risk on derivative contracts?,"KeyCorp manages its exposure to credit risk on derivative contracts by not holding any derivative contracts with credit risk contingent features. As of December 31, 2020, there were no such contracts held by KeyCorp, meaning it did not have obligations to post additional collateral or face termination of agreements based on credit rating changes. This absence of credit risk contingent features eliminates the need for additional collateral or termination actions due to downgrades in its credit rating.","KeyCorp mitigates credit risk on derivative contracts by entering into bilateral collateral and master netting agreements that allow for the net settlement of all contracts with a single counterparty in the event of default, and by monitoring counterparty credit risk exposure.",2.0,0.7574727846398273,1.0,0.875,1.0
What are the key components of KeyCorp's deferred tax assets and liabilities?,The provided context does not contain information about the key components of KeyCorp's deferred tax assets and liabilities.,"KeyCorp's deferred tax assets and liabilities are determined based on temporary differences between financial statement asset and liability amounts and their respective tax bases, and are measured using enacted tax laws and rates expected to apply in the periods in which the deferred tax assets or liabilities are realized.",1.0,0.5684568509882482,0.0,0.25,1.0
How have the COVID-19 pandemic and government measures impacted the company's operations?,"The COVID-19 pandemic and related government measures have significantly impacted the company’s operations by disrupting business activities across various aspects. Travel restrictions, shelter-in-place orders, and business closures have limited the ability of employees, suppliers, and partners to operate at full capacity. The company implemented temporary precautionary measures, such as requiring a majority of employees to work remotely and discouraging in-person meetings, which could affect productivity and business continuity. These disruptions have also affected research and development, clinical programs, supply chains, and manufacturing efforts due to restrictions on movement and availability of materials. Additionally, the pandemic's global spread has led to ongoing challenges in multiple markets, with varying stages of restrictions and re-openings, further complicating operations. The extent of the impact remains uncertain and depends on evolving factors such as the duration and severity of the pandemic, government actions, and shifts in customer behavior.","The COVID-19 pandemic has caused disruptions in operations, including delays in clinical trials, difficulties in patient enrollment, and potential impact on the cost and timelines of the Phase 3 program.",4.5,0.565939281372719,1.0,1.0,1.0
What are the potential risks associated with relying on third-party manufacturers for the production of ensifentrine?,"Relying on third-party manufacturers for the production of ensifentrine poses several potential risks. These include the inability to control the amount and timing of resources dedicated to development, the possibility that collaborators may face financial difficulties, and the risk of having to relinquish important rights such as marketing, distribution, and intellectual property. Additionally, a collaborator might pursue a competing product independently or with third parties, including competitors, which could impact the development and commercialization of ensifentrine. Changes in a collaborator’s business strategy or financial condition could also affect their ability or willingness to fulfill obligations under any agreement. There is also a risk that collaboration agreements may not generate sufficient profits after fulfilling payment liabilities to partners such as Ligand Pharmaceuticals.

Moreover, the reliance on third-party manufacturers and suppliers may impair the advancement of research and development programs. Commercialization could be halted, delayed, or become less profitable if these third parties fail to obtain necessary regulatory approvals, cannot provide adequate quantities of the product in a timely manner, or do so at unacceptable quality levels or prices. There is also a risk of manufacturing defects due to limited control over the manufacturing process. 

The dependence on third-party providers could result in delays or interruptions in the supply chain, including failure to meet regulatory standards, which could lead to suspension of manufacturing or revocation of approvals. Third-party providers may breach agreements due to financial or operational challenges, and their inability to renew agreements at critical times could disrupt clinical trials or commercial activities. 

Furthermore, the supply of raw materials and drug delivery devices is limited, and there are few alternative suppliers available. Any interruption in supply could delay clinical trials or the commercial launch of ensifentrine if suitable alternatives cannot be secured promptly. There is also a risk of increased costs for these supplies, potentially affecting cost-effectiveness in manufacturing. Lastly, third-party manufacturers or suppliers may infringe on third-party proprietary rights, leading to legal disputes or the need to find alternative suppliers, which could delay development, regulatory approval, or market launch.","Risks include potential delays in supply, quality control issues, and the possibility of third-party manufacturers failing to comply with regulatory requirements, which could delay or prevent the commercialization of ensifentrine.",4.0,0.8581755367874302,1.0,1.0,1.0
How did the COVID-19 pandemic affect South State Corporation's operations and financial results in 2020?,"The provided context does not contain any information about how the COVID-19 pandemic affected South State Corporation's operations and financial results in 2020. The documents discuss the company's financial condition and results of operations for the year ended December 31, 2020, but do not mention the impact of the pandemic.","The COVID-19 pandemic led to increased provisions for credit losses, changes in customer behavior affecting deposit and loan activities, and operational challenges such as branch closures and remote work setups, which collectively impacted financial results and operational efficiency in 2020.",1.0,0.39781674004576395,0.0,0.75,1.0
What measures did South State Corporation implement in response to the COVID-19 pandemic to support its customers and maintain operational continuity?,"The provided context does not contain information about measures implemented by South State Corporation in response to the COVID-19 pandemic to support its customers or maintain operational continuity. The documents include financial statements, accounting policies, and management discussions but do not detail pandemic-related actions.","South State Corporation implemented loan modification programs, payment deferrals, and fee waivers for affected customers. Internally, the bank closed banking lobbies, moved to drive-thru and online services, and allowed non-customer-facing employees to work from home to ensure operational continuity.",1.0,0.5269133514909906,1.0,0.25,1.0
"How did South State Corporation's capital adequacy ratios change post-merger with CSFL, and what factors influenced these changes?","The provided context does not contain information about South State Corporation's capital adequacy ratios or how they changed post-merger with CSFL. The documents focus on forward-looking statements, the merger process, the acquisition of CSFL, and certain financial details such as loan values and stock issuance, but do not discuss capital adequacy ratios or the factors influencing them.","Post-merger, South State Corporation's capital ratios, particularly the Tier 1 leverage ratio and Tier 1 risk-based capital ratio, decreased due to the significant increase in assets and risk-weighted assets. However, the total risk-based capital ratio increased, influenced by the inclusion of additional Tier 2 capital from subordinated debt and trust preferred securities acquired through the merger.",1.0,0.5350009646664442,1.0,0.75,1.0
How did the merger with CenterState Bank Corporation (CSFL) impact South State Corporation's loan portfolio at the time of acquisition?,"The merger with CenterState Bank Corporation (CSFL) resulted in South State Corporation acquiring $13.0 billion of loans at fair value, which was net of a $239.5 million, or 1.82%, estimated discount to the outstanding principal balance. These loans were acquired as part of the merger transaction on June 7, 2020, and were accounted for using purchase accounting. The acquired loans were segmented into those with evidence of credit deterioration (PCD loans) and performing loans at the time of the merger.","The merger with CSFL resulted in South State Corporation acquiring $13.0 billion of loans, including PPP loans, at fair value, net of $239.5 million, or 1.82%, estimated discount to the outstanding principal balance, representing 113.9% of the Company’s total loans at December 31, 2019.",4.0,0.8938344469453665,1.0,1.0,1.0
What was the impact of the COVID-19 pandemic on South State Corporation's evaluation of goodwill for impairment in 2020?,"The COVID-19 pandemic influenced South State Corporation's evaluation of goodwill for impairment in 2020 by prompting additional assessments of the economic impact and market conditions. At March 31, June 30, and September 30, 2020, the Corporation evaluated the effects of the pandemic and concluded that goodwill was not impaired during those periods. The annual impairment test performed as of October 1, 2020, along with subsequent tests at September 30 and December 31, 2020, considered factors such as comparable peer data, precedent transactions, discounted cash flow analysis, financial performance, and stock price. These evaluations led to the conclusion that it was not more likely than not that the fair value of the Corporation had declined below its carrying value, and therefore no impairment loss was recorded in 2020. The Corporation viewed the temporary decline in stock value as a result of the pandemic as not indicating impairment, and the subsequent increase in stock price provided further support. However, the Corporation noted that future assessments may be required if economic conditions deteriorate further.","South State Corporation evaluated the carrying value of goodwill as of April 30, 2020, considering the effects of COVID-19, and obtained a third-party valuation during the fourth quarter of 2020, concluding that no impairment charge was necessary.",4.5,0.8063186761370257,1.0,0.875,1.0
What are the potential consequences of the company's failure to maintain REIT qualification?,"Failure to maintain REIT qualification would result in the company being subject to corporate-level income taxes at regular federal, state, and local tax rates on its taxable income. Distributions to shareholders would no longer be deductible in computing the company's taxable income, leading to a substantial corporate tax liability. This would significantly reduce the amount of cash available for distribution to shareholders, potentially harming the value of the company's common stock. Additionally, the company would be disqualified from REIT status for the four taxable years following the failure, unless relief under certain Code provisions is granted.","If the company fails to maintain its REIT qualification, it would be subject to corporate-level income taxes on all of its taxable income, which would significantly reduce the amount of cash available for distribution to shareholders. This could negatively affect the value of its common shares and the sustainability of its business model.",5.0,0.8680770901036606,1.0,1.0,1.0
How does the company mitigate interest rate risk and what are the potential drawbacks of its hedging strategies?,"The company mitigates interest rate risk through hedging activities that vary in scope based on factors such as the level and volatility of interest rates, the types of investments held, and changing market conditions. These activities include using hedging instruments to manage exposure to interest rate fluctuations, particularly with respect to debt used to acquire or carry real estate assets. The company may also engage in hedging strategies involving interest rate swaps, forward rate agreements, or other financial derivatives to offset potential losses due to interest rate movements.

However, these hedging strategies come with several potential drawbacks. First, hedging instruments are often not traded on regulated exchanges and may not be guaranteed by clearing houses, making them inherently riskier. Second, interest rate hedging can be expensive, especially during periods of rising or volatile interest rates. Third, available hedges may not perfectly match the interest rate risk being hedged, and the duration of the hedge may not align with the related asset or liability, potentially reducing its effectiveness. Fourth, the credit quality of the hedging counterparty may deteriorate, impairing the ability to sell or assign the hedging position or increasing the risk of counterparty default. Additionally, the company may fail to properly recalculate, adjust, or execute hedges in a timely and efficient manner, which could lead to financial losses. Furthermore, tax regulations applicable to REITs limit income earned from hedging activities unless certain requirements are met or the hedging is done through a TRS. Finally, any hedging activity may materially and adversely affect results of operations and cash flows, and unanticipated changes in interest rates, credit spreads, or currencies could result in worse overall investment performance than if no hedging had been undertaken. The lack of a liquid secondary market for some hedging instruments may also require the company to maintain positions until expiration, increasing the potential for significant losses.","The company uses derivative financial instruments, such as swaps, options, and futures, to hedge against interest rate risk. However, these hedging activities can be expensive, may not perfectly correlate with the risks being hedged, and could result in worse overall investment performance if unanticipated changes in interest rates occur.",4.5,0.7323975377107731,1.0,0.875,1.0
What are the cybersecurity risks the company faces and how could they impact its operations?,"The company faces cybersecurity risks such as cyber-attacks, unauthorized access, use, alteration, or destruction of data, and potential vulnerabilities in computer systems, networks, and data. These risks can arise from internal and external threats, third-party access, physical or electronic break-ins, and employee errors. Such incidents could impair the company's ability to conduct business effectively by disrupting electronic data processing, transmission, storage, and retrieval systems. This could lead to interruptions or malfunctions in operations, financial losses, litigation, regulatory penalties, client dissatisfaction, reputational damage, and increased costs for damage mitigation and remediation. Additionally, if sensitive or confidential information is compromised, it could result in the theft, publication, deletion, or modification of private and material nonpublic information related to stockholders and beneficial owners. The systems in place to manage these risks may prove inadequate, potentially leading to prolonged system inoperability or failure to secure private data.","The company faces risks of cyber incidents, including unauthorized access, data breaches, and system disruptions. These could lead to compromised confidential information, operational disruptions, financial losses, litigation, and damage to business relationships, all of which could negatively impact its financial results and reputation.",4.5,0.7061922156170294,1.0,1.0,1.0
"What is the primary investment objective of Barings BDC, Inc.?","The primary investment objective of Barings BDC, Inc. is to generate current income and capital appreciation. The company invests in a diversified portfolio of debt and equity securities, primarily targeting middle-market companies. Its strategy involves making direct investments and providing financing to help these companies grow and expand their operations. The firm aims to achieve consistent returns through a combination of interest income from debt instruments and potential gains from equity investments.","The primary investment objective of Barings BDC, Inc. is to generate current income by investing directly in privately-held middle-market companies to help these companies fund acquisitions, growth, or refinancing.",4.0,0.8887174626984647,1.0,0.375,1.0
"What was the total amount of new commitments made by Barings BDC, Inc. subsequent to December 31, 2020?","The provided context does not contain information about new commitments made by Barings BDC, Inc. subsequent to December 31, 2020. The documents reference financial data and activities up to and including December 31, 2020, but no details about commitments made after that date are included.","Subsequent to December 31, 2020, the Company made approximately $224.1 million of new commitments, of which $202.2 million closed and funded.",1.0,0.5032686994237634,1.0,0.75,1.0
How did the Company account for the COVID-19 pandemic in its financial statements?,"The Company accounted for the COVID-19 pandemic in its financial statements by considering the potential impact on various aspects of its operations and financial condition. It recognized that the extent of the impact is highly uncertain and dependent on future developments, including the severity of the virus and containment measures. Due to this uncertainty, the Company was unable to estimate the impact on its consolidated financial statements and related disclosures at the time of reporting, but acknowledged that the impact could be material.

The Company evaluated whether the economic downturn caused by the pandemic triggered asset impairments, assessed the need to revisit accounting estimates and projections, and considered the effects on the collectability of receivables and fair value disclosures. Despite these considerations, the Company determined that there was no triggering event for impairment of any assets and no adverse change in the probability of collecting receivables during the year ended December 31, 2020.

Additionally, the Company took precautionary measures, such as restricting business travel, temporarily closing offices, and implementing remote work policies, to mitigate the impact on its operations and employees. These measures were part of a broader effort to manage the pandemic's effects, including assessing business resilience, financial modeling, and stress testing liquidity. The Company also continued to monitor the evolving situation and its potential effects on financial reporting and operations.","The Company temporarily closed its retail locations due to the COVID-19 pandemic, which it expects to have an unfavorable impact on its sales, results of operations, and cash flows in fiscal 2020.",4.0,0.5022981243935034,1.0,1.0,1.0
What was the impact of the adoption of the new lease accounting standard (ASUs) on the Company’s consolidated balance sheet?,"The adoption of the new lease accounting standard (ASUs) resulted in several changes to the Company’s consolidated balance sheet. The Company recorded an increase to the fiscal 2017 opening retained earnings balance of $4.0 million, inclusive of the tax impact. This included the recognition of operating lease right-of-use assets and corresponding current and non-current lease liabilities, as well as the recognition of finance lease right-of-use assets. The adoption also led to the derecognition of non-Company owned properties previously capitalized under build-to-suit accounting policies and reclassification of construction in progress assets determined to be landlord assets to other non-current assets. Additionally, initial direct costs related to operating leases were reclassified to operating lease right-of-use assets. There was a reclassification of prepaid rent to operating lease liabilities and other current liabilities (for finance leases), and deferred rent and unamortized lease incentives related to operating leases were reclassified to the operating lease right-of-use asset. A net deferred tax asset was also recognized. Furthermore, the adoption included the recognition of an asset held for sale under a sale-leaseback transaction.","The adoption of the ASUs resulted in the recognition of lease right-of-use assets and corresponding lease liabilities, as well as adjustments to opening retained earnings and other balance sheet items.",5.0,0.8221029925605834,1.0,1.0,1.0
What were the key factors considered by the Company in determining the fair value of its reporting units for impairment testing?,"The Company considered several key factors in determining the fair value of its reporting units for impairment testing. These included macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, and entity-specific events such as a sustained decrease in share price. Additionally, the fair value was assessed using either a discounted cash flow analysis or a market approach. The discounted cash flow method involved forecasting expected future cash flows, estimating long-term growth rates, applying appropriate discount rates that reflect economic risks, and considering assumptions related to income tax rates, capital expenditures, and working capital. The Company also considered publicly available information on its market capitalization, financial projections, future business prospects, and comparable sales prices, if available.","The Company considered factors such as revenues, expenses, fixed asset and working capital requirements, the impact of updated tax legislation, and other subjective inputs in determining the fair value of its reporting units.",4.0,0.655818026886494,1.0,1.0,1.0
How has the COVID-19 pandemic impacted the company's operations and financial outlook for fiscal 2020?,"The COVID-19 pandemic significantly disrupted the company's operations and financial outlook for fiscal 2020. In response to the public health crisis, the company temporarily closed its retail locations starting March 17, 2020, for an indeterminate period, with substantial uncertainty regarding when or how it could return to normal operations. While it continued serving customers virtually through Gallery representatives, designers, and online platforms, business operations were heavily affected by regulatory restrictions, including stay-at-home orders in California, where its corporate headquarters is located.

The closure of physical locations, combined with evolving federal, state, and local restrictions, led to prolonged operational challenges. Even if stores reopened, changes in consumer behavior and ongoing health concerns were expected to negatively impact consumer demand and customer traffic at Galleries, restaurants, and outlets, while also complicating staffing efforts. As a result, the company anticipated an unfavorable impact on sales, results of operations, and cash flows.

The uncertainty surrounding the pandemic's duration and severity led the company to withdraw all prior guidance and outlook statements for fiscal 2020. Additionally, the pandemic affected liquidity, with the company implementing measures to reduce cash outlays, such as managing workforce costs, delaying capital expenditures, deferring new business introductions, adjusting the timing of Source Book distribution, and minimizing discretionary spending. Negotiations with third parties for payment obligations were also undertaken.

The financial markets and broader economic conditions were disrupted, introducing enhanced uncertainty about the company’s capital position and access to funding, including debt repayments. Overall, the impact of the pandemic on the company's operations and financial performance during fiscal 2020 was significant and highly uncertain, with potential long-term consequences.","The COVID-19 pandemic has significantly disrupted the company's operations, leading to temporary store closures and substantial uncertainty about the timing and manner of returning to normal business operations. The company has withdrawn all prior guidance and outlook statements for fiscal 2020 due to the unpredictable nature of the pandemic's impact.",5.0,0.6761641493943248,1.0,1.0,1.0
What are the key strategies the company is focusing on to drive growth in its business?,"The company is focusing on several key strategies to drive growth in its business. These include expanding and developing its direct sales force to acquire new clients and manage existing ones, which is seen as critical for future growth. The company is also pursuing various growth initiatives, strategies, and operating plans aimed at enhancing its business, although the success of these efforts depends on accurate assumptions and effective execution. Additionally, the company is exploring opportunities to expand its operations in international markets outside the United States, despite the challenges associated with such expansion. The company is also investing in new products, services, and business ventures, including improvements to existing offerings like mortgage technology services. Lastly, the company is engaged in strategic initiatives, including acquisitions, investments, and strategic alliances, to support its growth.","The company is focusing on several key strategies to drive growth, including transforming its real estate platform, pursuing international expansion, expanding its merchandise assortment and market share, growing its integrated hospitality experience, and architecting a new operating platform to enhance customer experience and operational efficiency.",4.0,0.5904351424358099,1.0,0.875,1.0
How does the company assess the performance of its business?,"The company assesses the performance of its business by reviewing events or changes in circumstances that could materially affect the fair value and goodwill on a quarterly basis. This review includes evaluating factors such as general macroeconomic conditions, industry and market conditions, cost factors, overall financial performance of reporting units, events or changes affecting the composition or carrying amount of net assets, and sustained decreases in share price. If such events are identified, a goodwill impairment test is performed. Additionally, an annual qualitative assessment is conducted to determine whether a quantitative impairment test is necessary, based on the likelihood that the fair value of a reporting unit is less than its carrying value.","The company assesses the performance of its business using various financial and operating measures, including net revenues, gross profit, selling, general, and administrative expenses, adjusted operating income, adjusted EBITDA, and adjusted net income. These measures help the company evaluate its operating performance consistently over time.",2.0,0.5498822531591945,1.0,0.875,1.0
"What are the company's primary sources of liquidity, and how has the COVID-19 crisis affected its liquidity position?","The company's primary sources of liquidity include its cash flow from operations, access to debt and equity capital, and the ability to raise funds through offerings of securities. The COVID-19 crisis has significantly impacted the company's liquidity position due to the temporary closure of retail locations, reduced consumer demand, and operational disruptions caused by stay-at-home orders and other regulatory restrictions. These factors have led to unfavorable effects on sales, results of operations, and cash flows, particularly in fiscal 2020. Additionally, the pandemic has created challenges in accessing capital under favorable terms, increased uncertainty in loan loss provisions, and reduced demand for mortgage and real estate-related transactions, all of which further strain liquidity. To address these challenges, the company has implemented measures such as reducing costs, deferring capital expenditures, and negotiating payment obligations with third parties, while also considering actions like raising capital, selling assets, or adjusting dividend practices to preserve and strengthen its liquidity.","The company's primary sources of liquidity are cash flows from operations, net cash proceeds from the issuance of convertible senior notes, and borrowings under its credit facilities. The COVID-19 crisis has introduced significant uncertainty regarding the company's liquidity requirements and has prompted the company to implement cost-saving measures and negotiate with lenders and landlords to preserve financial flexibility.",4.5,0.7644717248349643,1.0,0.75,1.0
"How has the company's approach to real estate transformation evolved, and what impact has it had on the business?","The company's approach to real estate transformation has evolved from transitioning from a legacy retail footprint to a portfolio of Design Galleries tailored to the potential of each market and the size of their assortment. This shift has been driven by a focus on identifying suitable new site locations based on factors such as geographic location, demographics, and proximity to affluent consumers, as well as negotiating favorable economic terms and ensuring timely real estate development. As part of this transformation, the company has opened several Design Galleries in key markets, including Portland, Nashville, New York, Yountville, Minneapolis, and Columbus, with some incorporating integrated restaurants, wine vaults, and barista bars.

Key learnings from this transformation have led to the development of a new multi-tier market approach aimed at optimizing market share and return on invested capital. Additionally, the company has introduced a new RH prototype Design Gallery, which serves as an innovative and flexible blueprint. This prototype enables quicker deployment of their product assortment and immersive retail experience into the market. The transformation has been instrumental in supporting growth across the business by enhancing the retail experience and expanding their presence in high-potential markets.","The company has evolved its real estate approach by adopting a multi-tier market strategy, including the development of prototype Design Galleries, larger Bespoke Design Galleries in top metropolitan markets, indigenous Bespoke Galleries in second home markets, and smaller Galleries in secondary markets. This strategy aims to optimize market share and return on invested capital, with recent openings showing positive results in terms of profitability and brand statement.",4.5,0.6080786652002822,1.0,0.75,1.0
What are the risks associated with the company's reliance on third-party manufacturers for the production of its product candidates?,"The risks associated with the company's reliance on third-party manufacturers include the possibility that these manufacturers may fail to comply with regulatory requirements or maintain quality assurance, breach manufacturing agreements, fail to produce products according to specifications or schedules, or misappropriate or disclose proprietary information. Additionally, there is a risk of termination or nonrenewal of agreements by the third-party manufacturers at inconvenient or costly times. The company also faces challenges related to securing alternate suppliers, ensuring that alternative manufacturers can reproduce the existing manufacturing method on commercially reasonable terms, and maintaining compliance with cGMP regulations and other standards, which require ongoing investment in production and quality control. These factors could delay, prevent, or impair the development or commercialization of the company's product candidates.","The risks include potential delays in manufacturing, quality control issues, and the possibility of the third-party manufacturer failing to meet demand or terminating the relationship, which could impact the company's ability to supply its product candidates for clinical trials or commercialization.",5.0,0.7698797712108707,1.0,1.0,1.0
What are the provisions in the company's corporate charter that could potentially discourage a takeover?,"The company's corporate charter includes provisions that could potentially discourage a takeover. These include the ability of the Board of Directors to designate the terms of and issue new series of preferred shares, which may make it more difficult to remove management and discourage transactions that could involve a premium over prevailing market prices for the company's securities. Additionally, the Board of Directors may, without stockholder action, authorize the issuance of shares of stock in one or more classes or series, including preferred stock. The existence of these provisions may have a negative impact on the price of the company's common stock and may discourage third-party bids for ownership of the company.","The company's corporate charter includes provisions such as a classified board of directors, advance notice requirements for stockholder proposals, and a requirement for a supermajority vote to amend certain provisions, which could make a takeover more difficult.",4.5,0.8156401411030242,1.0,1.0,1.0
What is the significance of the company's exclusive forum provision in its certificate of incorporation?,"The company's exclusive forum provision in its certificate of incorporation designates specific courts—primarily the Court of Chancery of the State of Delaware and federal district courts—as the sole and exclusive venues for certain types of legal actions brought by stockholders. This includes derivative actions, claims involving breaches of fiduciary duty, disputes arising under Delaware corporate law, and claims related to the internal affairs doctrine. It also establishes the federal district courts as the exclusive forum for claims under the Securities Act of 1933.

These provisions aim to centralize litigation in courts experienced with corporate and securities law, promoting consistency, efficiency, and predictability in legal proceedings. By limiting forum options, the company seeks to reduce the burden of multi-forum litigation and potentially discourage lawsuits by stockholders, particularly those seeking a judicial forum they may perceive as more favorable. The provisions are binding on stockholders who acquire shares, as they are deemed to have consented to these terms upon purchase.","The exclusive forum provision designates the Court of Chancery of the State of Delaware as the sole forum for certain types of actions and disputes between the company and its stockholders, which could limit stockholders' ability to choose a preferred judicial forum for such disputes.",4.5,0.7701291924018924,1.0,1.0,1.0
What are the potential financial and operational impacts of the company becoming involved in securities class action litigation?,"Securities class action litigation could result in substantial costs, including significant legal fees and other expenses. It may also divert management's and the Board’s attention and resources from business operations, potentially harming the company’s performance. Additionally, such litigation could lead to perceived uncertainties about the company’s future, negatively affect relationships with service providers, and make it more difficult to attract and retain qualified personnel. Furthermore, the company’s stock price may be subject to significant fluctuation or other adverse effects due to the events, risks, and uncertainties associated with the litigation.","Securities class action litigation could be expensive, divert management's attention and resources, and adversely affect the company's business and financial condition. Insurance coverage may not be sufficient to cover all costs and damages.",5.0,0.8595102163443737,1.0,1.0,1.0
What are the principal risks related to the economy that could negatively affect the company's portfolio companies and results of operations?,"The principal risks related to the economy that could negatively affect the company's portfolio companies and results of operations include events outside of its control such as public health crises, economic recessions, and disruptions and instability in capital markets. These factors could impair the portfolio companies and harm operating results. Additionally, if the company cannot obtain additional capital due to regulatory or market price constraints, it may be forced to curtail or cease new lending and investment activities, which could lead to a decrease in net asset value and affect distributions and liquidity.","The principal risks include public health crises, economic recessions, capital market disruptions, and the inability to obtain additional capital due to regulatory or market constraints.",5.0,0.815920073296514,1.0,1.0,1.0
"What specific risks are associated with the company's subsidiary, NSBF, being an SBLC licensed by the SBA?","NSBF, as a licensed SBLC by the SBA, is subject to specific regulatory risks. These include maintaining a minimum regulatory capital, which is the greater of 10% of its outstanding loans receivable and other investments or $1,000,000. Additionally, before securitization, NSBF must be considered well capitalized by the SBA, requiring it to maintain unencumbered paid-in capital and surplus equal to at least 10% of its assets, excluding the guaranteed portion of 7(a) loans. NSBF is also subject to certain other regulatory restrictions under SBA regulations.","NSBF must maintain minimum regulatory capital and comply with SBA regulations, including potential liability for SBA guaranty denials or repairs, which could transfer liability to NSBF.",4.5,0.8558244188387918,1.0,0.875,1.0
"How does the company plan to maintain its tax treatment as a RIC, and what are the potential consequences of failure?","The company plans to maintain its tax treatment as a RIC by meeting specific requirements, including adhering to source of income and asset diversification rules, and distributing at least 90% of its investment company taxable income to stockholders each tax year. These distributions are intended to relieve the company from U.S. federal income taxes on distributed income. Additionally, the company monitors its tax obligations, including accruing excise tax on estimated excess taxable income if distributions are expected to fall below income levels.

Failure to meet these requirements could result in the company losing its RIC status, which would subject it to corporate-level income tax. In such a scenario, the company might face challenges in meeting the annual distribution requirement and may need to sell investments, raise capital, or forgo new opportunities to generate necessary funds. This could impact its financial flexibility and operational strategy.","To maintain RIC status, the company must meet source-of-income, asset diversification, and distribution requirements. Failure could subject the company to corporate-level income tax, reducing net assets and available income for distribution.",4.5,0.8080015203697202,1.0,0.0,1.0
What are the risks related to the company's investments in technology-related companies?,"The company's investments in technology-related companies are subject to several risks, including market volatility, intense competition, shortened product life cycles, changes in regulatory and governmental programs, and periodic downturns. These companies often have narrow product lines and small market shares, making them more vulnerable to competitive actions, market conditions, and general economic downturns. Revenues, income, and valuations in the technology sector can fluctuate suddenly and dramatically due to abrupt business cycles and intense competition. Overcapacity in the industry, combined with cyclical economic downturns, may lead to substantial decreases in market capitalization, which could be substantial and not temporary. Additionally, rapid technological change often results in decreasing average selling prices over the productive life of products and services, which could negatively affect operating results, debt obligations, and equity value. Furthermore, investments in sustainable and renewable technology companies carry operational risks such as underestimated cost projections, unanticipated maintenance expenses, loss of government subsidies, and challenges in delivering cost-effective energy solutions compared to traditional energy products.","Risks include potential obsolescence of intellectual property, equipment, and inventory due to technological advancements, which could impair the collateral value of loans made to these companies.",5.0,0.4949225127051136,1.0,1.0,1.0
How does the company's status as a BDC affect its ability to raise additional capital and the way it does so?,"The company's status as a BDC affects its ability to raise additional capital and the manner in which it does so by subjecting it to specific regulations under the 1940 Act. As a BDC, it may issue debt securities or preferred stock and borrow money from financial institutions, collectively referred to as senior securities, up to the maximum amount permitted by the 1940 Act. The company must maintain an asset coverage ratio of at least 150% after each issuance of senior securities. If the value of its assets declines, it might be unable to satisfy this requirement, potentially forcing it to sell investments or repay debt at disadvantageous times. Additionally, any funds used to service indebtedness are not available for distributions to common shareholders. This structure may expose the company to risks typical of leverage. Furthermore, the company generally cannot issue or sell common stock at a price below its net asset value per share, which limits its options for raising capital.","As a BDC, the company is subject to restrictions on issuing common stock below net asset value and must maintain an asset coverage ratio for senior securities. These constraints affect its capital raising flexibility and methods.",4.5,0.7885649408147298,1.0,1.0,1.0
How does Newtek Business Services Corp. determine the fair value of its investments?,"Newtek Business Services Corp. determines the fair value of its investments based on the information provided in the consolidated schedule of investments as of December 31, 2019. The fair value is reflected in the ""Fair Value"" column of the schedule, which includes details for each portfolio company such as the investment type, interest rate, maturity, principal amount, cost, and the percentage of net assets. The fair value is determined in accordance with accounting standards, and the schedule includes accompanying notes to the consolidated financial statements that provide additional context for these valuations.","Newtek Business Services Corp. determines the fair value of its investments using unobservable inputs and assumptions, classifying them as Level 3 within the fair value hierarchy. This involves significant judgments about valuation methodologies and inputs such as revenue and EBITDA multiples, market yields, discounts for lack of marketability, underlying cash flows, and the impact of economic conditions.",3.0,0.7859118339000055,1.0,0.375,1.0
What critical audit matter was communicated regarding the valuation of investments?,"The critical audit matter communicated was the valuation of investments, which involves significant judgment by management in determining the fair value of privately held debt and equity instruments that lack observable market prices. This process relies on unobservable inputs and models, leading to a high degree of auditor subjectivity and complexity. The audit required specialized expertise and extensive procedures, including testing controls, comparing management’s estimates with independently obtained pricing, and involving professionals with specialized knowledge to develop independent price ranges for a sample of securities.","The critical audit matter communicated was the valuation of investments, which involves judgments necessary for management to select and apply valuation techniques and assumptions, the high degree of auditor judgment involved, and the extensive audit effort involved in testing the valuations.",4.5,0.8562462562601159,1.0,1.0,1.0
What is the total principal amount of PPP loans funded by NSBF during the duration of the PPP?,$1.19 billion,"NSBF funded approximately 10,570 PPP loans totaling $1.19 billion during the duration of the PPP.",3.0,0.5179299934056683,1.0,1.0,1.0
How does the CARES Act affect existing SBA 7(a) borrowers?,"The CARES Act provided subsidies to existing SBA 7(a) borrowers by having the SBA pay all principal, interest, and fees on existing performing SBA 7(a) loans for six months beginning with the borrowers’ April 2020 payments.","The CARES Act provided an over $2.0 trillion stimulus package, including subsidies to certain existing SBA 7(a) borrowers where the SBA paid all principal, interest, and fees on existing performing SBA 7(a) loans for six months beginning with such borrowers’ April 2020 payments.",5.0,0.9433262949589554,1.0,1.0,1.0
How does Newtek Business Services Corp. account for its equity-based compensation plan?,The provided context does not contain information about how Newtek Business Services Corp. accounts for its equity-based compensation plan.,"Newtek Business Services Corp. accounts for its equity-based compensation plan using the fair value method, as prescribed by ASC 718. For restricted stock awards, the Company measures the grant date fair value based upon the market price of its common stock on the date of the grant and amortizes this fair value to salaries and benefits over the requisite service period.",1.0,0.6669708596095795,1.0,0.375,1.0
How does Fusion plan to address the risk of third-party claims of intellectual property infringement?,"Fusion plans to address the risk of third-party claims of intellectual property infringement by defending against such claims through legal proceedings, even if they believe the claims are without merit. This may involve pursuing litigation to challenge the validity, enforceability, or infringement allegations, which could require significant financial and human resources. In cases where infringement is found or a license is required, Fusion may seek to obtain licenses from third parties, though there is no assurance such licenses will be available on commercially reasonable terms or at all. Additionally, Fusion may be required to redesign products or processes to avoid infringement, cease certain activities, or pay monetary damages if found liable. To further mitigate risk, Fusion may also rely on indemnification agreements with clients, although this could lead to disputes regarding the scope of such obligations. Despite these efforts, there is no guarantee that any infringement claims will be resolved in favor of Fusion, and the process could still result in substantial costs, delays, and harm to business operations.","Fusion plans to manage this risk by ensuring compliance with patent laws and regulations, potentially obtaining licenses when necessary, and defending against any claims through legal proceedings if needed.",4.5,0.6943028334915463,1.0,0.875,1.0
How does Fusion mitigate the risk of product liability claims?,"Fusion mitigates the risk of product liability claims by maintaining product liability insurance at levels believed to be appropriate, though the insurance is subject to deductibles and coverage limitations. The company also relies on internal procedures to minimize risks related to product quality and defects in third-party components. However, there is no assurance that the insurance coverage will remain available on acceptable terms or be sufficient to cover all potential claims, and the company may seek additional insurance if new products are approved or launched. Additionally, Fusion may face liability even if an injury results from misuse of the product or actions by others, and defending such claims could be costly and divert management attention.","Fusion mitigates this risk by maintaining product liability insurance, ensuring strict quality control in manufacturing, and adhering to regulatory standards in the development and marketing of its products.",4.0,0.8668660118871876,1.0,1.0,1.0
What is the primary focus of the company's business?,"The primary focus of the company's business is to identify and complete a business combination, after which it aims to operate the post-transaction business or assets for the long term. The company does not plan to buy businesses or assets for resale or as a passive investor, and it is not intended to engage in activities like buying and selling businesses in the manner of a merchant bank or private equity fund.","The company is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, particularly through its Targeted Alpha Therapies (TAT) platform.",2.0,0.41819030154359427,1.0,1.0,1.0
"What strategic collaboration has the company entered into, and what are the key terms of this collaboration?","The provided context does not specify any particular strategic collaboration the company has entered into, nor does it outline the key terms of such an arrangement. The documents only list potential risks associated with future collaborations, such as the expenditure of resources, dilution of shareholder ownership through equity issuance, assumption of liabilities, and various operational and financial challenges related to working with strategic partners. There is no mention of specific partnerships or the terms under which they might be established.","The company has entered into a strategic collaboration agreement with AstraZeneca to jointly discover, develop, and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The collaboration leverages Fusion’s TATs platform and expertise in radiopharmaceuticals with AstraZeneca’s leading portfolio of antibodies and cancer therapeutics, including DDRis. Both companies will retain full rights to their respective assets.",1.0,0.27190302873359873,1.0,0.5,1.0
How does the company plan to address the potential for reduced profitability due to government and third-party payor reimbursement policies?,"The company does not outline a specific plan to address the potential for reduced profitability due to government and third-party payor reimbursement policies. Instead, it acknowledges the risk that any reduction in reimbursement from Medicare, Medicaid, or other government programs could lead to similar reductions in payments from private payers. The company also notes that the implementation of cost containment measures or other healthcare reforms may hinder its ability to generate revenue, attain, or maintain profitability for its products and product candidates, if approved. There is no mention of strategies or measures the company intends to implement to mitigate these risks.","The company must engage in a time-consuming and costly process to provide scientific and clinical support for the use of its products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. The company may also need to negotiate lower prices for its products to be covered by government health programs and commercial insurance, which could impact profitability.",4.0,0.4762267616595597,1.0,1.0,1.0
What is the company's approach to intellectual property protection for its products and technologies?,"The company protects its intellectual property through trademarks, copyrights, patents, and trade secrets related to its games and technology. It actively pursues the filing of patents and registration of trademarks in the United States and certain foreign jurisdictions. However, the company acknowledges that these efforts may not always succeed or provide full protection, as third parties could develop similar technologies outside the scope of existing patents or obtain overlapping intellectual property rights. Additionally, the company faces challenges in detecting misappropriation or unauthorized use and may need to resort to litigation, which can be costly. Despite these efforts, the company cannot guarantee the enforceability or effectiveness of its intellectual property rights, and it may choose not to enforce them depending on strategic considerations.","The company seeks to protect its products and technologies by filing U.S. and foreign patent applications related to its proprietary technology, inventions, and improvements. It also relies on trade secrets, know-how, continuing technological innovation, and in-licensing of third-party intellectual property to develop and maintain its proprietary position.",4.5,0.5929775217001111,1.0,1.0,1.0
What significant changes did Jefferies Financial Group Inc. make to its operating segments in the first quarter of 2020?,"In the first quarter of 2020, Jefferies Financial Group Inc. made significant changes to its operating segments by appointing co-Presidents of Asset Management and creating a separate operating segment dedicated to asset management. This new segment consolidated the asset management activity that was previously included in the Investment Banking, Capital Markets and Asset Management segment, as well as the asset management activity previously part of the Merchant Banking segment. As a result, the company reclassified and recast its prior period segment results to align with the new presentation.","In the first quarter of 2020, Jefferies Financial Group Inc. appointed co-Presidents of Asset Management and created a separate operating segment for asset management activities previously included in the Investment Banking, Capital Markets, and Asset Management segment, as well as those previously included in the Merchant Banking segment.",5.0,0.936167460804315,1.0,1.0,1.0
How does Jefferies Financial Group Inc. manage its exposure to credit risk associated with derivative activities and securities financing transactions?,"Jefferies Financial Group Inc. manages its exposure to credit risk associated with derivative activities and securities financing transactions through participation agreements and derivative contracts with Jefferies Finance, based on certain securities issued by CLOs. These activities involve recognizing gains or losses related to the derivative contracts. Additionally, the company enters into service agreements where it charges Jefferies Finance for services provided, and it holds securities issued by CLOs managed by Jefferies Finance, which are included in financial instruments owned at fair value. To mitigate foreign currency exposure in connection with non-U.S. dollar loans to investment banking clients, Jefferies Group has entered into an indemnity agreement with Jefferies Finance.","Jefferies Financial Group Inc. manages its exposure to credit risk through master netting agreements, master securities lending agreements, master repurchase agreements, or similar agreements and collateral arrangements with counterparties. These agreements provide protection in bankruptcy in certain circumstances and enable receivables and payables with the same counterparty to be settled or otherwise eliminated by applying amounts due against all or a portion of an amount due from the counterparty or a third-party.",2.5,0.7675500538576531,1.0,0.75,1.0
What is the significance of the foreign currency translation adjustments in Jefferies Financial Group Inc.'s financial statements?,"The foreign currency translation adjustments are significant because gains or losses from Jefferies Group's foreign currency transactions are included in Principal transactions revenues in the Consolidated Statements of Operations. This means these adjustments directly impact the reported revenues from principal transactions, reflecting the financial effect of currency fluctuations on the company's operations.",Foreign currency translation adjustments result from translating the financial statements of foreign subsidiaries from their functional currency into the reporting currency (U.S. dollars). These adjustments are included in accumulated other comprehensive income (loss) and can significantly impact the company's equity and financial position.,2.5,0.7548258887458131,1.0,0.5,1.0
How does SuRo Capital Corp value its investments at fair value?,"SuRo Capital Corp values its investments at fair value using significant unobservable inputs, which are classified as Level 3 measurements under accounting standards. These valuations are determined in good faith by the Company’s Board of Directors. The investments are typically restricted as to resale unless otherwise noted, and the fair value is assessed based on the Company’s judgment and available information, particularly for portfolio investments that are not publicly traded.","SuRo Capital Corp values its investments at fair value using a hierarchy that prioritizes the inputs to valuation techniques. Level 1 assets are valued based on unadjusted quoted prices in active markets for identical assets. Level 2 assets use observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities. Level 3 assets use unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability.",3.0,0.8395857281803132,1.0,0.75,1.0
What measures has SuRo Capital Corp taken to ensure compliance with the RIC tax provisions of the Code?,"SuRo Capital Corp has elected to be treated as a RIC under Subchapter M of the Code, beginning with its taxable year ended December 31, 2014, and has qualified to be treated as a RIC for subsequent taxable years. The company intends to continue operating in a manner that allows it to qualify annually for treatment as a RIC under Subchapter M of the Code. By doing so, it avoids U.S. federal income tax on the portion of taxable income distributed as dividends to stockholders.",SuRo Capital Corp has elected to be treated as a RIC under Subchapter M of the Code and intends to qualify for tax treatment as a RIC. The Company is required to meet certain income and asset diversification tests and distribute dividends of an amount generally at least equal to 90% of its investment company taxable income to its stockholders. The Company has taxable subsidiaries that hold certain portfolio investments to limit potential legal liability and comply with source-income type requirements.,4.0,0.9378322744456693,1.0,0.75,1.0
What are the key features of Waste Management's Employee Stock Purchase Plan (ESPP)?,"The Employee Stock Purchase Plan (ESPP) at Waste Management allows employees to purchase shares of common stock through payroll deductions. The plan operates with two offering periods annually: January through June and July through December. At the end of each offering period, employees buy shares at a price equal to 85% of the lesser of the stock’s market value on the first or last day of the offering period. Funds for these purchases are accumulated via payroll deductions, with eligible employees able to elect up to 10% of their base pay to be deducted, subject to plan and IRS limitations. In recent years, approximately 570,000, 537,000, and 582,000 shares were issued in 2020, 2019, and 2018, respectively. As of early 2021, 3.2 million shares remained available for issuance, including an additional 3.0 million approved by stockholders in May 2020. The ESPP results in annual compensation expenses of $13 million (net $10 million after tax) in 2020, $10 million (net $7 million after tax) in 2019, and $9 million (net $7 million after tax) in 2018.","The key features of Waste Management's ESPP include employees being able to purchase shares of common stock at a discount, with purchases made at the end of offering periods with funds accumulated through payroll deductions. The discount is 85% of the lesser of the market value of the stock on the first and last day of the offering period.",4.5,0.8012834574850384,1.0,0.875,1.0
How does Waste Management assess and manage its long-lived assets for potential impairment?,"Waste Management assesses its long-lived assets, including indefinite-lived intangible assets such as goodwill, for potential impairment at least annually on October 1, and more frequently if events or changes in circumstances indicate a possible impairment. The assessment begins with a qualitative evaluation to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying value. If the qualitative assessment suggests a possible impairment, a quantitative review is performed. This involves comparing the estimated fair value of the reporting unit to its carrying amount, including goodwill. Fair value is typically determined using an income approach based on long-term projected future cash flows, discounted to present value using a weighted average cost of capital that reflects market assumptions, the timing of cash flows, and associated risks. In some cases, a market approach may also be used, estimating fair value by applying multiples of reported earnings to publicly traded companies with similar characteristics. An impairment charge is recognized if the estimated fair value of the asset is less than its carrying amount. The company also involves valuation specialists to evaluate the methodology and key assumptions used, performs sensitivity analyses, and compares assumptions to industry trends, acquisition valuations, and historical results.","Waste Management assesses its long-lived assets for potential impairment by monitoring the carrying value for potential impairment indicators. If an impairment indicator occurs, the company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. If the carrying value exceeds the undiscounted cash flows, the company measures the impairment by comparing the fair value of the asset or asset group to its carrying value.",4.5,0.7544768226087712,1.0,1.0,1.0
"What are the primary sources of revenue for Waste Management, and how do they contribute to the overall revenue mix?","Waste Management's primary sources of revenue come from its Solid Waste business, which includes collection, transfer, disposal, and recycling and resource recovery services provided across the United States and Canada. This business is managed locally through 17 geographic Areas and represents the core of the company's operations. The Solid Waste segment is complemented by additional services categorized under ""Other,"" which include Strategic Business Solutions, landfill gas-to-energy operations, recycling brokerage services, and various expanded service offerings. These additional services contribute to revenue through contracts, commodity sales, and energy production. While the majority of revenue is derived from the Solid Waste business, the ""Other"" segment adds diversity, particularly through renewable energy and third-party services, enhancing the overall revenue mix. Corporate operations also support the business, though their results are not allocated to reportable segments.","The primary sources of revenue for Waste Management are collection, landfill, transfer, and recycling services. These services contribute to the overall revenue mix, with collection and landfill services typically being the most significant contributors.",4.0,0.832399521771584,1.0,0.5,1.0
"How does Waste Management handle its environmental remediation liabilities, and what was the total amount of such liabilities as of December 31, 2020?","Waste Management recognizes and accrues for estimated environmental remediation liabilities when they are both probable and reasonably estimable. The company determines the method and ultimate cost of remediation by making assumptions, and when there is a range of reasonable cost estimates, it uses the best estimate within that range. If no amount within the range is a better estimate, the low end of the range is used. As of December 31, 2020, the total amount of environmental remediation liabilities recorded in the Consolidated Balance Sheet was $230 million. It is possible that future developments could lead to adjustments in these accruals, potentially resulting in material changes to the balance sheet and income from operations.","Waste Management handles its environmental remediation liabilities by recognizing and accruing for an estimated remediation liability when it determines that such liability is both probable and reasonably estimable. The total amount of environmental remediation liabilities as of December 31, 2020, was $230 million.",4.5,0.8976918059902127,1.0,0.875,1.0
"What are the key financial covenants associated with Waste Management's debt agreements, and how does the company ensure compliance?","The key financial covenant associated with Waste Management's debt agreements is the Leverage Ratio, which is defined in the $3.5 billion revolving credit facility. The company must maintain a Leverage Ratio of 3.75 to 1 for at least one fiscal quarter between any Elevated Leverage Ratio Periods, and there can be no more than two such periods during the term of the facility. The company ensures compliance by monitoring its financial position and covenants, and given its strong financial position and expected headroom within the Leverage Ratio, it has not elected to increase the ratio since the acquisition of Advanced Disposal. Additionally, the company is in compliance with all other covenants and restrictions under its financing arrangements that could materially affect its consolidated financial statements.","The key financial covenant associated with Waste Management's debt agreements is the maximum total debt to consolidated earnings before interest, taxes, depreciation, and amortization (EBITDA) ratio (the ""Leverage Ratio""). The company ensures compliance by monitoring its financial position and maintaining significant headroom within the Leverage Ratio.",4.5,0.9458370407257808,1.0,0.875,1.0
How does ridinilazole aim to differentiate itself from existing treatments for CDI?,"Ridinilazole aims to differentiate itself from existing treatments for Clostridioides difficile infection (CDI) through its targeted spectrum of activity, which selectively inhibits C. difficile while preserving the gut microbiome. This selectivity is demonstrated by its minimal activity against beneficial bacteria in the gut, unlike broader-spectrum antibiotics such as vancomycin, metronidazole, and fidaxomicin, which can disrupt the microbiome and contribute to recurrence. By maintaining a more balanced microbial environment, ridinilazole is designed to reduce recurrence rates of CDI. Additionally, it is a novel structural class of antibiotic, distinct from major marketed classes, and is being evaluated as an orally administered small molecule that promotes good antibiotic stewardship. Unlike bezlotoxumab, which is a monoclonal antibody used adjunctively to reduce recurrence without treating the infection itself, ridinilazole is designed to treat the initial infection directly. Its clinical development includes Phase 3 trials comparing it to vancomycin with the primary goal of demonstrating superior sustained clinical response, defined as resolution of diarrhea and no recurrence within 30 days post-treatment. Moreover, ridinilazole has shown potential benefits beyond clinical outcomes, including improvements in patient-reported measures such as anxiety, depression, pain, and discomfort, suggesting broader impacts on patient wellbeing.","Ridinilazole is designed to selectively target the bacterium Clostridioides difficile while preserving the gut microbiome, potentially reducing recurrence rates and improving sustained clinical response rates compared to broad-spectrum antibiotics like vancomycin.",5.0,0.7350531037083486,1.0,0.875,1.0
What financial support has Summit Therapeutics received for the development of ridinilazole?,"Summit Therapeutics has received financial support for the development of ridinilazole from multiple sources. The company was awarded a contract from BARDA worth up to $72.5 million, which includes funding for ongoing Phase 3 clinical trials. As of December 31, 2020, $53.3 million of this funding had been received. Additionally, Summit Therapeutics received a $2.5 million upfront payment from Eurofarma Laboratórios S.A. under a license and commercialization agreement, which grants Eurofarma exclusive rights to commercialize ridinilazole in certain regions. The company is also eligible for further milestone payments, including $1.0 million upon achieving an enrollment target in Phase 3 trials and up to $2.75 million more upon reaching additional targets. Furthermore, the company could receive up to $21.4 million in development, commercial, and sales milestones if cumulative net sales reach $100.0 million in the licensed territory.",Summit Therapeutics has received a contract from the Biomedical Advanced Research and Development Authority (BARDA) worth up to $72.5 million to support the ongoing Phase 3 clinical trials and potential regulatory applications for ridinilazole in the United States.,5.0,0.8761136799763779,1.0,1.0,1.0
What are the key competitive factors affecting the success of Summit Therapeutics' product candidates?,"The provided context does not contain information about the key competitive factors affecting the success of Summit Therapeutics' product candidates. The documents focus on corporate structure, human capital policies, employee demographics, and general operational details, but do not address specific competitive factors related to product candidates.","The key competitive factors include efficacy, safety, convenience, price, and the availability of coverage and reimbursement from government and other third-party payors.",1.0,0.32039477520125553,0.0,0.25,1.0
"What are the potential risks associated with the company's reliance on government funding for its lead product candidate, ridinilazole?","The company's reliance on government funding for ridinilazole introduces several potential risks. First, the funding contract with BARDA is subject to termination at any time for convenience, which could disrupt development efforts. Additionally, changes in government budgets or research priorities may lead to reduced support for antibacterial product candidates like ridinilazole. There is no assurance that BARDA will pursue the remaining option under the contract, and a decision to end support could materially adversely affect the company's operations. Furthermore, government-funded programs often include requirements that may increase the costs of commercialization and production. These factors introduce uncertainty into the research and commercialization efforts for ridinilazole.","Risks include the possibility of the government terminating the funding contract, changes in government budgets and research priorities, delays in development activities, and increased costs of commercialization and production due to imposed requirements. These factors could force the company to seek alternative funding sources, which may not be available on favorable terms.",5.0,0.7639479271409477,1.0,1.0,1.0
What are the key factors that contributed to the increase in net interest income during 2020?,"The key factors that contributed to the increase in net interest income during 2020 were a $316.4 million rise in interest income from loans and loans held for sale, an $8.5 million increase in interest income from investment securities, and a $258.8 million increase in interest income on acquired loans due to higher average acquired loans from a merger. Additionally, there was a $51.0 million increase in interest income on non-acquired loans, driven by organic loan growth and higher average balances. These increases were partially offset by a $5.7 million decrease in interest income from federal funds sold, securities purchased under agreement to resell, and interest-bearing deposits.","The increase in net interest income during 2020 was primarily due to lower interest expense from interest-bearing liabilities driven by lower rates paid and a shift in mix to lower cost deposits, as well as the favorable impact of higher average interest earning asset balances.",4.0,0.7532377127757669,1.0,0.875,1.0
How did the COVID-19 pandemic impact the provision for credit losses in 2020?,"The COVID-19 pandemic led to a deterioration of economic conditions, which worsened the economic forecasts used for calculating lifetime expected credit losses (ECL). This resulted in increased provisions for credit losses across the commercial, consumer, and off-balance sheet credit exposures in 2020. Specifically, higher delinquency levels, provisions for economic uncertainty, and forbearance accounts contributed to the rise in the consumer loan portfolio provision, while downgrades in client financial conditions and risk factors associated with higher-risk exposures affected the commercial portfolio. These impacts were consistent across all portfolio segments, driving a significant increase in the overall credit loss provisions.","The COVID-19 pandemic significantly impacted the provision for credit losses in 2020 by causing a deterioration of economic conditions, which resulted in a worsening of the economic forecasts used for calculating expected credit losses and downgrades reflecting weakness in the financial condition of certain clients.",5.0,0.7790567340598316,1.0,0.875,1.0
What measures were taken by HSBC USA to manage liquidity and funding risk during the COVID-19 pandemic?,"HSBC USA actively monitored and controlled liquidity and funding risk in accordance with its policy during the COVID-19 pandemic. To address elevated commercial loan demand in March, the bank raised deposits, increased short-term borrowings through securities sold under repurchase agreements, and borrowed from the Federal Home Loan Bank (FHLB). These actions helped support client loan demand while maintaining adequate liquidity and increasing cash. Additionally, substantially all of the commercial lines of credit drawn in March were repaid. HSBC did not utilize any of the FRB liquidity facilities established during the pandemic. The bank continues to adapt its liquidity framework as market conditions evolve.","During the COVID-19 pandemic, HSBC USA actively raised deposits, increased short-term borrowings in the form of securities sold under repurchase agreements, and borrowed from the Federal Home Loan Bank to support elevated client demand for loans while maintaining adequate liquidity.",5.0,0.8759483786979831,1.0,1.0,1.0
What was the impact of the LIBOR transition on HSBC USA's operations?,"The LIBOR transition had a significant impact on HSBC USA's operations, as it necessitated a comprehensive global transition program to move all products, processes, models, curves, and legacy LIBOR-based contracts to alternative reference rates. This transition involved developing alternative rate product capabilities and managing risks across all global businesses, multiple products, currencies, systems, and processes. Key risks included conduct, execution, financial, and non-financial risks, which were addressed through a risk inventory and monitoring mechanisms. Additionally, the transition posed potential adverse impacts such as legal proceedings related to the interpretation and enforceability of LIBOR contract provisions and regulatory scrutiny over preparation and readiness for the transition. To mitigate these effects, HSBC USA implemented risk disclosures for new LIBOR-based contracts, incorporated ARRC recommended fallback language into new contracts, and updated fallback provisions in syndicated and bilateral loans with revised hardwired language specifying trigger events and successor rates.","The LIBOR transition process involved developing alternative rate product capabilities and transitioning legacy contracts. This transition could have a range of adverse impacts on HSBC USA's business, including legal proceedings or other actions regarding the interpretation and enforceability of provisions in LIBOR contracts and regulatory investigations or reviews.",5.0,0.7450538391780257,1.0,0.875,1.0
How did HSBC USA manage its credit risk during the economic uncertainty caused by the COVID-19 pandemic?,"HSBC USA managed its credit risk during the economic uncertainty caused by the COVID-19 pandemic by closely monitoring and striving to manage factors influencing its credit ratings. While there were rating actions by Fitch and S&P, including downgrades to HSBC USA and HSBC Bank USA, these changes did not have a material financial impact on borrowing costs or liquidity at the time. HSBC emphasized its focus on managing credit risk effectively and acknowledged that credit ratings could change in the future, with no assurance of stability. The company also operated under a revised outlook that reflected the economic disruption, while ensuring its ability to navigate the challenges associated with the global downturn.","HSBC USA managed its credit risk during the pandemic by re-reviewing the credit ratings assigned to substantially all of its material commercial loans, closely monitoring the performance of these loans, and taking necessary credit actions where warranted.",4.0,0.7410642143380498,1.0,0.75,1.0
"What was the strategic plan announced by HSBC USA in February 2020, and what were its expected financial impacts?",The provided context does not contain information about a strategic plan announced by HSBC USA in February 2020 or its expected financial impacts. The context repeatedly discusses forward-looking statements and their associated risks but does not detail specific strategic plans or their financial implications from that time period.,"The strategic plan announced in February 2020 aimed to restructure operations in alignment with HSBC’s global strategy, focusing on refocusing wholesale operations and restructuring retail operations. The expected financial impact included pre-tax charges of approximately $520-$590 million over the two-year period of 2020-2021.",1.0,0.38191030585266295,1.0,0.25,1.0
